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ABSTRACT

ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ANIONIC
COMPONENTS IN THE DIET AND HERBAL MEDICINES ON ORGANIC ANION
TRANSPORTERS (SLC22 FAMILY)
By Li Wang, M.S.
A dissertation submitted in partially fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2013
Major Director: Douglas H. Sweet, Ph.D.
Associate Professor
Department of Pharmaceutics, School of Pharmacy

Numerous natural products are widely used as first-line/alternative therapeutics and dietary
supplements in both western and eastern society. However, the safety and efficacy profiles for
herbal products are still limited. Organic anion transporters (OATs; SLC22 family) are expressed
in many barrier organs and mediate in vivo body disposition of a broad array of endogenous
substances and clinically important drugs. As some dietary flavonoids and phenolic acids were
previously demonstrated to interact with OATs, it is necessary to explore the potential interaction

of such components found in natural products in order to avoid potential OAT-mediated drugdrug interactions (DDIs).
The inhibitory effects of 23 natural products were assessed on the function of human (h)
OATs, hOAT1 (SLC22A6), hOAT3 (SLC22A7), and hOAT4 (SLC22A11) and/or the murine (m)
orthologs mOat1 and mOat3. For compounds exhibiting marked inhibition at initial screening,
dose-response curves (IC50 values) and DDI indices were determined. At the initial screening
concentrations, 14, 19, and 2 test compounds exhibited significant inhibition on hOAT1, hOAT3,
and hOAT4, respectively. Additionally, all test Danshen (a Chinese herbal medicine) hydrophilic
components significantly reduced mOat1- and mOat3-mediated substrate uptake at 1 mM. For
selected compounds, the IC50 and Ki values were estimated to be in the micromolar or even
nanomolar range. Considering the clinical plasma concentration and unbound fraction in plasma,
DDI indices for gallic acid, gentisic acid, lithospermic acid, protocatechuic acid, rosmarinic acid,
salvianolic acid B, and tanshinol indicated DDIs may occur in vivo in situations of coadministration of these compounds and clinical therapeutics known to be OAT substrates.
Finally, a new, rapid, and sensitive liquid chromatography-tandem mass spectrometry (LCMS/MS) method was developed and validated to quantify gallic acid and gentisic acid in cell
lysates in order to measure cellular uptake of these compounds in mOat1- or mOat3-expressing
cells. Significant cellular uptake of gallic acid was observed in mOat1-expressing cells,
compared with background control cells. The absorptive uptake was completely blocked by
probenecid (known OAT inhibitor) at 1 mM. These results indicate that gallic acid is a substrate
for mOat1 and suggest that human OAT1 might be involved in the active renal secretion of gallic
acid.

CHAPTER 1

RENAL ORGANIC ANION TRANSPORTERS (SLC22 FAMILY): EXPRESSION,
REGULATION, ROLES IN TOXICITY, AND IMPACT ON INJURY AND DISEASE
Drawn from manuscript published in AAPS J. Jan 2013; 15(1): 53-69

1.A INTRODUCTION
Two vital functions performed by the kidney are the removal of substances from the blood
followed by their elimination via urine and the reabsorption of specific compounds from the
glomerular filtrate back into the systemic circulation. Much of the secretion and reabsorption of
charged organic solutes occurs in the proximal tubule. However, the plasma membrane of the
proximal tubule cells presents a barrier to the passive diffusion of such charged, hydrophilic
molecules and renal transcellular solute flux is a complex process involving dozens of membrane
bound transporter proteins. Two major superfamilies of transport proteins that have been
identified are the ATP binding cassette (ABC) transporters, which can directly bind and
hydrolyze ATP as a driving force for the unidirectional transport of substrates across cell
membranes, and the solute carriers (SLC), transport proteins that are indirectly coupled to
cellular energy and utilize the membrane potential difference and/or the stored energy of
concentration gradients as driving forces (1-3). Currently, the human SLC superfamily has at
1

least 55 separate gene families encompassing a combination of 362 confirmed and putative
transporter proteins (1). The SLC22 family is comprised of the organic cation/anion/zwitterion
transporters with ~30 identified/putative members and includes the organic cation transporters
(OCTs and OCTNs), which mainly interact with cationic and zwitterionic organic molecules, and
the organic anion transporters (OATs), which predominantly interact with anionic and
zwitterionic organic molecules (2-4).
In vitro characterization of cloned transporters has demonstrated that OAT function is
impacted by an enormous variety of structurally diverse organic anions. Many drugs, including
diuretics, antihypertensives, antibiotics, antivirals, and anticancer agents, are organic anions at
physiological pH and, thus, subject to active tubular secretion which, in turn, impacts their
pharmacokinetic, pharmacodynamic, and toxic properties. In addition, endogenous substances
(e.g., metabolic intermediates/byproducts and hormones) and environmental toxins and toxicants
(e.g., mycotoxins and pesticides) also exist as anionic species. Indeed, the attributes of known
OAT substrates indicate that renal OAT function is central to organism homeostasis and the
progression of certain disease states. Further, interindividual variation in therapeutic response
within human populations may be linked to altered renal OAT affinity, expression level, and/or
spatial distribution as a result of dietary or genetic factors. Clearly, a more thorough
understanding of OAT function is necessary if we wish to accurately assess their impact on drug
efficacy and the extent of exposure to endogenous and xenobiotic toxins/toxicants.
This review will focus on the OATs of the SLC22 transporter family and in particular on
those OATs for which transport activity has been demonstrated and expression/function in
kidney established (Table 1.1). Basic cloning, expression profile, and functional characterization
information for each transporter has been summarized in great detail recently and will not be

2

repeated here (3, 4). Rather, evidence supporting the involvement of renally expressed OATs in
drug clearance, food/drug-drug interactions, and renal pathology will be emphasized. Appendix I
provides a listing of compounds demonstrated to interact with various OATs and reported kinetic
parameters (Km, Ki, or IC50 values), when available, that serves as an update (2010-2012) to the
comprehensive table from reference (3). An update of the current information regarding the
regulation of OAT expression is also provided. Throughout this review the convention of
referring to human transporters with all capital letters (i.e., OAT1) and non-human transporters
with initial capital followed by lower case letters (i.e., Oat1), is used.

3

Table 1.1. Functional SLC22 family organic anion transporters
Transporter
(gene designation)
Human
OAT1 (SLC22A6)
OAT2 (SLC22A7)
OAT3 (SLC22A8)
OAT4 (SLC22A11)
OAT5 (SLC22A10)a
OAT7 (SLC22A9)
OAT10 (SLC22A13)
URAT1 (SLC22A12)
Rodent
Oat1 (Slc22a6)
Oat2 (Slc22a7)
Oat3 (Slc22a8)
Oat5 (Slc22a19)a
Oat6 (Slc22a20)
Oat8 (Slc22a25)
Oat9 (Slc22a27)
Oat10 (Slc22a13)
Urat1 (Slc22a12)

Organic anion
transport
demonstrated

mRNA expression
detected in kidney

Protein expression
confirmed in kidney

✓
✓
✓
✓
-✓
✓
✓

✓
✓
✓
✓
--✓
✓

✓
✓
✓
✓
---✓

✓
✓
✓
✓
✓
✓
✓
-✓

✓
✓
✓
✓
-✓
✓
✓
✓

✓
✓
✓
✓
-✓
✓
✓
✓

a

Human OAT5 (SLC22A10) and rodent Oat5 (Slc22a19) are not orthologs, i.e., are not coded for
by the same gene and therefore do not represent the same transporter; rat and mouse Oat5 are
paralogs, i.e., represent the same gene across species and thus code for the same transporter
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1.B ORGANIC ANION TRANSPORTERS IN RENAL PROXIMAL TUBULE
As indicated in Table 1.1, species differences in known OAT family members do exist, with
OAT4 (SLC22A11), OAT5 (SLC22A10), and OAT7 (SLC22A9) being unique to humans and
Oat5 (Slc22a19), Oat6 (Slc22a20), Oat8 (Slc22a25), and Oat9 (Slc22a27) being restricted to
non-human species (most thoroughly explored in mice and rats). It is important to clarify that
OAT5 (SLC22A10) and Oat5 (Slc22a19) are not orthologs. Of the 11 OATs for which transport
activity has been demonstrated, OAT1 (SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8),
OAT4, and URAT1 (SLC22A12) proteins have been detected and localized in human kidney and
Oat1 (Slc22a6), Oat2 (Slc22a7), Oat3 (Slc22a8), Oat5, Oat8, Oat9, Oat10 (Slc22a13), and Urat1
(Slc22a12) proteins have been detected and localized in rodent kidney (2-5). OAT1/Oat1,
OAT2/Oat2, and OAT3/Oat3 are targeted to the basolateral membrane of renal proximal tubule
cells (Figure 1.1) and mediate the movement of substrate molecules from the blood into the cells
via dicarboxylate/organic anion exchange (2-4). In the apical membrane, OAT4 appears to
mediate substrate reabsorption from urine through exchange with dicarboxylates or hydroxyl
ions and URAT1/Urat1 mediates reabsorption of urate and other substrates by monocarboxylate
exchange (Figure 1.1). In rodent proximal tubules, Oat5 may mediate substrate reabsorption via
dicarboxylate exchange, however no information is available regarding the driving forces and
directionality of Oat9 (2-5). While Oat8 was identified as a dicarboxylate/organic anion
exchanger, immunohistochemistry localized this transporter to the apical membrane of
intercalated cells in the collecting ducts, with no signal in proximal tubule. Finally, organic anion
transport by OAT10 (SLC22A13) was reported to be driven by exchange with dicarboxylates or
hydroxyl ions, similar to OAT4, however localization information is restricted to brush border
membrane vesicles prepared from rat kidney (2-4).
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Figure 1.1. Organic anion transporters of the SLC22 family in human and rodent renal
proximal tubule cells
As illustrated, human and rodent orthologs of OAT1/Oat1, OAT2/Oat2, OAT3/Oat3,
OAT10/Oat10, and URAT1/Urat1 have been identified. Notable species differences are OAT4
having no identified rodent ortholog and Oat5 and Oat9 having no known human orthologs. Oat8
mRNA has been detected in rodent kidney, however it is expressed in cortical collecting ducts,
not in the proximal tubule; its membrane targeting is not known. The driving forces governing
Oat9 function have not been elucidated.
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1.C REGULATION OF OAT EXPRESSION
Mounting evidence suggests that OAT expression can be regulated at both the mRNA and
protein level. Examination of the promoter regions of the hOAT1, hOAT2, hOAT3, hOAT4, and
hURAT1 genes identified putative binding sequences for several transcription factors including
activating transcription factor 1 (ATF1), cAMP responsive element binding protein 1 (CREB1),
hepatocyte nuclear factors 1α, 1β, and 4α (HNF1α, HNF1β, HNF4α), paired box protein Pax-1,
B-cell lymphoma 6 protein, and Wilm’s tumor protein 1 (6-9). The presence of DNA binding
sequence motifs for known transcription factors suggest they might be involved in the regulation
of OATs and a number of recent studies have investigated this possibility.
Deletion analysis of the hOAT3 promoter indicated the sequence from -214 to -77 basepairs
was required for basal level transcriptional activity and this region was found to contain a
cAMP-response element (CRE) (8). Mutation of this sequence resulted in reduced hOAT3
promoter activity. Both ATF1 and CREB1 are known to bind to CRE, and subsequent
electrophoretic mobility shift assays (EMSA) confirmed binding of these transcription factors to
the hOAT3 promoter (8). Further, phosphorylation of CREB1 and ATF1 in response to activation
of protein kinase A (PKA) appeared to induce increased hOAT3 expression, suggesting
stimulatory effects of PKA on hOAT3 activity might be explained through increased
transcriptional activity (8).
The transcription factors HNF1α and HNF1β are expressed in the epithelia of many organs
including liver, kidney, and intestine (10-12). When explored in Hnf1α knockout mice, it was
observed that renal mRNA expression of mOat1, mOat2, mOat3, and mUrat1 was reduced (13,
14). Examination of the mOat1 and hOAT1 promoter regions revealed a HNF1 binding motif at 56 to -44 basepairs (15). Forced expression of HNF1α and HNF1β increased activity of both
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promoters, with HNF1α producing the greatest increase, followed by co-expression of HNF1α
and HNF1β, and expression of HNF1β alone producing little to no effect. EMSA analysis
detected binding of HNF1α homodimers and HNF1α/HNF1β heterodimers to the hOAT1
promoter (15). The promoter sequence of hOAT3 (-308 to +6 basepairs) also contains a HNF1α
motif, as do the rat and mouse orthologs (16). Mutation of the HNF1α motif reduced basal
hOAT3 promoter activity. Similar to hOAT1, expression of HNF1α increased hOAT3 and mOat3
promoter activity more than co-expression of HNF1α and HNF1β, however, in contrast,
expression of HNF1β alone also increased activity, although to a lesser extent (16). EMSA
analysis confirmed binding of HNF1α homodimers and HNF1α/HNF1β heterodimers to the
hOAT3 promoter (16). Repression of endogenous HNF1α expression in a human-derived liver
cell line (Huh7) with a small interfering RNA (siRNA) construct significantly decreased
expression of hOAT5 and hOAT7 message, but was without effect on hOAT2 mRNA expression
level (17). Binding and upregulation of hOAT5 and hOAT7 promoter activity by HNF1α was also
demonstrated, but as mentioned previously, these OATs are not expressed in kidney (17). The
hURAT1 (-253 to +83 basepairs) and mUrat1 (-261 to +80 basepairs) minimal promoter regions
were found to contain a HNF1 motif and mutation of the sequence in hURAT1 abolished
promoter activity (14). Both hURAT1 and mUrat1 responded to forced HNF1α and HNF1β
expression like hOAT3 and mOat3, suggesting HNF1α homodimers, HNF1α/HNF1β
heterodimers, and HNF1β homodimers all stimulate promoter activity with the same respective
order of potency as on hOAT3/mOat3 (14). In contrast to the other OATs, EMSA analysis
confirmed that HNF1β homodimers, in addition to HNF1α homodimers and HNF1α/HNF1β
heterodimers, could bind to the promoter region of hURAT1 (14). Lastly, two HNF1 motifs (at 97 to -85 and -41 to -29) were located in the hOAT4 promoter (18). Overexpression of either
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HNF1α or HNF1β alone, or in combination, enhanced hOAT4 promoter activity, and this
enhanced activity was blunted by mutation of either motif and abolished when both motifs were
mutated (18). When examined under conditions of endogenous HNF1α expression level (HepG2
cells), or endogenous HNF1α and HNF1β levels in combination (Caco-2 cells), promoter activity
was only responsive to the HNF1 motif at the -97 to -85 positions (18). Like hURAT1, EMSA
analysis demonstrated that HNF1β and HNF1α homodimers, as well as HNF1α/HNF1β
heterodimers, could bind this HNF1 motif; binding to the -41 to -29 motif was reported as barely
detectable (18). Since it has been determined that, in renal proximal tubules, HNF1α/HNF1β
heterodimers and HNF1β/HNF1β homodimers predominate, one or both of these complexes
likely influences OAT expression in vivo (12).
Another HNF family member, HNF4α, was observed to enhance the activity of both hOAT1
(-2747 to +88 basepairs) and hOAT2 (-679 to +54 basepairs) promoter constructs (19, 20).
HNF4α is known to have several potential sequence motifs; a direct repeat of hexamers
separated by one (DR-1) or two (DR-2) nucleotides, or an inverted repeat of hexamers separated
by 8 nucleotides (IR-8). For hOAT1, promoter scanning revealed the presence of a DR-2 motif
(at -875 to -862 basepairs) and an IR-8 motif (at -123 to -104 basepairs) (19). Co-expression of
HNF4α with constructs containing either one or both of these motifs resulted in increased hOAT1
promoter activity, which was diminished by mutation (19). Subsequent EMSA experiments
confirmed binding of HNF4α homodimers to each of these motifs in the hOAT1 promoter (19).
The promoter region of hOAT2 was found to contain a DR-1 type HNF4α consensus motif at
position -329 to -317 that is conserved in the rat ortholog (20). Presence of the wildtype
sequence correlated with HNF4α activated hOAT2 promoter activity and sequence mutation
resulted in loss of HNF4α activation (20). EMSA analysis demonstrated HNF4α binding to
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hOAT2 promoter fragments containing the motif and introduction of HNF4α siRNA constructs
markedly reduced endogenous hOAT2 mRNA expression in Huh7 cells (20).
Recently, microarray analysis identified B-cell lymphoma 6 protein (BCL6) as a transcription
factor exhibiting male dominant expression in rats (9). Since rOat1 and rOat3 had previously
been reported to exhibit male dominant expression that is modulated by steroid hormones (21),
the investigators examined the promoter regions for BCL6 consensus binding motifs. Five
putative BCL6 sequence motifs were identified in the promoter region of rOat1 and six in the
promoter of rOat3, no mention of whether these sites are found in the promoters of hOAT1
and/or hOAT3 was made (9). Expression activity of a construct corresponding to -2,252 to +113
basepairs of the rOat1 promoter, which contained 4 of the identified BCL6 sites, was increased
when BCL6 was co-expressed. Activity of a truncated construct (-1,266 to +113 basepairs)
containing only 2 of the sites showed a similar level of activity, suggesting that either not all of
the potential binding sites are functional or that response to binding of BCL6 is “all or none”,
and interaction with multiple sites does not further modulate expression level (9). A similar
effect was observed for rOat3, with a clear increase in promoter activity upon co-expression of
BCL6, but with no difference in the magnitude of effect between constructs containing six (2,567 to +12 basepairs), three (-752 to +12 basepairs), or two (-444 to +12 basepairs) BCL6
binding motifs (9).
In addition to transcriptional regulation, there is evidence supporting post-translational
regulation of OATs by protein kinases. As recently reviewed (3), there appeared to be a general
trend for decreased OAT1/Oat1 and OAT3/Oat3 activity via non-specific protein kinase C (PKC)
activation. However, a reported exception to this was stimulation of rat and mouse Oat1- and rat
and mouse Oat3-mediated transport upon activation of the atypical isoform PKCζ (22). Increased
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transport of para-aminohippurate (PAH), estrone sulfate, and adefovir was observed in renal
cortical slices in response to PKCζ activation (22). The effect on estrone sulfate transport was
not observed in slices prepared from Oat3 knockout mice. Direct binding of PKCζ to hOAT3
was demonstrated in a yeast two-hybrid system and binding to rOat3 was demonstrated by
immunoprecipitation and immunoblotting (22). Recently, another study confirmed the binding
and stimulatory effects of PKCζ on hOAT3 (23). In addition, the isoforms PKCδ and PKCε,
were observed to bind to hOAT3 (23). This was associated with increased hOAT3 at the cell
surface, with no effect on total cellular hOAT3, suggesting redistribution of hOAT3 from
intracellular compartments as the mechanism behind upregulation of transport activity (23). In
contrast, activation of the PKCα isoform by angiotensin II has been demonstrated to decrease
transport activity of hOAT1 and hOAT3 in concert with decreased cell surface expression (24).
Therefore, it appears as though the effects of PKC activation on OAT activity are PKC isoform
dependent, and can lead to either upregulation or downregulation of OAT activity depending
upon the specificity of PKC isoform activation. Thus, rapid short-term modulation of OAT
activity appears possible through changes in transporter cell surface expression via cycling in
and out of the membrane from a cytoplasmic pool of transporters under the control of kinases,
whereas long-term changes might involve alteration of gene transcriptional activity and,
presumably, protein synthesis.
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1.D OATs IN RENAL INJURY AND PROTECTION
Many clinical therapeutics, endogenous metabolic toxins, and xenobiotic toxins/toxicants
accumulate in renal proximal tubules cells and induce renal injury. Cellular damage can take a
variety of forms including oxidative stress, protein acylation, DNA-adduct formation,
mitochondrial dysfunction (impaired ATP synthesis), lipid peroxidation, and necrosis. In
opposition, a number of molecules purported to exert protective effects, such as antioxidant, antiinflammatory and anti-proliferative activities, also enter renal proximal tubule cells. There is
growing evidence from both in vitro and in vivo systems implicating OATs in the renal targeting
of these substances.
Inorganic mercury (Hg2+) accumulates preferentially in the kidneys and can result in acute
renal failure. Typical manifestations of mercury intoxication include renal vasoconstriction,
reduced glomerular filtration rate (GFR), enzymuria, tubular dilatation, and formation of
epithelial cell casts. Early in vitro and in vivo studies indicated that entry of mercury from the
systemic circulation into proximal tubule cells occurred via the same transport pathway as PAH
(recently reviewed in (2, 4). Subsequent studies using Madin Darby canine kidney (MDCK) cells
stably expressing hOAT1 indicated a direct correlation between hOAT1 expression and uptake
and toxicity of mercury-thiol conjugates (25, 26). Recently, direct in vivo evidence supporting
the role of OAT1/Oat1 in mediating mercury nephrotoxicity was obtained in studies utilizing
Oat1 knockout mice (27). Renal function and histopathology were examined in wildtype and
Oat1 knockout mice 18 hours post-intraperitoneal injection with HgCl2 (4 mg/kg). Wildtype
mice treated with HgCl2 exhibited significantly increased kidney:body weight ratio (indicative of
edema) and blood urea nitrogen (BUN) levels, as compared to saline injected wildtype animals
(27). These indicators of renal injury and renal insufficiency were significantly blunted in Oat1
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knockout mice treated with HgCl2 (27). Furthermore, histopathological markers of
nephrotoxicity observed in mercury treated wildtype mice, including tubular dilatation and
necrosis, and sloughing of the brush border membrane, were virtually undetectable in kidneys
from Oat1 knockout mice (27). These findings strongly support a major role for OAT1/Oat1 in
the pathology of renal mercury toxicity.
Renewed interest in complementary and alternative therapies, particularly in Western
cultures, has led to the increased use of herbal therapies. Often these are complex mixtures of
dried plants or plant extracts with poorly defined active components and unregulated
manufacturing processes. As they are marketed for their beneficial health effects, such therapies
are frequently viewed as being safe, however, a number of herbal medicines have produced
unwanted toxicities and drug interactions (28, 29). For example, Aristolochia plants, used in
herbal remedies for thousands of years in both Eastern and Western countries, contain the
nephrotoxic agent aristolochic acid (AA), identified as the causative agent in what is now
referred to as aristolochic acid nephropathy (AAN) (30-33). The proximal tubule has been
identified as the main target site for AAN in both humans and rodent models (34, 35). AA
collectively refers to a complex mixture of carboxylic acids, the major components of which are
AA-I and AA-II. The only structural difference between the two compounds is the presence of an
O-methoxy group at the 8-position of AA-I (36). Both AA-I and AA-II have metabolic
intermediates capable of forming DNA adducts that produce carcinogenic effects, however this
property is not linked to their toxicity, as only AA-I is nephrotoxic (37, 38). When examined
directly in overexpressing HEK-293 cell lines, AA-I was demonstrated to be a competitive
inhibitor of hOAT1, hOAT3, and hOAT4 with Ki values of 0.63 ± 0.15, 0.50 ± 0.10 and 20.63 ±
1.7 µM, respectively (39). Significantly increased AA-I DNA adducts were observed in all three
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transporter expressing cell lines as compared to non-transporter expressing cells, and this
increase was reversed in the presence of probenecid, supporting hOAT-mediated accumulation
of AA-I (39). In another in vitro study, both AA-I and AA-II were shown to inhibit hOAT1,
hOAT3, and hOAT4, but produced no effect on hOAT2 activity (40). Reported IC50 values
indicated that AA-I was a slightly better inhibitor than AA-II on all three transporters, although
the differences were not great; (in µM) 0.44 ± 0.08 and 1.06 ± 0.09 (hOAT1), 0.65 ± 0.08 and
1.28 ± 0.18 (hOAT3), and 61.3 ± 8.35 and 72.0 ± 9.32 (hOAT4), for AA-I and AA-II,
respectively (40). Recently, direct uptake of AA-I and AA-II was demonstrated for mOat1,
mOat2, and mOat3 indicating both compounds are high affinity substrates for these transporters
(36). Michaelis constants (Km values) correlated well with inhibitory values reported for the
human orthologs; (in µM) 0.791 ± 0.007 and 1.498 ± 0.371 (mOat1), 0.356 ± 0.050 and 0.673 ±
0.1192 (mOat2), and 0.514 ± 0.057 and 1.047 ± 0.360 (mOat3), for AA-I and AA-II,
respectively (36). Discrepancy of the results for mOat2 and hOAT2 in cellular uptake of AA-I
and AA-II may represent species differences.
Analysis of structural determinant effects on uptake indicated that the carboxyl group of AAI is key to high-affinity interaction with mOat1, mOat2, and mOat3, whereas the nitro group only
impacted interactions with mOat1 (36). Accumulation of AA-I in mouse renal cortical slices was
found to be probenecid-, PAH-, and estrone sulfate-sensitive, correlating with an OAT-mediated
transport process (36). Furthermore, this accumulation in slices resulted in AA-I DNA adduct
formation that was reversed by probenecid (36). In agreement with these findings, a recent in
vivo study in mice demonstrated that probenecid reduced the urinary excretion of AA-I and
protected the kidney from AA-I induced nephrotoxicity (41). Results in mOat1 and mOat3
knockout mice indicated that loss of function of either transporter was associated with decreased
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renal accumulation of AA-I and lessened the severity of renal injury as compared to wildtype
animals (41). Significant downregulation of rOat3, but not rOat1, protein also was observed after
long-term (7 days) administration of an AA mixture (42). Taken together, these findings strongly
suggest an OAT-mediated mechanism in the pathology of AAN and suggest inhibition of renal
OAT activity might serve as a potential therapeutic strategy following AA exposure.
Phenolic acids represent a growing class of OAT substrates/inhibitors. They are common
dietary constituents as they are produced from the amino acids phenylalanine and tyrosine in
plants (43). Many phenolic acids are also metabolically derived from anthocyanidins and
anthocyanins after consumption (44). They are purported to have beneficial health effects in
chronic diseases, e.g., diabetes, cardiovascular disorders, and cancer, through free radical
scavenging, anti-proliferative, and anti-inflammatory activities (43, 45-47), hence their growing
popularity as alternative medicines/dietary supplements. Interaction of the related dietary
polyphenols and human OATs was being investigated as many as seven years ago, when ellagic
acid was identified as a substrate for hOAT1 (IC50 = 207 nM), rOat1, and hOAT4, but not mOat2,
hOAT3, or mOat5 (48). More recently, the phenolic acids, lithospermic acid, protocatechuic acid,
rosmarinic acid, salvianolic acid A, salvianolic acid B, and tanshinol, identified as active
components of the traditional Chinese medicine Danshen (Salvia miltiorrhiza) which is utilized
in cardiovascular disease, were shown to inhibit mOat1- and mOat3-mediated transport (49).
Lithospermic acid, rosmarinic acid, and salvianolic acid A were found to be potent competitive
inhibitors; Ki constants were 14.9 ± 4.9 vs. 31.1 ± 7.0 for lithospermic acid, 5.5 ± 2.2 vs. 4.3 ±
0.2 µM for rosmarinic acid, and 4.9 ± 2.2 µM vs. 21.3 ± 7.7 µM for salvianolic acid A, on
mOat1 and mOat3, respectively (49). An extensive study showed the phenolic acids caffeic acid,
dihydrocaffeic acid, dihydroferulic acid, and ferulic acid were substrates of hOAT1 and/or
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hOAT3, while a number of their glucuronide- and sulfate-conjugated metabolites were effective
inhibitors (50). An independent study identified caffeic acid as a competitive inhibitor of both
hOAT1 and hOAT3 (IC50 = 16.6 and 5.4 µM, respectively) and demonstrated the potential for
food-drug interactions via inhibition of hOAT1 and hOAT3-mediated transport of antifolates and
antivirals (51). Inhibition of hOAT1 by gallic acid, protocatechuic acid, sinapinic acid, and
vanillic acid, and of hOAT3, by ferulic acid, gallic acid, gentisic acid, protocatechuic acid, and
sinapinic acid has been observed (52). IC50 values ranged from 1.24-18.08 µM on hOAT1 and
from 7.53-87.36 µM on hOAT3 (Appendix I) (52). Inhibition of hOAT1 by gallic acid, and of
hOAT3 by gallic or gentisic acid, was identified as having potential for clinically significant
food/drug-drug interactions. Human OAT4 activity was not affected by any of these compounds
(52). Whether or not any dietary polyphenols/phenolic acids actually promote human health or
improve disease outcomes remains unresolved. However, these studies provide clear evidence
for the potential of phenolic acids to interact with OATs and to produce food-drug interactions,
emphasizing the need to better understand the impact of transport processes on the distribution
and elimination of these compounds. Regardless of any health benefits through anti-oxidant or
anti-inflammatory-type activities, these compounds might provide an alternative treatment in the
management of OAT-mediated nephrotoxicity, without producing significant side effects.
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1.E OAT FUNCTION AND EXPRESSION IN MODELS OF RENAL INJURY AND
DISEASE
Renal function plays a vital role in the clearance of drugs and endogenous/exogenous toxins
and toxicants. The overall renal clearance of substances is determined by the net effect of
glomerular filtration, tubular secretion, and reabsorption processes. Renal disease states that
result in dysfunction or loss of function can greatly influence the rate of elimination and tissue
level of transporter substrates (53, 54). OATs, which are known to mediate the accumulation of
organic anions from the blood and urine into proximal tubule cells, can be affected by renal
failure and disease in terms of mRNA and protein expression level, transport activity, and
membrane cycling, showing altered renal clearance of their substrates (53-55).
Progression of chronic renal failure (CRF) leads to impaired activity and function of the
proximal tubule. In the laboratory, this pathological condition is mimicked with the 5/6
nephrectomy model, which replicates the onset of uremia and chronic kidney disease-related
complications observed in humans (56). More recently this model has been used to examine
changes in OAT protein levels in response to CRF (57-59). When examined 14 days postsurgery, Ji et al. found a 50% decrease in the renal clearance of unbound PAH, but no significant
changes in rOat1 or rOat3 protein levels by Western blot (57). In agreement, Torres and coworkers reported significant decreases in filtered, secreted, and excreted PAH at 168 days postsurgery in 5/6 nephrectomized animals vs. sham-operated controls (59). However, in this study
changes in renal PAH handling correlated with an ~40% decrease in rOat1 protein expression in
kidney homogenates and basolateral membrane preparations from CRF rats. Rat Oat3 protein
levels were also significantly reduced in kidney homogenates, but not in the basolateral
membranes (59). Finally, Naud, et al. detected reduced rOat1 (~40%), rOat2 (~40%), rOat3

17

(~87%), and rUrat1 (~38%) proteins in CRF vs. control animals 42 days after surgery, but renal
clearance was not examined in these animals (58).
While this model has the potential to yield much information on the effects of CRF on renal
OAT expression and function, several important differences between these studies need to be
noted (57-59). First, while described generically as 5/6 nephrectomized animals, the
methodologies used to establish the model varied considerably, with one study removing the
right kidney and ligating the posterior and anterior segmental branches of the left renal artery in a
single operation (57), and the others utilizing a “two-stage 5/6 nephrectomy” procedure wherein
the two poles of the left kidney were removed in one operation, followed by removal of the right
kidney during a second operation one week later (58, 59). Second, as indicated, the interval postsurgery when the observations were made varied widely between the studies. Third, the origins
of the antibodies used to visualize the OATs via immunoblotting, and the predicted weights of
the protein bands detected, differed. Ji et al., developed custom antibodies that detected ~77 kD
and ~72 kD bands for rOat1 and rOat3, respectively. These bands are bigger than the predicted
molecular weights of ~61 kD for rOat1 and ~59 kD for rOat3, however there is evidence
supporting post-translational glycosylation of OATs in vivo. Their findings are in good
agreement with published results with a polyclonal antibody directed against hOAT1 which
recognized an ~80 kD band in crude renal cortex homogenate that was reduced to ~60 kD upon
treatment with glycosidase, and matched an ~60 kD band corresponding to an unglycosylated
hOAT1 in vitro transcription/translation reaction product (60). The study by Torres, et al. used a
commercial rOat1 antibody (Alpha Diagnostics, Inc.) and reported an ~57 kD rOat1 band, and a
custom rOat3 antibody and reported an ~130 kD band for rOat3 (59). As indicated above, the
result for rOat1 would correspond nicely with its unglycosylated form, however, these were
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native kidney homogenates and no glycosidase treatment was performed. Since the protein
samples were reduced (boiled in the presence of mercaptoethanol and sodium dodecyl sulfate)
the reported rOat3 signal seems unexpectedly large. Naud, et al. used all commercial antibodies,
with anti-rOat1 and anti-rUrat1 from Abbiotec and anti-rOat2 and anti-rOat3 from Alpha
Diagnostics, Inc., and did not report the predicted molecular weight for any of the detected bands
(58). To aid interpretation of future studies it may be useful to standardize the 5/6 nephrectomy
surgical techniques used, optimize/standardize the time post-surgery experiments are conducted,
and perform more rigorous antibody characterizations prior to use, e.g., comparison of signal
across preparations from transporter expressing cell lines and/or transporter knockout mouse
tissues to confirm specificity/lack of cross-reactivity and predicted molecular weight of detected
protein(s).
In contrast to CRF, even a small reduction in renal blood flow can lead to hypoxic injury
and/or acute renal failure (ARF). ARF is commonly seen in critically ill patients and exhibits a
mortality rate exceeding 50% (61). Ischemia/reperfusion injury associated with disease or
physical injury is a common trigger for ARF, and once induced, ARF can lead to a systemic
build up of uremic toxins via a combination of reduced GFR and impaired tubular transport.
Ischemia/reperfusion injury is also observed in kidneys utilized for transplant and can result in
marked impairment of PAH extraction (62). This observation led to immunohistochemical
studies examining the cellular distribution of hOAT1 in biopsies obtained from cadaveric renal
allografts 1 hour post-reperfusion (63). While most allografts were seen to maintain some degree
of basolaterally targeted hOAT1, it appeared to be greatly reduced as compared to control tissues
and was accompanied by the appearance of fine and coarse ‘cytoplasmic aggregates’ positive for
hOAT1 (63). This correlated with depressed net tubular secretion of PAH in 15 out of 18 patients
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examined 3-7 days post-transplant (63). No clear association between total ischemic time, which
varied from 13-32 hours, could be made and it should be noted that patients were taking a
number of drugs known to interact with hOAT1 and hOAT3 when PAH secretion was measured.
None-the-less, these data support the contention that renal organic anion transport impairment
observed in some instances of disease, injury, or transplant induced ARF might be due to loss of
OATs in the proximal tubule cell membranes.
Experimentally induced ARF, achieved via clamping of the renal arteries, is a common
approach used to model this type of renal injury in the laboratory. When this same group
examined localization of rOat1 in the induced ARF model, redistribution of rOat1 was
observable with as little as 5 minutes of ischemia, but the amount of rOat1 protein did not
diminish until 1 hour post-reperfusion, and was still not fully recovered after 10 days (64). A
similar study examined rOat1 and rOat3 expression for 14 days following ischemia induced ARF
(65). Both transporter proteins showed a similar response to ARF, exhibiting a significant
reduction (~50%) from 6 hours to 3 days post-ischemia, returning to control levels by 7 days
post-injury (65). This loss and recovery of transporter protein levels correlated with effects on
the net renal secretion of PAH (a measure insulated from changes in GFR), which was
significantly reduced from 6 hours to 3 days post-reperfusion as compared to sham-operated
animals, returning to control levels by 7 days (65). Matsuzaki et al. also reported downregulation of rOat1 and rOat3 protein expression level in rat kidney 48 hours after ischemia (66).
Significant decline in accumulation of PAH and estrone sulfate in renal slices from ARF animals
suggested reduced transport capacity mediated by rOat1 and rOat3 (66). Interestingly,
administration of cobalt, a treatment proposed to stabilize hypoxia inducible factor 1, an oxygensensitive transcription factor which serves to upregulate certain genes under low oxygen

20

conditions, significantly blunted the downregulation of rOat3 protein, partially restoring estrone
sulfate accumulation in renal slices (66). The treatment was without effect on rOat1 or PAH
accumulation (66).
The apical transporter rOat5 also has been demonstrated to be downregulated in response to
ischemia induced ARF (67). When examined 1 hour post-reperfusion after 5 minutes of ischemia,
no change in rOat5 protein level was detected in renal homogenates or apical membrane
preparations. However, if ischemia was maintained for 1 hour, a significant reduction (~40%) in
rOat5 was observed (67). Regardless, rOat5 protein levels detected in urine (relative to urinary
creatinine) were significantly elevated 1 hour after either 5 or 60 minutes of ischemia, leading
the authors to suggest that urinary excretion of rOat5 protein may serve as a sensitive, noninvasive measure of renal functional and structural integrity following renal injury or during
renal dysfunction (67). Since there is no identified human ortholog of rodent Oat5, the clinical
utility of this finding is unclear. However, urinary hOAT1, hOAT3, and hOAT4 protein levels
were recently examined in patients diagnosed with acute kidney injury (AKI) (68). Two AKI
patient groups were identified, those who recovered without intervention (“early reversible
proximal tubular damage”) and those who required intervention in the form of dialysis (“severe
AKI”). Patients who suffered “early reversible proximal tubular damage” exhibited increased
urinary levels of hOAT1 and hOAT3, but decreased levels of hOAT4, as compared to controls,
and patients experiencing “severe AKI” exhibited increased urinary levels of all three
transporters (68). The authors speculated that in patients with “early reversible proximal tubular
damage” the transporters became mistargeted, with basolateral hOAT1 and hOAT3 translocating
to the apical membrane and sloughing into the urine with apical hOAT4 moving ‘inward’,
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whereas “severe AKI” resulted in proximal tubule cell apoptosis. Whether such a profound
mechanism is the underlying cause of the observed patterns is unclear at this time.
There is clear evidence that prostaglandin E2 (PGE2) plays a role in the downregulation of
OAT1/Oat1 and OAT3/Oat3 in response to ARF and CRF. Dose-dependent downregulation of
both rOat1 and rOat3 protein expression by PGE2 (IC50 ~25 nM) was demonstrated in NRK-52E
cells, which are a rat renal proximal tubular cell model (69). Cortical PGE2 levels are elevated in
response to ARF and CRF and inhibition of the cyclooxygenase (COX) cascade was shown to
exert protective effects (70-72). Since COX-1 and COX-2 mediate prostaglandin synthesis from
arachidonic acid, it is thought that COX inhibitors work by preventing generation of cortical
PEG2 in response to injury. Accordingly, in the ischemia/reperfusion rat model, administration of
the nonselective COX inhibitor indomethacin (1 mg/kg) immediately post-ischemia completely
reversed ARF-induced downregulation of rOat1 and rOat3 protein expression levels within 24
hours (73). Moreover, renal PAH net secretion was also recovered (73). In a different study, the
COX-2 specific inhibitor, parecoxib, was found to produce similar effects when administered 1
hour (20 mg/kg intraperitoneally) prior to the start of ischemia (74). When examined 12 hours
post-reperfusion both rOat1 and rOat3 protein levels were significantly higher than in ARF
animals that did not receive parecoxib, however the levels were still significantly reduced as
compared to sham control animals (74). Similarly, PAH secretion was markedly restored in
parecoxib animals, but still blunted as compared to sham controls (74). Whether this difference is
due to the shorter duration post-reperfusion that the animals were examined (12 vs. 24 hours) or
to the more selective action of parecoxib vs. indomethacin is not known. Together, these data
strongly implicate induced PGE2 as being responsible for the downreguation of OATs observed
in CRF, ARF, and human renal allografts.
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1.F OATs AND DRUG-DRUG INTERACTIONS
Following the development of probenecid as an agent to block the renal elimination of
penicillin almost 70 years ago, clinical reports of probenecid-mediated DDIs resulting in altered
distribution and renal elimination of a variety of drugs, including other β-lactams, cephalosporin
antibiotics, fluoroquinolone antimicrobials, diuretics, and chemotherapeutic agents, began to
appear (75-78). Modern studies using cloned transporters and knockout mouse lines have
demonstrated a clear role for OATs in mediating, at least in part, a number of these DDIs (3, 7985). Recently, a clinical study using healthy volunteers demonstrated that when probenecid was
administered concomitantly with mesna, a cancer chemotherapy adjuvant used to decrease the
renal toxicity of some chemotherapeutic agents, the fraction of mesna secreted was reduced by
67% and total mesna renal clearance was decreased by 55% (86). Moreover, hOAT1, hOAT3,
and hOAT4 were demonstrated to mediate the probenecid-sensitive transport of mesna and
dimensa in vitro, with inhibitory constants (Ki) in the ~15-30 µM range, values below their
clinical concentrations, strongly implicating OATs in this DDI as well as having a vital role in
the effectiveness of this therapy (86).
Patients taking paravastatin and gemfibrozil in combination to control their cholesterol and
triglyceride levels have experienced alterations in pravastatin pharmacokinetics (increased
plasma levels and decreased renal clearance) and been reported to suffer from increased
pravastatin-associated adverse events (87). Subsequent work indicated this DDI might be the
result of gemfibrozil inhibition of hOAT3-mediated paravastatin transport in these patients (88).
Another lipid altering agent, gemcabene, has been implicated in exacerbating blood pressure
reduction when co-administered with the angiotensin converting enzyme inhibitor, quinapril, in
hypertensive patients (89). When examined in vitro, gemcabene was found to inhibit hOAT3
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transport of quinaprilat, the pharmacologically active quinapril metabolite, in a dose-dependent
manner, suggesting a DDI involving hOAT3 as the molecular basis for the observed increase in
pharmacological activity (89).
Clearly, renally expressed OATs are poised to make great contributions to the
pharmacokinetic profiles of many clinical therapeutics, having significant impact on their dosing
regimens, pharmacodynamics, efficacy, and toxicity. OATs have great potential to be the sites for
many clinically relevant DDIs, and the conclusive identification of their contributions to such
interactions is expanding. In recognition of these facts, a recent whitepaper by the “International
Transporter Consortium” (90), in conjunction with guidance documents issued by the United
States

Food

and

Drug

Administration

(FDA)

(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM292362.pdf)

and

by

the

European

Medicines

Agency

(http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?
webContentId=WC500090112&murl=menus/document_library/document_library.jsp&mid=WC
0b01ac058009a3dc&jsenabled=true), have provided recommendations concerning which
transporters are thought to have sufficient evidence regarding their impact on drug disposition
and pharmacokinetics (e.g., hOAT1, hOAT2, and hOAT3) to warrant investigation of new
molecular entities for interactions, as a substrate or inhibitor, during the drug development
process. In the whitepaper, it was recommended that in vitro studies with transporter expressing
cell lines should be conducted to determine if the compound is a substrate, if the renal clearance
is greater than or equal to 50% of the total clearance (considered to be substantial and clinically
important) and greater than 1.5 times the unbound fraction times the GFR (90). The FDA
guidance recommends that greater than 2 fold accumulation over background in transporter
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expressing cells is necessary to regard the compound as a substrate. If these conditions are met,
clinical DDI studies should be considered. For compounds found to be inhibitors of these
transporters, if the ratio of the unbound maximum serum level (Cmax or Css) divided by the
compound-specific inhibition potency (Ki or IC50) is greater than or equal to 0.1, clinical DDI
studies are recommended. In 2010, VanWert et al. provided a comprehensive table on OATs
summarizing the orthologs studied, compounds reported to interact with each of the OATs,
whether they were confirmed substrates or only examined as inhibitors, and their affinities
(reported Km, Ki, or IC50 values) that is a useful reference tool when exploring such assessments
(3). In Appendix I of this work we provide an update to the 2010 table, focusing on recent
publications (2010-2012) in this area.
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1.G CONCLUSIONS
Over the last fifteen years great progress has been made in identifying the biological
properties, physiological roles, and biopharmaceutical significance of OATs. However, more
effort is required to better define the role of OATs in ‘normal’ physiology, their changing
function across an organism’s lifespan, and their response to toxic exposure, whether
environmental or as part of disease progression. While single nucleotide polymorphisms (SNPs)
have been identified in both coding and regulatory regions of hOAT1, hOAT3, hOAT4, and
hURAT1, most identified SNPs have failed to significantly impact OAT expression and function
(91-96). Thus, modulations in OAT expression and transport activity through transcriptional and
post-translational mechanisms might exert greater influence on the individual variations in
pharmacokinetics and drug efficacy observed in clinical investigations, at different
developmental stages (e.g., pediatric vs. geriatric), and during progression of certain diseases
(97-99). A more thorough understanding of these processes, in addition to OAT substrate
specificity, might lead to new approaches for protecting renal function after injury or toxic insult,
or for manipulating renal secretory or reabsorptive pathways to more effectively remove or
reclaim endogenous metabolites and xenobiotics. Greater insight to the pathophysiogical changes
to normal renal proximal tubule cell functions vital to OAT activity, e.g., production of the
intracellular mono- and dicarboxylates utilized as counterions by exchangers, would also be
invaluable. As we move forward in our study of renal OAT function and make determinations as
to the likely significance of DDIs involving OATs we need to remember that, while we have
come a long way, there is still much we do not know and this changing context (e.g.,
developmental stage, long-term polypharmacy, disease) might transcend a previously trivial
interaction to one of great significance.
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CHAPTER 2

RESEARCH HYPOTHESES AND SPECIFIC AIMS

2.A HYPOTHESES:
2.A.1 Flavonoids, phenolic acids, and other organic acid components of natural products exhibit
significant inhibitory effects on human OATs (e.g., hOAT1, hOAT3, and hOAT4) and their
murine orthologs (e.g., mOat1 and mOat3).
2.A.2 Compounds identified as strong OAT inhibitors have the potential to perpetrate
transporter-mediated drug-drug interactions based on their affinity (Ki and IC50) and clinical
unbound plasma concentration.
2.A.3 Compounds identified as strong OAT inhibitors and undergone active tubular secretion
have the potential to be substrates for OATs.
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2.B SPECIFIC AIMS TO ADDRESS THE ABOVE HYPOTHESES:
2.B.1 SPECIFIC AIM 1
To characterize the inhibitory effects of components of natural products on transport activity
mediated by human (h) OATs, hOAT1, hOAT3, and hOAT4 and the murine orthologs mOat1
and mOat3 using stably-expressing cell lines and radiolabeled prototypical substrates and known
OAT inhibitors.
2.B.2 SPECIFIC AIM 2
1. To determine initial rates of cellular transport of prototypical substrates in OAT expressing
cells and estimate the Km values for individual transporters.
2. To estimate IC50 and Ki values for the selected compounds for individual transporters.
3. To collect clinical literature values for unbound plasma concentrations of the selected
compounds and calculate the DDI index (ratio of unbound Cmax/ IC50 (or Ki) based on
“Guidance for Industry: Drug Interaction Studies” recently issued by the FDA.
2.B.3 SPECIFIC AIM 3
1. To develop a robust, specific, and sensitive liquid chromatography tandem mass spectrometry
(LC-MS/MS)-based method for quantification of gallic acid and gentisic acid in cell lysate. A
complete method validation, required by “Guidance for Industry: Bioanalytical Method
Validation” issued by the FDA, will be conducted to evaluate sensitivity, selectivity, withinrun and between-run precision and accuracy, recovery, stability, and matrix effects.
2. To apply the developed assay on the measurement of the cellular uptake of gallic acid and
gentisic acid in stably transfected mOat1- and mOat3-expressing cells.
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CHAPTER 3

ACTIVE HYDROPHILIC COMPONENTS OF THE MEDICINAL HERB SALVIA
MILTIORRHIZA (DANSHEN) POTENTLY INHIBIT ORGANIC ANION
TRANSPORTERS 1 (SLC22A6) and 3 (SLC22A8)
Drawn from manuscript published in Evid Based Complement Alternat Med. vol.2012, Article ID
872458, 8 pages, 2012.

3.A INTRODUCTION
The Chinese herbal medicine, Danshen (Salvia miltiorrhiza), has been employed for
thousands of years in the relief of symptoms of cardiovascular disease (100-102). Despite this
long history of medicinal use, the issue of which component(s) is(are) responsible for its
therapeutic effects, and the precise biochemical mechanisms underlying their absorption,
distribution and elimination, remain largely unknown. Increasingly, six hydrophilic compounds,
lithospermic acid (LSA), protocatechuic acid (PCA), rosmarinic acid (RMA), salvianolic acid A
(SAA), salvianolic acid B (SAB), and tanshinol (TSL), are gaining favor as the Danshen
components responsible for the beneficial effects on heart disease (103-105). Since these
compounds are organic, small in size (154-718 Da), and exist as anions at physiological pH, it is
possible that they are substrates and/or inhibitors of the organic anion transport pathway that
exists in organs such as the kidney, liver, intestine, and choroid plexus (3).
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We now know that this organic anion transport pathway is actually a complex system of
transport proteins that belong to a variety of gene families. Members of the solute carrier (SLC)
superfamily, composed of ~55 gene families containing almost 400 identified transporters, are an
important component of this pathway (2, 3, 106). Of particular interest for the Danshen
components examined in this work is the SLC22 (organic cation/anion/zwitterion transporters)
family, which includes both the organic cation transporters and the organic anion transporters
(OATs). Members of the OAT family are found in virtually every barrier tissue in the body and
mediate the transepithelial flux (absorption, distribution and elimination) of a multitude of
endogenous and xenobiotic compounds (2, 3, 106). Typical endogenous OAT substrates include
sulfated steroid conjugates, indoxyl sulfate, uric acid, and acidic metabolites of monoamine
neurotransmitters. Xenobiotic substrates include clinically important therapeutics such as
antibiotic (benzylpenicillin), antiviral (adefovir, cidofovir) and anticancer (methotrexate) agents,
statins, and angiotensin-converting enzyme inhibitors, as well as environmental toxins such as
ochratoxin A and aristolochic acid (2, 3, 36)
Currently, there are 29 putative SLC22 family members, 18 of which are believed to be
OATs. Of those, transport activity has been demonstrated for eleven, OAT1-10 and URAT1 (2,
3). OATs expressed in the proximal tubule cells of the kidney mediate the blood to urine
secretory flux and urine to blood reabsorptive flux of substrate compounds (2, 3, 106). Since
these compounds are negatively charged, OATs provide a passageway through which they can
readily cross the lipid bilayer of cells. Substrate entry into proximal tubule cells from the blood
across the basolateral membrane is energized by exchange for intracellular α-ketoglutarate (i.e.,
organic anion/dicarboxylate exchange). In humans and rodents this process involves the
basolateral exchangers, organic anion transporter 1 (Oat1; Slc22a6) and 3 (Oat3; Slc22a8) (107,
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108). OAT-mediated exit of organic anions from the cell into the urine is accomplished via
facilitated diffusion using the electrochemical gradient. There appears to be distinct species
differences between rodents and humans in terms of OATs targeted to the apical membrane of
proximal tubule cells. For example, while both species express Urat1 (Slc22a12), humans also
have OAT4 (SLC22A9; no current rodent ortholog), whereas rodents have Oat5 (Slc22a19; no
human ortholog identified) (2, 3).
The basolateral uptake transporters Oat1 and Oat3 share a high degree of amino acid
sequence identity (mOat1 vs. mOat3 = 48% and hOAT1 vs. hOAT3 = 50%). This protein
homology likely contributes to the greatly overlapping substrate profiles exhibited by these two
transporters. However, despite this general similarity, the individual affinities for the same
substrate often differ greatly between Oat1 and Oat3 (3). Further, unique substrates that interact
with Oat1, but not with Oat3 (and vice-versa) have been identified (3). Preclinical in vivo studies
utilizing knockout mouse lines have also demonstrated that, in terms of renal transport function,
expression of Oat1 does not fully compensate for loss of Oat3 (and vice-versa) (80-82, 85). For
example, Oat1 knockout mice exhibited complete loss of active tubular para-aminohippuric acid
(PAH) secretion and decreased renal clearance of the diuretic, furosemide, which was
accompanied by significantly decreased efficacy (monitored as decreased natriuresis and
increased ED50) (85). Pharmacokinetic studies performed in Oat3 knockout mice detected
reduced clearance and increased plasma half-life of benzylpenicillin, ciprofloxacin, and
methotrexate (80-82). However, PAH clearance was unaffected in these animals (81).
To more fully understand the therapeutic efficacy (and/or adverse effects) of herbal products
and optimize their clinical use, a more thorough identification of the active components they
contain and greater knowledge of the mechanisms determining their pharmacokinetic and
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pharmacodynamic properties, e.g., transporter interactions, need to be elucidated. The aim of the
present study was to characterize the effects of six active hydrophilic Danshen components on
the transport activity of mOat1 and mOat3. Danshen components producing the greatest
inhibition were examined further in studies designed to elucidate the mechanism of inhibition
(competitive vs. non-competitive vs. uncompetitive). Combining this information with dose
response data we derived inhibitory constants (Ki values). Evidence was gathered showing that
LSA, RMA, and SAA serve as potent competitive inhibitors of mOat1 and mOat3 and indicating
the potential for marked herb-drug interactions, such as altered pharmacokinetics and
pharmacodynamics of co-administered clinical therapeutics that are OAT substrates.
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3.B MATERIALS AND METHODS
3.B.1 Purified chemicals
The Danshen components LSA, PCA, RMA, SAA, SAB, and TSL
≥ 96%
( purity) were
obtained from Tauto Biotech (Shanghai, China). Their chemical structures are illustrated in
Figure 3.1. Tritiated PAH ([3H]PAH) and estrone sulfate ([3H]ES) were purchased from
PerkinElmer Life and Analytical Sciences (Waltham, MA) and unlabeled PAH, ES, and
probenecid were purchased from Sigma-Aldrich (St. Louis, MO).
3.B.2 Tissue culture
Derivation of the stably transfected Chinese hamster ovary (CHO) cell lines expressing
mOat1 (CHO-mOat1), mOat3 (CHO-mOat3), and the empty vector (FRT) transfected control
cell line (CHO-FRT), was described previously (80, 82). Cell lines were maintained at 37°C with
5% CO2 in DMEM F-12 media (Mediatech, Inc., Herndon, VA) containing 10% serum, 1%
Pen/Strep and 125 µg/ml hygromycin B.
3.B.3 Cell accumulation assays
Cell transport assay procedures were adapted from those previously published (82, 109). In
brief, 2 × 105 cells/well were seeded in 24-well tissue culture plates and grown in the absence of
antibiotics for 48 hr. On the day of the experiment cells were equilibrated with transport buffer
for 10 min [500 µL of Hanks’ balanced salt solution containing 10 mM HEPES, pH 7.4].
Equilibration buffer was replaced with 500 µL of fresh transport buffer containing 5 µM
[3H]PAH or 1 µM [3H]ES (0.25 µCi/mL) with or without inhibitors. After incubation, cells were
immediately rinsed three times with ice-cold transport buffer, lysed, and analyzed via liquid
scintillation counting. Uptake values were normalized to corresponding total protein content in
cell lysates as determined by the Bradford method. Substrate accumulation is reported as
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Figure 3.1. Chemical structures of six active hydrophilic Danshen components.
MW, molecular weight.
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picomoles of substrate per milligram protein. Substrate concentration and accumulation time
used for kinetic analysis of mOat3 (1 µM ES for 1 min, Km = 12.2 ± 4.8 µM) were determined
previously (82). Substrate concentration (Figure 3.3) and accumulation time (data not shown) for
mOat1 kinetic analysis (5 µM PAH for 2 min, Km = 13.0 ± 3.3 µM) were determined in this
study. Kinetic calculations were performed using GraphPad Prism Software version 5.0
(GraphPad Software Inc., San Diego, CA). Michaelis constant (Km) values were calculated by
nonlinear regression using the Michaelis-Menten model. Mode of inhibition was identified by
using mixed model inhibition analysis (110):

Vmax Apparent =

Vmax
(1 + [ I ] / (α × K i ))

K m Apparent = K m
Y=

1 + [ I ] / Ki
(1 + [ I ] / (α × K i ))

Vmax Apparent × x
K m Apparent + x

where Vmax, Ki, and I represent the maximum transport velocity without inhibitor, the inhibition
constant generated from the data set under analysis, and the concentration of inhibitor,
respectively. In this study, three curves were constructed (no inhibitor, plus two selected
inhibitor concentrations) with uptake of substrate plotted as a function of its concentration for
each condition. These untransformed data were fit to the equations shown above using nonlinear
regression to estimate the α values summarized in Table 3.1. The parameter, α, can then be used
to determine the mode of inhibition. When α is very large (α > 1), it indicates competitive
inhibition. Otherwise, it indicates noncompetitive inhibition (α = 1) or uncompetitive inhibition
(0 < α < 1). To estimate Ki values, IC50 values were calculated using nonlinear regression and
inserted into the Cheng-Prusoff equation: Ki = IC50/(1 + [Substrate]/Km) (111). Results were
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confirmed by repeating all experiments at least three times with triplicate wells for each data
point in every experiment.
3.B.4 Statistics
Data are reported as mean ± S.D. or mean ± S.E.M. as indicated. Statistical differences were
assessed using one-way ANOVA followed by post-hoc analysis with Dunnett’s t-test or using
Student’s unpaired t-test, as indicated (α = 0.05).
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3.C RESULTS
3.C.1 Inhibition of mOat1 and mOat3 by hydrophilic Danshen components
Accumulation of PAH in the CHO-mOat1 cell line (98.5 ± 14.6 pmol/mg protein/10 min)
was ~30 fold greater than that in the background control CHO-FRT cells (3.3 ± 0.7 pmol/mg
protein/10 min; Figure 3.2A). Initially, an uptake assay with excess (1 mM) Danshen
components was performed to identify which, if any, of the compounds might interact with
mOat1 (Figure 3.2A). Each of the Danshen components, LSA, PCA, RMA, SAA, SAB, and TSL,
significantly inhibited PAH uptake in CHO-mOat1 cells (P < 0.001) under these conditions. LSA,
SAB, and TSL produced approximately 70-85% inhibition, whereas PCA, RMA, and SAA, each
reduced PAH accumulation to the background level (> 95% inhibition), similar to the
prototypical OAT inhibitor, probenecid. Further, addition of these compounds (1 mM) did not
significantly influence the low, probenecid-insensitive (i.e., non-specific) PAH uptake in the
CHO-FRT cells (data not shown), indicating that the reduction in uptake of PAH in the CHOmOat1 cells is attributable to inhibition of mOat1 activity and that CHO-FRT PAH level serves
as an appropriate background correction factor.
Stably transfected mOat3-expressing (CHO-mOat3) cells showed significantly greater
accumulation of ES (~20 fold) relative to control CHO-FRT cells (5.02 ± 0.19 vs. 0.25 ± 0.04
pmol/mg protein/10 min, respectively; Figure 3.2B). Similar to mOat1, all of the Danshen
components (1 mM) significantly inhibited mOAT3-mediated ES uptake (P < 0.001). SAB and
TSL produced approximately 53% and 55% inhibition, respectively. LSA, PCA, RMA, and SAA,
like probenecid, blocked virtually all (> 91%) mOat3-mediated ES transport (Figure 3.2B). As
with PAH, these compounds (1 mM) failed to consistently or significantly influence non-specific
ES uptake in CHO-FRT cells (data not shown), indicating that the reduction in uptake of ES in
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Figure 3.2. Inhibition profile of mOat1 and mOat3
A: Inhibition of mOat1-mediated uptake of [3H]PAH (5 µM) by LSA, PCA, RMA, SAA, SAB,
TSL, and probenecid (1000 µM) was measured in the CHO-mOat1 cells (10 min). Background
PAH accumulation was measured in CHO-FRT cells in the absence of inhibitor and is shown to
provide a clear gauge of the low background in the experimental system. B: Inhibition of mOat3mediated uptake of [3H]ES (1 µM) by LSA, PCA, RMA, SAA, SAB, TSL, and probenecid (1000
µM) was measured in the CHO-mOat3 cells (10 min). Background ES accumulation was
measured in CHO-FRT cells in the absence of inhibitor and is shown to provide a clear gauge of
the low background in the experimental system. Values are mean ± S.D. of triplicate values. ***
denotes p < 0.001 as determined by one-way ANOVA followed by Dunnett’s t-test.

38

the CHO-mOat3 cells is attributable to inhibition of mOat3 activity and that CHO-FRT ES level
serves as an appropriate background correction factor.
3.C.2 Determination of the type of inhibition induced by Danshen components on mOat1 and
mOat3
Although PCA exhibited as potent inhibition as LSA, RMA, and SAA, it is not a major
component in Danshen preparations. Therefore, the mechanism of inhibition of mOat1/mOat3mediated transport of PAH/ES was investigated for LSA, RMA, and SAA (Table 3.1). Our
previous work with CHO-mOat3 cells showed that ES accumulation was linear through the first
5 min and that ES exhibited a Km of 12.2 ± 4.8 μM (82). In this study, time course evaluations in
CHO-mOat1 cells indicated PAH accumulation was linear through at least the first 5 min and Km
was estimated as 13.0 ± 3.3 μM (Figure 3.3). Using these parameter estimates as guidelines,
kinetic experiment conditions were set to 1 µM ES for 1 min and 5 µM PAH for 2 min. The
background corrected untransformed data for LSA, RMA, and SAA on mOat1 or mOat3 were fit
to the mixed inhibition model, which incorporates competitive, non-competitive, and
uncompetitive inhibition modes. The estimated α values were found to be much larger than 1,
indicating that inhibition of mOat1- and mOat3-mediated transport by LSA, RMA, and SAA was
competitive in nature (Table 3.1).
3.C.3 Inhibition potencies of LSA, RMA, and SAA
To allow direct comparison of inhibition potencies of LSA, RMA, and SAA for mOat1 and
mOat3, experiments were conducted to determine the inhibition constant (Ki) values (Figures 3.4
and 3.5 and Table 3.2). Since LSA, RMA, and SAA were found to be competitive inhibitors of
mOat1- and mOat3-mediated transport, subsequent Ki analysis was performed using competitive
inhibition. Applying increasing concentrations of unlabeled test compounds (10-7 to 5×10-4 M),
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inhibition of mOat1- or mOat3-mediated transport was measured (Figures 3.4 and 3.5).
Inhibition constants were estimated as 14.9 ± 4.9 µM for LSA, 5.5 ± 2.2 µM for RMA, and 4.9 ±
2.2 µM for SAA on mOat1-mediated transport (Table 3.2). Values determined in the CHOmOat3 cell line were 31.1 ± 7.0 µM for LSA, 4.3 ± 0.2 µM for RMA, and 21.3 ± 7.7 µM for
SAA (Table 3.2). For all of these analyses the coefficient of determination (r2) was > 0.9. No
significant differences between Ki values for mOat1 and mOat3 were detected as determined by
a Student’s unpaired t-test.
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Figure 3.3. Michaelis-Menten kinetics of PAH transport in CHO-mOat1 cells
In order to calculate Ki values for mOat1, the Km value for PAH needed to be determined in the
CHO-mOat1 cell system. Uptake of [3H]PAH was measured for 2 min at room temperature in
CHO-mOat1 (closed triangles) and CHO-FRT (open squares) cells in order to construct a
saturation curve. The corrected curve (closed circles) was obtained by subtracting the nonspecific background uptake as measured in the CHO-FRT cells from CHO-mOat1 accumulation
to allow analysis of mOat1-mediated activity. Experiments were repeated three times in triplicate
and Michaelis constant (Km) values were calculated by nonlinear regression using the MichaelisMenten model. The Km for PAH on mOat1 was estimated as 13.0 ± 3.3 μM (mean ± S.E.M.).
Graph shown is from a representative experiment with values plotted as mean ± S.D. (n=3).
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Figure 3.4. Ki determination for LSA, RMA, and SAA in the CHO-mOat1 cell line
Two minute uptake of [3H]PAH (5 µM) in CHO-mOat1 cells was measured in the presence of
increasing concentrations (10-7 to 5×10-4 M) of LSA, RMA, and SAA. Data were corrected for
non-specific background measured in the CHO-FRT cells prior to kinetic analysis. Ki values
were determined with non-linear regression and the “one-site competition” model using
GraphPad Prism software. Experiments were repeated three times in triplicate with the mean Ki
± S.E.M. reported in Table 3.2. Graphs shown are from representative experiments with values
plotted as mean ± S.D. (n=3).
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Figure 3.5. Ki determination for LSA, RMA, and SAA in the CHO-mOat3 cell line
One minute uptake of [3H]ES (1 µM) in CHO-mOat3 cells was measured in the presence of
increasing concentrations (10-7 to 4×10-4 M) of LSA, RMA, and SAA. Data were corrected for
non-specific background measured in the CHO-FRT cells prior to kinetic analysis. Ki values
were determined with non-linear regression and the “one-site competition” model using
GraphPad Prism software. Experiments were repeated three times in triplicate with the mean Ki
± S.E.M. reported in Table 3.2. Graphs shown are from representative experiments with values
plotted as mean ± S.D. (n=3).
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Table 3.1. Estimated α values from a mixed inhibition model analysis for LSA, RMA, and
SAA
Compound
LSA
RMA
SAA

mOat1
6.7 × 1011
1.3 × 1012
2.6 × 1014

Values are reported as mean. The S.E.M. is not applicable in this analysis.
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mOat3
1.9 × 1015
2.5 × 1019
3.4 × 1014

Table 3.2. Estimated Ki (µM) values for mOat1- and mOat3-mediated transport
Compound

mOat1

mOat3

LSA
RMA
SAA

14.9 ± 4.9
5.5 ± 2.2
4.9 ± 2.2

31.1 ± 7.0
4.3 ± 0.2
21.3 ± 7.7

Ki Ratio
(mOat1/ mOat3)
0.48
1.29
0.23

Values are reported as mean ± S.E.M. (n=3). No significant differences between Ki values for
mOat1 and mOat3 were detected (P < 0.05) as determined by Student’s unpaired t-test.
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3.D DISCUSSION
Many natural products, which are extracted from living organisms, have beneficial biological
or pharmacological activities and have been used as medicines throughout the world for more
than 1,000 years. Today, they are often used as first-line therapeutics, dietary supplements, or
complementary/alternative medicines and it is reported that ~20% of adults in the United States
are taking an herbal product (112). Over the last decade a number of studies have identified
transporter proteins, including OATs, as sites of drug-drug and natural product-drug interactions.
For example, the dietary polyphenol, ellagic acid, which exhibits beneficial antioxidant and
anticancer properties, was demonstrated to be one of the most potent inhibitors of hOAT1 (IC50 =
207 nM) identified to date (48). Recently, the nephrotoxin aristolochic acid, which is produced
by Aristolochia sp. plants, was identified as the causative agent for “Chinese herbs nephropathy”
(now referred to as aristolochic acid nephropathy). When investigated, aristolochic acid was
found to be a high affinity substrate for both mOat1 (Km = 790 nM) and mOat3 (Km = 514 nM),
suggesting these transporters may be key mediators in the renal proximal tubule cell
accumulation of this toxicant (36, 113). Thus, this interaction likely explains the biochemical
mechanism underlying the acutely targeted, proximal tubule specific nature of aristolochic acid
toxicity. Clearly, OATs expressed in the renal proximal tubule represent highly probable sites of
natural product-drug (or natural product-endogenous substrate) interactions. Further studies such
as these are needed in order to establish informed safety and efficacy profiles for herbal products.
Danshen, a traditional herbal medicine, continues to be used in the treatment of angina,
myocardial ischemia, and other cardiovascular diseases throughout the world including Asia,
Europe, and North America (100). In 2010, the Danshen pharmaceutical product, Fufang
Danshen Dripping Pill, successfully completed Phase II clinical trials in the United States

46

(http://clinicaltrial.gov/ct2/show/NCT00797953?term=tasly&rank=1). To date, however, no
formal studies examining the interaction between OATs and hydrophilic Danshen compounds,
which are small organic acids and known to be major components in its pharmaceutical products,
have been reported. Therefore, in the present study we investigated whether any of the six
purported active Danshen components, LSA, PCA, RMA, SAA, SAB, and TSL, interacted with
the transporters mOat1 and/or mOat3 (Figures 3.1 and 3.2).
A major advantage of this study is that, while Danshen preparations (and indeed the majority
of herbal medicines) include multiple active components, purified preparations of individual
Danshen extract components were used. Thus, the strength of interaction of each compound
could be quantified independently vs. the merged effects of a mixture containing all of the
compounds. Similarly, since the transporters were expressed in isolation, the interaction of each
individual compound with each individual transporter could be specifically assessed vs. the in
vivo situation where multiple transporter proteins are expressed simultaneously in a tissue and
the measured response is possibly an amalgamation of the activities of multiple transporter
proteins. While under certain conditions all six compounds significantly inhibited mOat1- and
mOat3-mediated transport, LSA, RMA, and SAA emerged as potent competitive inhibitors,
(Figures 3.4 and 3.5 and Tables 3.1 and 3.2). The rank order of their potencies was different
between the two transporters with RMA ≈ SAA > LSA for mOat1 and RMA > SAA≈ LSA for
mOat3. While statistically not different, the Ki ratio (Table 3.2) suggests that mOat1 may have a
slightly higher affinity (lower Ki) for LSA and SAA than mOat3. However, in general all of the
values are quite similar and exhibit well below an order of magnitude in difference. The
estimates are comparable to those reported for the strong OAT inhibitor, probenecid, Ki = 6.4
and 4.6 µM for mOat1 and mOat3, respectively (114, 115). Thus, LSA, RMA, and SAA may
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affect the disposition and elimination of co-administered drugs that are also mOat1 and mOat3
substrates. This may be particularly relevant in patients suffering from coronary disease where
Danshen pharmaceutical products could be combined with drugs such as angiotensin converting
enzyme inhibitors and studies with the human orthologs of these transporters need to be
conducted.
In vivo pharmacokinetic studies have indicated that elimination of hydrophilic Danshen
components involves active renal secretory pathways. In rats, the unbound renal clearance of
TSL was ~5X greater than the glomerular filtration rate (116). A separate study in rats found that
spiking additional SAA into Danshen preparations increased the AUC of SAB (82.4%) and TSL
(26.7%), and markedly reduced their clearances (46.8% and 32.9% for SAB and TSL,
respectively) (117). As we determined SAA was a potent competitive mOat1/mOat3 inhibitor,
and SAB and TSL can interact with mOat1 and mOat3, our data suggest that these in vivo results
may be explained by competition for transport on Oat1/Oat3. An in vivo pilot study conducted in
healthy humans reported Cmax values for LSA and RMA of 2.1 μM and 6.7 μM after i.v. dosing
of a Danshen product (104). These Cmax values are ~0.07-1.56 fold higher than the Ki values for
mOat1 and mOat3 determined in the present study (Table 3.2). As recommended by the FDA
Guidance for Drug Interaction Studies, when unbound Cmax/IC50(or Ki) ≥ 0.1, it indicates that
drug-drug interactions may occur in vivo (118). Unfortunately, the plasma protein binding for
LSA and RMA have not been reported, while TSL showed 25% plasma protein binding in rat
plasma (116). However, if we assume RMA to be highly protein bound (90%), the unbound
Cmax/Ki ratio for RMA would be 0.12 and 0.16 on mOat1 and mOat3, respectively, indicating
potential for herb-drug interactions. Naturally, if human OAT orthologs show similar (or higher)
affinities, possible herb-drug interactions should be considered.
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A recent investigation indicated that flavonoid and hydroxycinnamic acid aglycones and their
phase II metabolites (e.g., sulfate and glucuronide conjugates) significantly inhibit hOAT1 and
hOAT3 transport activity (50, 119). It is known that after oral administration in healthy
volunteers, the majority of RMA exists as such conjugated forms, as well (120, 121). Currently,
there are no reports on characterization of LSA and SAA metabolites in human plasma, while
SAA might undergo methylation and glucuronidation in rats (122). Therefore, studies elucidating
the metabolic pathways of these compounds are needed such that potential interactions of their
metabolites with Oat1 and/or Oat3 can be examined.
In addition, there are other transporter families known to interact with small organic anions,
e.g., the multidrug resistance associated proteins (MRPs, ABCC family) and the organic anion
transporting polypeptides (OATPs, SLCO family). For the most part these latter two transporter
families and the OATs have fairly distinct substrate interactions, however, the possibility that
they also may contribute to the overall clinical pharmacokinetic profile of Danshen components
in vivo needs to be considered until investigated directly. For example, it was recently suggested
that SAB might be an OATP substrate based upon inhibition of total and biliary clearance of
SAB by rifampicin, an OATP inhibitor, in rats (123).
Finally, the amount of each active component in Danshen preparations varies with different
cultivation regions and manufacturing processes (103). The variation of RMA in raw plant
material was observed to be ~16 fold between different growing regions and the dose of RMA
ranged from 4.1-160 mg (~40 fold) in injectable dosage forms produced by different
manufacturers (103, 104). In a clinical study, the Cmax of RMA after i.v. infusion of a 160 mg
dose was 1.2-1.6 fold higher than the Ki values for mOat1 and mOat3 (104). These data suggest
that, clinically, patients either would or would not have the potential for significant herb-drug
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interactions solely depending upon which manufacturer’s product they were administered. Thus,
although tanshinone II A, SAB, and protocatechuic aldehyde have been used as quality control
markers in the manufacture of Danshen pharmaceutical dosage forms, the work presented here
indicates that perhaps the content of LSA, RMA, and SAA, should be monitored and controlled
as well.
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CHAPTER 4

COMPETITIVE INHIBITION OF HUMAN ORGANIC ANION TRANSPORTERS 1
(SLC22A6) AND 3 (SLC22A8) BY MAJOR COMPONENTS OF THE MEDICINAL
HERB SALVIA MILTIORRHIZA (DANSHEN)
Drawn from manuscript published in Drug Metab Pharmacokinet 2012; 28(3):220-8

4.A INTRODUCTION
Danshen, the dried root of Salvia miltiorrhiza, has been used as a traditional Chinese
medicine for thousands of years in the treatment of angina, myocardial ischemia, and other
cardiovascular diseases (100-102). In vitro and in vivo studies demonstrated that Danshen could
improve microcirculation, facilitate coronary vasodilatation, and increase blood flow (124-127).
Danshen products are readily available throughout the world including Asia, Europe, and North
America, and annual sales volume is in the hundreds of millions of dollars (100). According to
the China State Food and Drug Administration database of drug manufacturing certificates, there
are currently more than 980 commercial Danshen preparations, 289 of which are injectable
dosage forms (http://www.sda.gov.cn/WS01/CL0001/). The oral dosage form, Fufang Danshen
Dripping Pill, was approved for Phase II and Phase III clinical trials by the United States Food
and Drug Administration in 1997 (IND No. 56956). In 2010, the Phase II clinical trials were
successfully completed (http://clinicaltrial.gov/ct2/show/NCT00797953?term=tasly&rank=1),
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but no formal clinical trials for any injectable Danshen formulations have been reported. Use of
the injectable products is of particular concern, as the spectra and amounts of the compounds
they contain are not well standardized. More than 70 lipophilic and hydrophilic compounds have
been separated and identified from Danshen extract (128). However, which component(s) is/are
responsible for the beneficial pharmacological effects of Danshen is virtually unknown. Among
hundreds of Danshen pharmaceutical products, lithospermic acid (LSA), rosmarinic acid (RMA),
salvianolic acid A (SAA), salvianolic acid B (SAB), and tanshinol (TSL) exhibited markedly
high content and were considered as major components (103-105).
Currently, the clinical pharmacokinetic literature on Danshen is extremely limited. One study
assayed LSA, RMA, SAA, SAB, and TSL in human urine and plasma samples obtained after
oral dosing and found TSL was the only compound detectable (116). However, this study
examined just a single formulation and dose. In contrast, LSA, RMA, SAA, SAB, and TSL were
all detected after administration of an injectable Danshen preparation (104). To improve the
clinical safety of Danshen herbal therapies (especially injectables), better estimation of the
composition and dose of active components, as well as a greater knowledge of the processes
affecting their pharmacokinetic and pharmacodynamic properties, including potential
transporter-mediated herb-drug interactions, is required.
Since these Danshen components are relatively small (198-718 Da) and exist as anions at
physiological pH, it is possible that they are organic anion transporter (OAT; SLC22) family
substrates or inhibitors. OATs are key mediators in the distribution and elimination of a
multitude of endogenous compounds and xenobiotics, which include clinically important
therapeutics such as antibiotics, antiviral and anticancer agents, statins, and angiotensinconverting enzyme inhibitors (2, 3, 106). A number of clinical and pre-clinical studies have
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demonstrated that concomitant administration of drugs that are eliminated from the body by
renally expressed OATs may result in longer plasma half-life and reduced renal clearance.
For example, co-administration of probenecid, a known OAT inhibitor, has been
demonstrated to diminish the renal clearance of benzylpenicillin and ciprofloxacin (77, 129). In
accord with these clinical findings, in vivo pharmacokinetic studies using organic anion
transporter 3 (Oat3) knockout mice demonstrated that loss of murine Oat3 (mOat3) activity
increased the plasma half-life and reduced the clearance of benzylpenicillin, ciprofloxacin, and
methotrexate (80-82). Further, cephalosporin antibiotics, including cephaloridine, cephalothin,
cefadroxil, cefamandole, cefazolin, cefoperazone, cefotaxime, and ceftriaxone, exhibited low
inhibition constant (Ki) values for hOAT1 (0.03-6.14 µM), indicating the potential for drug-drug
interactions during combined therapy with other therapeutics that are hOAT1 substrates (84).
Recent work with the cancer chemotherapy adjuvants, mesna and dimesna, demonstrated in vitro
that hOAT1 and hOAT3 transport these compounds and in vivo that concomitant probenecid
administration reduced their renal elimination in healthy human volunteers (86). In addition,
concomitant gemfibrozil administration was found to influence the pharmacokinetic properties of
pravastatin in patients, increasing pravastatin-related adverse effects, and it has been proposed
that the mechanism may be due to competition for hOAT3-mediated tubular secretion (87, 88).
Similarly, co-administration of the lipid altering compound, gemcabene, with the angiotensin
converting enzyme inhibitor, quinapril, resulted in a reduction in blood pressure in hypertensive
humans and rats (89). In rats, co-dosing of gemcabene and quinapril resulted in significantly
elevated plasma levels of quinaprilat, the pharmacologically active metabolite of quinapril (89).
Further, in vitro experiments demonstrated dose-dependent inhibition of hOAT3- and rat Oat3mediated quinaprilat transport by gemcabene, at clinically relevant levels, implicating drug-drug
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interaction on hOAT3 as the mechanism for elevated circulating levels of quinaprilat and greater
pharmacological activity (89). In response to the increase in known transporter-mediated drugdrug interactions such as these the United States Food and Drug Administration and the
European Medicines Agency have issued guidance documents regarding circumstances under
which drug interactions with specified transporters (including hOAT1 and hOAT3) need to be
investigated
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM292362.pdf
and http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.js
p?webContentId=WC500090112&murl=menus/document_library/document_library.jsp&mid=
WC0b01ac058009a3dc&jsenabled=true).
Our recent study investigating the inhibition profiles of LSA, RMA, SAA, SAB, and TSL on
murine Oat1 and Oat3 (mOat1 and mOat3)-mediated substrate uptake demonstrated that LSA,
RMA, and SAA exerted markedly stronger inhibitory effects compared to SAB and TSL (49).
Kinetic analysis revealed that LSA, RMA, SAA were potent competitive inhibitors of both
transporters, exhibiting Ki values ranging from 4.9-14.9 µM for mOat1 and from 4.3-31.1 µM
for mOat3. However, the affinities of Danshen compounds with human OATs remained
unknown, and the potential for marked species differences between transporter orthologs has
been well documented (3). Therefore, the aim of the present study was to characterize the
inhibitory effects of LSA, RMA, and SAA on para-aminohippuric acid (PAH) transport
mediated by hOAT1 or estrone sulfate (ES) transport mediated by hOAT3. Further, studies
designed to elucidate the mechanism of inhibition (competitive vs. non-competitive vs.
uncompetitive) were also conducted. Using this information we derived inhibitory constants (Ki
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values) for each compound to allow direct comparison of their potencies between transporter
paralogs and orthologs. Finally, using published human pharmacokinetic values, unbound
Cmax/Ki (recommended by FDA Guidance for Drug Interaction Studies) were calculated as an
indicator of the in vivo drug-drug interaction potential for these compounds (49). Together, these
data demonstrated that LSA, RMA, and SAA serve as potent competitive inhibitors of hOAT1
and hOAT3 and that there is strong potential for herb-drug interactions, such as altered
pharmacokinetics and pharmacodynamics of co-administered clinical therapeutics that are OAT
substrates.
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Figure 4.1. Chemical structures for the Danshen components LSA, RMA, and SAA.
MW, molecular mass.
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4.B MATERIALS AND METHODS
4.B.1 Chemicals
Purified (≥ 96.0%) lithospermic acid (LSA), rosmarinic acid (RMA), salvianolic acid A
(SAA), were purchased from Tauto Biotech (Shanghai, China). The chemical structures are
shown in Figure 4.1. Tritiated para-aminohippuric acid ([3H]PAH) and estrone sulfate ([3H]ES)
were purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA). Unlabeled
PAH, ES, and probenecid were obtained from Sigma-Aldrich (St. Louis, MO).
4.B.2 Tissue culture
The derivation of stably transfected Chinese hamster ovary (CHO) cells expressing hOAT1,
human embryonic kidney 293 (HEK) cells expressing hOAT3, and their corresponding empty
vector transfected control cell lines, has been described previously (20, 29). The CHO and HEK
cell lines were maintained at 37°C with 5% CO2 in DMEM F-12 or DMEM high glucose media
(Mediatech, Inc., Herndon, VA) containing 10% serum, 1% Pen/Strep and either 1 mg/mL G418
(CHO cell lines) or 125 µg/ml hygromycin B (HEK cell lines), respectively.
4.B.3 Cell accumulation assays
Accumulation assay protocols were adapted from those previously published (82, 109). In
brief, cells were seeded in 24-well tissue culture plates (2 × 105 cells/well) and grown in the
absence of antibiotics for two days prior to uptake assays. Before initiation of transport
experiments, the cells were equilibrated with 500 µL of transport buffer [Hanks’ balanced salt
solution containing 10 mM HEPES (Sigma-Aldrich, St. Louis, MO), pH 7.4] for 10 min. The
equilibration buffer was replaced with 500 µL of fresh transport buffer containing 1 µM
[3H]PAH or 1 µM [3H]ES (0.25 µCi/mL) in the presence or absence of inhibitors as indicated in
the figure legends. Substrate concentration and accumulation time used for kinetic analysis of
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hOAT1 (1 µM PAH for 3 min, Km = 15.4 µM) were based upon previous determinations in this
cell line (130) and those for hOAT3 were determined in this study. After incubation for the
indicated time, cells were immediately rinsed three times with ice-cold transport buffer, lysed
with 1 M NaOH, and neutralized with 1 M HCl and 0.1 M HEPEs. Aliquots were removed for
liquid scintillation counting and total protein determination using a Bio-Rad Protein Assay Kit
(Bio-Rad Laboratories, Hercules, CA). Substrate accumulation was calculated as picomoles of
substrate per milligram of protein. Michaelis constant (Km) and inhibition constants (Ki) were
determined using nonlinear regression with the appropriate models in GraphPad Prism Software
version 5.0 (GraphPad Software Inc., San Diego, CA). Mode of inhibition was identified by
using mixed-model inhibition analysis as described in our previous work (49). The mode of
inhibition was determined by the parameter α. Large value of α (α > 1) indicates competitive
inhibition. Results were confirmed by performing experiments at least three times with triplicate
samples.
4.B.4 Statistics
Statistical analysis was done with one-way ANOVA followed by post-hoc analysis with
Dunnett’s t-test or using Student’s two-tailed unpaired t-test (α for significance set at 0.05). Data
are reported as mean ± S.D. or mean ± S.E.M., as indicated.
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4.C RESULTS
4.C.1 Inhibitory effects of hydrophilic Danshen components on hOAT1 and hOAT3 function
The stably transfected hOAT1-expressing (CHO-hOAT1) cell line exhibited marked (~5x)
accumulation of PAH relative to empty vector-transfected CHO-ev (background) cells (Figure
4.2A). CHO (background) cells exhibited a probenecid-insensitive background for PAH that was
equal to ~20% of the total accumulation obtained in transporter expressing cells (CHO-ev
(background): 0.93 ± 0.19 pmol/mg protein/10 min vs. CHO-hOAT1 (control): 4.39 ± 0.20
pmol/mg protein/10 min). This non-specific PAH signal was not significantly influenced by
addition of the Danshen compounds (1 mM), indicating that the reduction in substrate
accumulation in CHO-hOAT1 cells is attributable to inhibition of hOAT1 activity and this value
represents an appropriate background correction factor (data not shown). Rudimentary
assessment of the ability of the three Danshen components (1 mM), LSA, RMA, and SAA, to
inhibit hOAT1 revealed that, similar to the OAT inhibitor probenecid, each of the compounds
significantly inhibited (> 83%) PAH uptake in CHO-hOAT1 cells (p < 0.001) under these
conditions (Figure 4.2A).
ES accumulation in hOAT3-expressing (HEK-hOAT3) cells was significantly greater of (~4fold) than that observed in empty vector-transfected HEK-ev (background) cells (HEK-ev: 2.46
± 0.80 pmol/mg protein/10 min vs. HEK-hOAT3: 9.55 ± 1.41 pmol/mg protein/10 min, Figure
4.2B). As with hOAT1, hOAT3-mediated uptake was significantly (p < 0.001) inhibited by each
Danshen component (> 98% inhibition at 1 mM; Figure 4.2B). LSA, RMA, and SAA (1 mM)
failed to significantly influence non-specific uptake of ES in HEK-ev (background) cells (data
not shown). Thus, illustrating that hOAT3 expression correlates with ES accumulation and that
HEK-ev ES level can be used for background correction.
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Figure 4.2. Inhibition of hOAT1- and hOAT3-mediated transport by Danshen components
A: Inhibition of hOAT1-mediated uptake of [3H]PAH (1 µM) by LSA, RMA, SAA, and
probenecid (1000 µM) was measured in the CHO-hOAT1 cell line (10 min). B: Inhibition of
hOAT3-mediated uptake of [3H]ES (1 µM) by LSA, RMA, SAA, and probenecid (1000 µM)
was measured in the HEK-hOAT3 cells (10 min). Background PAH and ES accumulation was
measured in the respective empty vector transfected control cell lines and is included to provide
a clear gauge of the background in the experimental system. Graphs shown are from
representative experiments with values plotted as mean ± S.D. of triplicate values. Black bars:
substrate accumulation in the absence of inhibitor in transporter expressing cells, open bars:
substrate accumulation in mock transfected cells, grey bars: substrate accumulation in the
presence of inhibitors in transporter expressing cells; *** denotes p < 0.001 as determined by
one-way ANOVA followed by Dunnett’s t-test.
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4.C.2 Mode of inhibition
In order to calculate the more universal kinetic parameter, Ki, studies were conducted to
determine the mechanism of inhibition of hOAT1 and hOAT3 by LSA, RMA, and SAA.
Substrate concentration and accumulation time used for kinetic analysis of hOAT1 (1 µM PAH
for 3 min, Km = 15.4 µM) were based upon previous determinations in this cell line (130). For
HEK-hOAT3 cells, ES accumulation was linear through at least the first minute and Km was
estimated as 14.5 ± 4.5 μM (data not shown and Figure 4.3). These parameters were then used to
design saturation analysis experiments for hOAT1 and hOAT3 in the absence vs. presence of
two different concentrations of LSA, RMA, or SAA. Substrate uptake under these conditions
was determined, background corrected, and fit to the mixed-model inhibition, which incorporates
competitive, non-competitive, and uncompetitive inhibition modes. Estimated α values were
much greater than 1, indicating that LSA, RMA, and SAA inhibition of hOAT1- and hOAT3mediated transport was competitive in nature (Table 4.1).
4.C.3 Determination of inhibition potencies of LSA, RMA, and SAA for hOAT1 and hOAT3
Using increasing concentrations of unlabeled test compounds (10-9 to 2×10-4 M), inhibition
of hOAT1- and hOAT3-mediated transport of ([3H]PAH) or ([3H]ES), respectively, was
measured (Figures 4.4 and 4.5 and Table 4.2). As indicated above, LSA, RMA, and SAA were
determined to be competitive inhibitors of hOAT1 and hOAT3, thus Ki, rather than IC50 values,
could be calculated by selecting competitive inhibition during analysis. Ki values were estimated
as 20.8 ± 2.1 µM for LSA, 0.35 ± 0.06 µM for RMA, and 5.58 ± 0.29 µM for SAA on hOAT1mediated transport and as 0.59 ± 0.26 µM for LSA, 0.55 ± 0.25 µM for RMA, and 0.16 ± 0.03
µM for SAA on hOAT3-mediated transport. For all of these analyses the coefficient of
determination (r2) was > 0.9. The Ki values for LSA and SAA on hOAT3 were ~1-2 orders of
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magnitude lower than those for hOAT1 (p < 0.001, Ki ratio = 35 for each), whereas the Ki for
RMA was similar between the two transporters (Table 4.2).
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Figure 4.3. Michaelis-Menten kinetics of ES transport in HEK-hOAT3 cells
Uptake of [3H]ES was measured for 1 min at room temperature in HEK-hOAT3 cells (closed
triangles) and HEK-ev (background) cells (open squares) across increasing ES concentrations.
The background corrected curve (closed circles) was obtained by subtracting the non-specific
background uptake as measured in the HEK-ev cells from HEK-hOAT3 accumulation to allow
analysis of hOAT3-mediated activity. Experiments were repeated three times in triplicate and
Michaelis constant (Km) values were calculated by nonlinear regression using the MichaelisMenten model. The Km for ES on hOAT3 was estimated as 14.5 ± 4.5 μM (mean ± S.E.M.).
Graph shown is from a representative experiment with values plotted as mean ± S.D. (n=3).
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Figure 4.4. Ki determination for LSA, RMA, SAA, SAB, and TSL on hOAT1
One minute uptake of [3H]PAH (1 µM) in CHO-hOAT1 cells was measured in the presence of
increasing concentrations (10-7 to 2×10-3 M) of LSA, RMA, SAA, SAB, and TSL. Data were
corrected for non-specific background measured in the CHO-ev1 (background) cells prior to
kinetic analysis. Ki values were determined with non-linear regression and the “one-site
competition” model using GraphPad Prism software. Experiments were repeated three times in
triplicate with the mean Ki ± S.E.M. reported in Table 4.2. Graphs shown are from representative
experiments with values plotted as mean ± S.D. (n=3).
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Figure 4.5. Ki determination for LSA, RMA, and SAA, SAB, and TSL on hOAT3
One minute uptake of [3H]ES (1 µM) in HEK-hOAT3 cells was measured in the presence of
increasing concentrations (10-8 to 2×10-3 M) of LSA, RMA, SAA, SAB, and TSL. Data were
corrected for non-specific background measured in the HEK-ev (background) cells prior to
kinetic analysis. Ki values were determined with non-linear regression and the “one-site
competition” model using GraphPad Prism software. Experiments were repeated three times in
triplicate with the mean Ki ± S.E.M. reported in Table 4.2. Graphs shown are from representative
experiments with values plotted as mean ± S.D. (n=3).
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Figure 4.6. Dose-response curves for SAB and TSL with respect to mOat1 and mOat3
One minute uptake of [3H]PAH or [3H]ES (1 µM) in CHO-mOat1 (upper panels) or CHO-mOat3
(lower panels) cells was measured in the presence of increasing concentrations (10-7 to 5×10-3 M)
of SAB and TSL. Data were corrected for non-specific background measured in the CHO-FRT
(background) cells prior to kinetic analysis. IC50 values were determined with non-linear
regression and the “log(inhibitor) vs. response” model using GraphPad Prism software.
Experiments were repeated three times in triplicate with the mean IC50 ± S.E.M. reported in
Table 4.3. Graphs shown are from representative experiments with values plotted as mean ± S.D.
(n=3).
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Table 4.1. Estimated α values from mixed-model inhibition analysis
Compound
LSA
RMA
SAA
SAB
TSL

hOAT1
1.5 × 1015
2.1 × 1014
3.1 × 1015
6.8 × 1019
8.8 × 1016

Values are reported as mean. The S.E.M. is not applicable in this analysis.
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hOAT3
9.6 × 1013
3.2 × 1017
4.2 × 1016
8.2 × 1017
3.5 × 1015

Table 4.2. Estimated Ki values (µM) and DDI indices for hOAT1 and hOAT3
Compound
LSA
RMA
SAA
SAB
TSL

hOAT1

hOAT3

20.8 ± 2.1
0.35 ± 0.06
5.6 ± 0.3
22.2 ± 1.9
40.4 ± 12.9

0.59 ± 0.26***
0.55 ± 0.25
0.16 ± 0.03***
19.8 ± 8.4
8.6 ± 3.3

Ki Ratio
(hOAT1/hOAT3)
35
0.6
35
1.1
4.7

fua
(%)
-c
9.5e
6.8e
100e

DDI indexb
hOAT1
hOAT3
d
0.01
0.4d
1.6
1.0
0.02
0.02
0.5
2.1

Values are reported as mean ± S.E.M. (n=3). ***, significance of Ki values between hOAT1 and
hOAT3 is p < 0.001 as determined by two-tailed Student’s unpaired t-test. afu: Fraction unbound
in plasma; bClinical data taken from reference (104); c-: Unknown; dAssuming LSA is highly
protein bound (fu = 10%); e Fraction unbound in plasma from reference (137).
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Table 4.3. Comparison of Ki values (µM) between mOat1 and mOat3 and their human
orthologs
Compound
LSA
RMA
SAA
SAB
TSL

mOat1a

mOat3a

14.9 ± 4.9
5.5 ± 2.2
4.9 ± 2.2
236 ± 90b
136 ± 17b

31.1 ± 7.0
4.3 ± 0.2
21.3 ± 7.7
845 ± 287b
1940 ± 486b

Ki Ratio
(mOat1/hOAT1)
0.7
16
0.9
11
3.4*

Ki Ratio
(mOat3/hOAT3)
53*
7.8***
133
43*
226*

Values are reported as mean ± S.E.M. (n=3). * denotes significant difference between murine
and human Ki values p < 0.05 and *** denotes significant difference between murine and human
Ki values p < 0.001 as determined by two-tailed Student’s unpaired t-test. aData for LSA, RMA
and SAA were taken from reference (49). bCorresponding Ki values assuming competitive
inhibition (see text for explanation).
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4.D DISCUSSION
The popularity of natural products as dietary supplements and/or alternative medicines has
been increasing. Indeed, a recent survey found that ~20% of the adult population in the United
States reported using one or more natural products (112). Because herbal medicines are produced
from plants they are considered “natural” and, therefore, are often perceived as having no toxic
effects by patients. However, many different side effects/adverse events are known to be
associated with natural products, including herb-drug interactions (131, 132). A number of herbdrug interactions involving metabolic enzymes (e.g., CYP450’s) are well established, however,
herb-drug interactions at the level of transporter proteins are not as well characterized.
Despite this, there is a growing literature base concerning the interaction of natural products
with OATs. For example, the dietary polyphenol, ellagic acid, was found to potently inhibit
hOAT1 (IC50 = 207 nM) and hOAT4 (48). The aglycone of the natural sweetener, stevioside,
was identified as an inhibitor of both hOAT1 (Ki = 2.0 μM) and hOAT3 (Ki = 5.4 μM) (133).
Similarly, dietary flavonoid and hydroxycinnamic acid aglycones, as well as their Phase II
glucuronide and sulfate conjugates, produced pronounced inhibition of hOAT1- and hOAT3mediated transport (50, 119). Finally, the nephrotoxin, aristolochic acid, the causative agent for
“Chinese herbs nephropathy” which is found in herbal products containing Aristolochia sp.,
exhibited significant interaction with hOAT1 (Ki = 600 nM), hOAT3 (Ki = 500 nM), and hOAT4
(Ki = 20.6 μM) (39). Thus, herb-drug interactions involving OATs and components of natural
products, that impact the pharmacokinetics and pharmacodynamics of administered drugs, may
occur.
In the present study, we sought to determine the inhibitory effects of three major Danshen
components, LSA, RMA, and SAA on hOAT1- and hOAT3-mediated transport (Figures 4.2, 4.4,
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and 4.5). In order to calculate Ki values on hOAT3, the Km value for ES (test substrate) needed to
be determined in the HEK-hOAT3 cell system (Figure 4.3). Saturation analysis revealed an
estimated Km of 14.5 ± 4.5 μM, which is similar to other reported values of 6.3-9.5 μM (98, 134,
135). LSA, RMA, and SAA were found to be potent competitive inhibitors of hOAT1- and
hOAT3-mediated transport (Figures 4.4 and 4.5 and Tables 4.1 and 4.2). Their calculated Ki
values are similar to reported Km and Ki values for endogenous steroid and prostaglandin
hormones on hOAT1 and hOAT3 (3). Therefore, LSA, RMA, and SAA may affect the
disposition and elimination of not only co-administered drugs, but also of endogenous substances
that are OAT substrates. The rank order of their potencies was different between the two
transporters with RMA > SAA > LSA for hOAT1 and SAA > LSA ≈ RMA for hOAT3.
Regardless, LSA and SAA exhibited significantly higher affinity (lower Ki values) for hOAT3
than for hOAT1, with each compound showing a ~35-fold preference, whereas, RMA exhibited
similar affinity for both transporters (Table 4.2).
In the draft guidance for industry, “Drug Interaction Studies — Study Design, Data Analysis,
Implications for Dosing, and Labeling Recommendations”, re-issued by the Food and Drug
Administration in February 2012, it was proposed that a DDI index, indicative of a compound’s
potential to cause marked in vivo drug-drug interactions when its value exceeds 0.1, can be
calculated as the [unbound] Cmax/Ki (or IC50) ratio (136). In 2005, an in vivo pilot study
conducted in healthy humans reported Cmax values for LSA and RMA of 2.23 μM and 5.55 μM
after i.v. administration of a Danshen product, in which the dose of LSA and RMA were 3 and
160 mg, respectively (104). Further, Yang et al. (2007) determined that, for RMA, the fraction
unbound in plasma was 9.5% (137). Thus, using the published Cmax and plasma protein binding
values for RMA, as well as the Ki values determined in this study (Table 4.2), DDI indices of 1.6
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and 1.0 were calculated for hOAT1 and hOAT3, respectively, indicating a strong potential for
clinical herb-drug interactions. In the absence of plasma protein binding data for LSA, DDI
indices for hOAT1 (0.01) and hOAT3 (0.4) were calculated assuming LSA to be highly (90%)
protein bound (Table 4.2). Under such circumstances, the DDI index for hOAT3 would be
greater than 0.1. The pharmacokinetic profile of SAA is virtually unknown. Clearly, greater
understanding of the pharmacokinetic properties of LSA, RMA, and SAA, and the transporters
that help determine them, is necessary to avoid potential herb-drug interactions. For Danshen
pharmaceutical products this would be particularly relevant in coronary patients, where they may
be taken in combination with drugs, such as angiotensin converting enzyme inhibitors, which are
known to be hOAT1/hOAT3 substrates.
Additionally, there is marked variation in the amount of each active component in plant
cultivated in different regions and in Danshen products prepared by different manufacturing
processes (103, 104, 138). For example, the content of RMA in raw plant material varied as
much as 16 fold between different cultivation regions and the dose of RMA ranged from 4.1-160
mg (~40 fold) in Danshen injectables produced by different manufacturers (103, 104). Moreover,
the dose of RMA ranged from 1.16-3.47 mg from different batches of a Danshen injectable from
the same pharmaceutical manufacturer (138). These data illustrate that clinically significant herbdrug interactions would or would not occur depending upon which manufacturer’s product was
administered and/or the diligence of the quality control protocol utilized by a single
manufacturer. Therefore, although tanshinone II A, SAB, and protocatechuic aldehyde have been
chosen as quality control markers for Danshen pharmaceutical dosage forms in accordance with
the Chinese Pharmacopeia, our data suggest that the content of other Danshen components, e.g.,
LSA and RMA, should be considered for monitoring and control as well.
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Recently, we investigated the interaction between mOat1 and mOat3 and Danshen’s
hydrophilic components (49). As for the human orthologs, the rank order of potencies was
slightly different between the two transporters with RMA≈ SAA > LSA for mOat1 and RMA >
SAA ≈ LSA for mOat3. On comparing the mouse and human data, notable species differences
appear to exist in terms of inhibitory potency (Table 4.3). Human OAT1 exhibited ~16-fold
higher affinity for RMA as compared to mOat1, while LSA and SAA showed similar inhibition
potencies across species. In contrast, all three compounds exhibited much higher affinity for
hOAT3 over mOat3, by 1 order of magnitude for RMA and by ~2 orders of magnitude for LSA
and SAA. Interestingly, for LSA and SAA the two species are reversed, with hOAT3 having
higher affinity for both over hOAT1 vs. mOat1 having higher affinity for both over mOat3
(Tables 4.2 and 4.3). While the human orthologs had ~10 fold lower Ki values for RMA than the
murine transporters, within species the values were similar for each transporter. These species
differences indicate that any interactions observed in vivo in mice at clinically relevant doses of
LSA, RMA, and SAA would potentially be of even greater magnitude in humans. This highlights
the importance of delineating species differences in affinity in vitro prior to interpreting results
from in vivo pharmacokinetic studies in pre-clinical models and attempting to extrapolate them
to humans.
As discussed earlier, additional Danshen components also might show significant inhibitory
effects on OATs. For example, caffeic acid was demonstrated to be an OAT inhibitor, with
reported IC50 values of 16.6 µM for hOAT1 and 5.4 µM for hOAT3 (51). However, because of
low plasma concentration (0.56 µM) and modest plasma protein binding (66%), the calculated
DDI index is less than 0.1, indicating caffeic acid was not likely to cause significant OAT
inhibition at clinically relevant concentrations (104, 139). Protocatechuic acid and some
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hydroxycinnamates (major metabolites of chlorogenic acids) were also identified as inhibitors of
hOAT1 and hOAT3 (52). However, again, the extremely low content in Danshen products
renders them unlikely to contribute to OAT-mediated Danshen-drug interactions in vivo.
In summary, the active Danshen components, LSA, RMA, and SAA were demonstrated to
elicit significant competitive inhibition on hOAT1- and hOAT3-mediated substrate uptake at
clinically relevant concentrations. DDI indices for RMA on hOAT1 and hOAT3, and for LSA on
hOAT3, suggest a strong potential for drug-drug interactions in patients when coadministered
with drugs that are known hOAT1 and/or hOAT3 substrates. In addition, notable species
differences were observed between human and murine OAT orthologs with human OATs
showing higher affinity. All of these Danshen components preferentially interacted with hOAT3
compared to mOat3, while only RMA showed higher affinity with hOAT1 (vs. mOat1). This
information should improve interpretation and extrapolation of pharmacokinetic data generated
in pre-clinical studies. Finally, these components might serve as effective quality control markers
to be monitored during the manufacturing process to improve product consistency, efficacy, and
safety.
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CHAPTER 5

POTENTIAL FOR FOOD/DRUG-DRUG INTERACTIONS BY PHENOLIC ACIDS ON
HUMAN ORGANIC ANION TRANSPORTERS 1 (SLC22A6), 3 (SLC22A8), AND 4
(SLC22A11)
Drawn from manuscript published in Biochem Pharmacol. Oct 2012; 84(8): 1088-1095

5.A INTRODUCTION
The term, phenolic acid, describes a large group of compounds that contain an aromatic ring
bearing hydroxyl and carboxyl substituents (140). In plants, phenolic acids are synthesized from
phenylalanine or tyrosine via the shikimate pathway and they are widely distributed in fruits,
vegetables, and beverages (43). As phenolic acids have been reported to possess anti-oxidant,
anti-carcinogenic, and anti-inflammatory activities, they are believed to reduce the risk of
developing chronic diseases, e.g., diabetes, cardiovascular disorders, and certain cancers (43, 140,
141). A number of phenolic acids showed marked systemic exposure in vivo after daily
consumption of phenolic acid-rich food (141, 142).
Additionally, in vivo metabolism generates phenolic acids. For example, gentisic acid was
identified as one of the major metabolites of salicylate, and urinary elimination of gentisic acid
accounted for 0.4-1.7% of the total administered dose of salicylate drugs (143, 144). Another
study indicated that ferulic and isoferulic acids may be metabolites of caffeic acid (145). Finally,
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anthocyanins (ACNs) were recently identified as an important dietary source of phenolic acids.
ACNs are flavonoids which are widely distributed in flowers, berries, grapes, red wine, and
blood orange juice, producing blue and red color (146). Daily consumption of ACNs was
estimated as 3-215 mg (146). Yet, it was reported in clinical studies that the bioavailability of
ACNs was poor (146). However, in vitro studies demonstrated that phenolic acids represent
major stable degradation products of ACNs, and this was confirmed in clinical studies (44, 147,
148). Thus, phenolic acids are commonly found in the systemic circulation even in individuals
not actively taking phenolic acid containing dietary supplements or alternative medicines.
Several transporter families are responsible for the systemic disposition of organic acids.
Among these, the Solute Carrier 22 (SLC22; organic cation/anion/zwitterion transporters) family
is a key mediator in the distribution and renal tubular secretion of a multitude of endogenous and
exogenous organic anions (2, 3). Many toxins, toxicants, and drugs (including antibiotics,
antiviral and anticancer agents) are known organic anion transporter (OAT) substrates (2, 3).
Further, some phenolic acids, e.g., tanshinol, rosmarinic acid, and salvianolic acid B, exhibit
their highest tissue concentration in the kidney compared to other tissues, e.g., liver, intestine,
and brain, after dosing (116, 149). In accordance, the kidney is known to express more OAT
family members than any other tissue (3). In particular, human organic anion transporter 1
(hOAT1; SLC22A6), hOAT2 (SLC22A7), and hOAT3 (SLC22A8), expressed in the basolateral
membrane of renal proximal tubule cells, and hOAT4 (SLC22A11), hURAT1 (SLC22A12), and
hOAT10 (SLC22A13) located in the apical membrane, are major constituents of the renal
organic anion transport pathway.
OAT-mediated drug-drug interactions (DDIs), manifesting as altered renal clearance and
longer terminal plasma half-life, have been observed in a number of clinical and pre-clinical
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studies. For example, renal clearance of benzylpenicillin and ciprofloxacin was reduced when
co-administered with probenecid, a known OAT inhibitor, in clinical practice (77, 129). In accord
with these clinical findings, pharmacokinetic studies using organic anion transporter 3 knockout
mice demonstrated significantly reduced renal elimination of benzylpenicillin, ciprofloxacin, and
methotrexate (80, 81). In response to our increased knowledge of such clinically relevant drugtransporter interactions, and the impact they have on drug safety, the United States Food and
Drug Administration (FDA) and the European Medicines Agency have issued guidance
documents outlining conditions under which, prior to approval, any new drug entity should be
investigated for potential DDIs on seven identified transporters; OAT1, OAT3, organic cation
transporter 2 (OCT2), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3,
multidrug resistance transporter 1 (MDR1), and breast cancer resistance protein (BCRP)
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM292362.pdf
and http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.js
p?webContentId=WC500090112&murl=menus/document_library/document_library.jsp&mid=
WC0b01ac058009a3dc&jsenabled=true). Thus, the potential clinical significance of OAT1- and
OAT3-mediated DDIs is already clearly recognized.
As most phenolic acids are small and mainly exist as anions at physiological pH, it is
possible that they are OAT substrates or inhibitors. For example, some hydroxycinnamic acids,
including caffeic acid, dihydrocaffeic acid, dihydroferulic acid, and ferulic acid were identified
as hOAT1 and/or hOAT3 substrates (50). This study further demonstrated that these compounds,
as well as their glucuronide- and sulfate-conjugated metabolites, inhibited hOAT1 or hOAT3
transport activity (50). Caffeic acid was identified as a competitive inhibitor for hOAT1 and
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hOAT3, with IC50 estimates of 16.6 µM and 5.4 µM, respectively (51). As a consequence,
hOAT1/hOAT3-mediated transport of antifolates and antivirals was inhibited by caffeic acid
(51). Finally, ellagic acid, which is a dietary polyphenol found in many fruits and vegetables,
was demonstrated to be a potent inhibitor for hOAT1 (IC50 = 207 nM) and hOAT4 (48).
Therefore, it is necessary to explore the potential interaction of phenolic acids with OATs, in
order to determine what transport processes influence the distribution and elimination (and hence
efficacy and toxicity) of these compounds. This information is also vital to avoid potential
drug/food-drug interactions.
In the present study, the inhibitory effects of nine dietary phenolic acids, p-coumaric acid,
ferulic acid, gallic acid, gentisic acid, 4-hydroxybenzoic acid, protocatechuic acid, sinapinic acid,
syringic acid, and vanillic acid, on the transport of para-aminohippuric acid (PAH) mediated by
hOAT1 and the transport of estrone sulfate (ES) mediated by hOAT3 and hOAT4 were
characterized. For potent inhibitors, dose-response studies were conducted in order to derive
inhibitory constants (IC50 and Ki values) to aid evaluation of potential for clinical DDIs. Among
these phenolic acids, gallic acid exhibited highest affinity for hOAT1 and hOAT3, with
corresponding maximum DDI indices (unbound maximum plasma concentration/IC50) of 5.52
and 0.76, respectively. Gentisic acid exhibited a marked DDI index of 7.25 for hOAT3
(assuming 90% binding to plasma protein). These findings suggested there is a strong potential
for gallic acid- and gentisic acid-associated food/drug-drug interactions with co-administered
clinical therapeutics that are OAT substrates, including altered drug pharmacokinetics,
pharmacodynamics, and toxicity.
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5.B MATERIALS AND METHODS
5.B.1 Chemicals
p-Coumaric acid, ferulic acid, gallic acid, gentisic acid, 4-hydroxybenzoic acid, sinapinic
acid, and vanillic acid≥ (97% purity) were purchased from Sigma -Aldrich (St. Louis, MO).
Protocatechuic acid and syringic acid
≥ 95%
( purity) were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). The chemical structures for these compounds are shown
in Figure 5.1. Tritiated para-aminohippuric acid ([3H]PAH) and estrone sulfate ([3H]ES) were
purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA) and unlabeled PAH,
ES, and probenecid were purchased from Sigma-Aldrich.
5.B.2 Tissue culture
Derivation of stably transfected Chinese hamster ovary (CHO) cells expressing hOAT1
(CHO-hOAT1) and hOAT4 (CHO-hOAT4), as well as stably transfected human embryonic
kidney 293 (HEK) cells expressing hOAT3 (HEK-hOAT3), and their corresponding empty
vector transfected background control cell lines, has been described previously (82, 130, 150).
CHO-hOAT1 cells were maintained at 37°C with 5% CO2 in phenol red-free RPMI 1640 media
(Gibco-Invitrogen, Grand Island, NY) containing 10% serum, 1% Pen/Strep and 1 mg/mL G418.
CHO-hOAT4 cells were maintained at 37°C with 5% CO2 in EMEM Alpha Modification media
(Sigma-Aldrich) containing 10% serum, 1% Pen/Strep and 0.5 mg/mL G418. HEK cell lines
were maintained at 37°C with 5% CO2 in DMEM high glucose media (Mediatech, Inc., Herndon,
VA) containing 10% serum, 1% Pen/Strep and 125 µg/ml hygromycin B.
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Figure 5.1. Chemical structures of the nine dietary phenolic acids investigated in this study
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5.B.3 Cell accumulation assay
The procedure for the cell accumulation assay was described in previous publications (82). In
brief, 2 × 105 cells/well were seeded in 24-well tissue culture plates and grown in the absence of
antibiotics for 48 hr. Before initiating the cell transport experiment, cells were preincubated in
transport buffer for 10 min [500 µL of Hanks’ balanced salt solution containing 10 mM HEPES,
pH 7.4]. After equilibration, this solution was replaced with 500 µL of fresh transport buffer
containing 1 µM non-radiolabeled substrates spiked with trace amounts of [3H]PAH (0.5 µCi/mL)
or [3H]ES (0.25 µCi/mL) with or without test compounds. At the end of incubation, cells were
quickly rinsed three times with ice-cold transport buffer and lysed. The intracellular
accumulation of tritiated substrates was counted by liquid scintillation and reported as picomoles
of substrate per milligram total protein. All uptake data were corrected for background
accumulation in corresponding control cells. Exposure to as high as 1 mM of each phenolic acid
did not significantly influence the non-specific substrate signal observed in CHO empty vector
control cells or HEK empty vector control cells, as compared to unexposed cells (data not
shown). Therefore, substrate accumulation in corresponding empty vector control cell lines
under control conditions represents appropriate values for background correction. Substrate
concentrations and accumulation times used for kinetic analysis of hOAT1 (1 µM PAH for 3 min,
Km = 15.4 µM) were determined previously (130) and for kinetic analysis of hOAT3 (ES for 1
min, Km = 14.5 ± 4.5 µM) were measured in our laboratory (data not shown). Kinetic
calculations were performed using GraphPad Prism Software version 5.0 (GraphPad Software
Inc., San Diego, CA). The half maximal inhibitory concentrations (IC50) were calculated using
nonlinear regression with the appropriate model. Assuming competitive inhibition, Ki values
were derived using the Cheng-Prusoff equation: Ki = IC50/(1 + [Substrate]/Km). Results were
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confirmed by repeating all experiments at least three times with triplicate wells for each data
point in every experiment.
5.B.4 Statistics
Data are reported as mean ± S.D. or mean ± S.E.M. as indicated. Statistical differences were
assessed using one-way ANOVA followed by post-hoc analysis with Dunnett’s t-test (α = 0.05).
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5.C RESULTS
5.C.1 Inhibitory effects of phenolic acids on hOAT1-mediated PAH uptake.
CHO-hOAT1 cells showed significant accumulation of PAH (6.23 ± 0.89 pmol mg protein-1
10 min-1) compared to that in the empty vector transfected background control cells (2.34 ± 0.50
pmol mg protein-1 10 min-1), and this OAT1-mediated accumulation was inhibited by probenecid
(Figure 5.2). The dietary phenolic acids, p-coumaric acid, ferulic acid, gallic acid, gentisic acid,
4-hydroxybenzoic acid, protocatechuic acid, sinapinic acid, syringic acid, and vanillic acid, were
assessed for inhibitory effects on PAH uptake in CHO-hOAT1 cells at 100 µM (Figure 5.2).
Protocatechuic acid and vanillic acid produced approximately 53% and 80% inhibition, whereas
ferulic acid, gallic acid, and sinapinic acid completely blocked PAH accumulation (> 99%
inhibition). p-Coumaric acid produced no effect, while gentisic acid, 4-hydroxybenzoic acid, and
syringic acid actually stimulated uptake. Exposure to 100 µM of each phenolic acid had no effect
on CHO-hOAT1 cell viability or integrity (data not shown).
Dose-response studies, applying increasing concentrations of test compounds (10-7 to 5×10-4
M), were performed to determine the IC50 values for gallic acid, protocatechuic acid, sinapinic
acid, and vanillic acid in order to allow direct comparison of inhibition potencies of these
compounds (Figure 5.3 and Table 5.1). The IC50 value for ferulic acid on hOAT1 has been
reported as 9.01 µM (50). Gallic acid showed stronger affinity with hOAT1 (IC50=1.24 ± 0.36
µM), compared to protocatechuic acid (IC50=18.08 ± 2.59 µM), sinapinic acid (IC50=11.02 ±
1.55 µM), and vanillic acid (7.65 ± 2.92 µM). Previous studies investigating the type of
inhibition (competitive vs. uncompetitive vs. noncompetitive) produced on hOAT1 and hOAT3
for a variety of compounds have all determined the interaction to be competitive (51, 151).
Therefore, assuming competitive inhibition, inhibition constants (Ki) were estimated as 1.08 ±
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Figure 5.2. Inhibition of hOAT1-mediated uptake by dietary phenolic acids
Ten minute cellular uptake of [3H]PAH (1 µM) was measured in CHO-hOAT1 cells in the
absence (6.23 ± 0.89 pmol mg protein-1 10 min-1) and presence of dietary phenolic acids (100 µM)
or probenecid (1,000 µM). All data were corrected by background PAH accumulation measured
in corresponding empty vector transfected background control cell (2.34 ± 0.50 pmol mg protein1
10 min-1). Values are mean ± S.D. of triplicate values. Significant inhibition denoted by ** p <
0.01 and *** p < 0.001 as determined by one-way ANOVA followed by Dunnett’s t-test.
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Figure 5.3. Dose-response curves for gallic acid, protocatechuic acid, sinapinic acid, and
vanillic acid with respect to hOAT1
One minute uptake of [3H]PAH (1 µM) in CHO-hOAT1 cells was measured in the presence of
increasing concentrations (10-7 to 5×10-4 M) of test compounds. Data were corrected for nonspecific background measured in the corresponding empty vector transfected background control
cell. IC50 values were determined with nonlinear regression and the “log(inhibitor) vs. response”
model using GraphPad Prism software. Experiments were repeated three times in triplicate with
the mean IC50 ± S.E.M. reported in Table 5.1. Graphs shown are from representative experiments
with values plotted as mean ± S.D. (n=3).
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0.26 µM for gallic acid, 13.36 ± 1.60 µM for protocatechuic acid, 10.05 ± 1.74 µM for sinapinic
acid, and 7.19 ± 2.74 µM for vanillic acid on hOAT1-mediated transport (Table 5.1).
5.C.2 Inhibitory effects of phenolic acids on hOAT3-mediated ES uptake.
We next examined the effects of these compounds on hOAT3-mediated transport. ES, a
model substrate for hOAT3, was used to evaluate the transport activity of hOAT3 expressing
cells. Significantly greater accumulation of ES (~5 fold) was observed in stably transfected
hOAT3-expressing cells (HEK-hOAT3) relative to empty vector transfected background control
cells (20.7 ± 3.5 vs. 4.10 ± 0.92 pmol mg protein-1 10 min-1, respectively). Similar to hOAT1,
probenecid completely inhibited (> 99% inhibition) hOAT3-mediated ES uptake (Figure 5.4).
However, unlike hOAT1, all of the tested compounds (100 µM) significantly inhibited hOAT3mediated ES uptake. Gallic acid and sinapinic acid showed the strongest inhibitory effects on
hOAT3-mediated ES uptake (> 84% inhibition), followed by ferulic acid (79% inhibition),
gentisic acid (75% inhibition), and protocatechuic acid (61% inhibition). The inhibitory effects
for the remaining compounds on hOAT3 transport activity were less than 60% (p-coumaric acid:
59% inhibition; 4-hydroxybenzoic acid: 38% inhibition; syringic acid: 46% inhibition; vanillic
acid: 42% inhibition). Exposure to 100 µM of each phenolic acid had no effect on HEK-hOAT3
cell viability or integrity (data not shown).
Based on known plasma concentration levels, plasma protein binding, and the level of
inhibition observed, kinetic studies were conducted to derive IC50 values for ferulic acid, gallic
acid, gentisic acid, protocatechuic acid, and sinapinic acid on hOAT3 transport activity. Using
increasing concentrations of unlabeled test compounds (10-6 to 10-3 M), IC50 values were
measured as 7.35 ± 3.73 µM for ferulic acid, 9.02 ± 3.24 µM for gallic acid, 81.34 ± 20.50 µM
for gentisic acid, 81.82 ± 26.82 µM for protocatechuic acid, and 24.08 ± 1.46 µM for sinapinic
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acid (Figure 5.5 and Table 5.1). Estimated Ki values were calculated assuming that these
compounds were competitive inhibitors (Table 5.1).
5.C.3. Inhibitory effects of hydrophilic Danshen components on hOAT4-mediated ES uptake.
As shown in Figure 5.6, stably transfected hOAT4-expressing (CHO-hOAT4) cells showed
marked accumulation of ES (~13 fold) compared to empty vector transfected background control
cells (64.1 ± 6.6 vs. 5.34 ± 0.36 pmol mg protein-1 10 min-1, respectively). ES (1 mM) exhibited
self-inhibition on hOAT4-mediated ES uptake (> 99% inhibition). Among the test compounds,
only sinapinic acid (100 µM) showed a significant inhibitory effect (33% inhibition).
Accordingly, the IC50 value for sinapinic acid on hOAT4 transport activity is likely to be greater
than 100 µM, therefore, no further kinetic studies were performed. As observed for hOAT1, but
in contrast to hOAT3, syringic acid showed significant stimulation (35%) of hOAT4-mediated
ES uptake.
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Figure 5.4. Inhibition of hOAT3-mediated uptake by dietary phenolic acids
Ten minute cellular uptake of [3H]ES (1 µM) was measured in HEK-hOAT3 cells in the absence
(20.7 ± 3.5 pmol mg protein-1 10 min-1) and presence of dietary phenolic acids (100 µM) or
probenecid (1,000 µM). All data were corrected by background ES accumulation measured in
HEK-FRT cells (4.10 ± 0.92 pmol mg protein-1 10 min-1). Values are mean ± S.D. of triplicate
values. Significant inhibition denoted by *** p < 0.001 as determined by one-way ANOVA
followed by Dunnett’s t-test.
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Figure 5.5. Dose-response curves for ferulic acid, gallic acid, gentisic acid, protocatechuic
acid, and sinapinic acid, with respect to hOAT3
One minute uptake of [3H]ES (1 µM) in HEK-hOAT3 cells was measured in the presence of
increasing concentrations (10-6 to 10-3 M) of tested compounds. Data were corrected for nonspecific background measured in the HEK-FRT cells. IC50 values were determined with nonlinear regression and the “log(inhibitor) vs. response” model using GraphPad Prism software.
Experiments were repeated three times in triplicate with the mean IC50 ± S.E.M. reported in
Table 5.1. Graphs shown are from representative experiments with values plotted as mean ± S.D.
(n=3).

89

Figure 5.6. Inhibition of hOAT4-mediated uptake by dietary phenolic acids
Ten minute cellular uptake of [3H]ES (1 µM) was measured in CHO-hOAT4 cells in the absence
(64.1 ± 6.6 pmol mg protein-1 10 min-1) and presence of dietary phenolic acids (100 µM) or
unlabeled ES (1,000 µM). All data were corrected by background ES accumulation measured in
corresponding empty vector transfected background control cell (5.34 ± 0.36 pmol mg protein-1
10 min-1). Values are mean ± S.D. of triplicate values. Significant inhibition denoted by * p <
0.05 as determined by one-way ANOVA followed by Dunnett’s t-test.
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Table 5.1. Estimated IC50 (µM), Ki (µM) and DDI index values for hOAT1- and hOAT3-mediated transport of dietary phenolic acids
hOAT1
Compounds

IC50 (µM)

Ki (µM)

fub
(%)

NDd
1.08±0.26
ND

7.35±3.73
9.02±3.24
86.81±21.78

6.87±3.49
8.44±3.03
81.34±20.50

26.5
68.4
?e

Reported
Cmax
(µM)
0.012-1.04
0.22-10
0.7-6,290

18.08±2.59

13.36±1.60

87.36±28.57

81.82±26.82

79.3

0.12-0.49

0.005-0.02

0.001-0.004

11.02±1.55
7.65±2.92

10.05±1.74
7.19±2.74

25.74±1.56
ND

24.08±1.46
ND

?
43.7

?
0.03-0.10

?
0.002-0.006

?
ND

IC50 (µM)

Ki (µM)

Ferulic acid
Gallic acid
Gentisic acid

9.01c
1.24±0.36
ND

Protocatechuic acid
Sinapinic acid
Vanillic acid

hOAT3
a

DDI index
hOAT1

hOAT3

0.0004-0.03
0.12-5.52
ND

0.0004-0.04
0.02-0.76
0.0008-7.25

References
(for fu and Cmax)
(142, 152-154)
(142, 154, 155)
(156-159)
(148, 154, 156,
160, 161)
(154, 156, 161)

Values are reported as mean ± S.E.M. a Ki values were estimated assuming competitive inhibition; b fu: Fraction unbound in plasma; c Reported from (50); d ND: Not
determined; e ?: unknown; f Assuming gentisic acid is highly protein bound (fu = 10%)
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5.D DISCUSSION
Phenolic acids have consistently displayed beneficial therapeutic effects for cardiovascular
diseases, cancers, and chronic inflammation both in vitro and in vivo (160). In addition to
‘natural’ exposure to phenolic acids through dietary sources such as many fruits and vegetables,
phenolic acids are increasingly used in clinical practice as complementary/alternative medicines
(162). This has resulted in a greater understanding of the clinical pharmacokinetic properties of
phenolic acids. However, to understand their pharmacological actions and pharmacokinetic
behaviors at the biochemical level and, thus, better predict potential DDIs and/or toxicities, it is
essential to identify and characterize the active transport mechanisms that impact these processes.
Such information may explain how and why these compounds are targeted to specific organ(s)
for therapeutic effects and elimination from the body.
In the present study, we characterized the interactions of nine phenolic acids with three
human OATs; hOAT1, hOAT3, and hOAT4. All of the phenolic acids examined are bioavailable
as indicated by plasma or urinary data. As illustrated, each transporter exhibited a unique pattern
of interaction with the examined phenolic acids (Figures 5.2, 5.4, and 5.6). In general, all of the
compounds produced an effect on hOAT1 and hOAT3, whereas, only two compounds showed
interaction with hOAT4. All of the tested compounds exhibited significant inhibition for hOAT3
transport activity at 100 µM, while there were only five compounds (ferulic acid, gallic acid,
protocatechuic acid, sinapinic acid, and vanillic acid) that significantly blocked hOAT1-mediated
PAH uptake under the same condition. Sinapinic acid (100 µM) was the only phenolic acid
showing significant inhibition of hOAT4-mediated ES uptake. However, given the modest nature
of the interaction on hOAT4 at 100 µM, it was concluded that this was highly unlikely to be
clinically relevant. Overall, these data implicated hOAT1 and hOAT3, but not hOAT4, as having
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an important role in potential food/drug-drug interactions involving these phenolic acids.
Whether or not these transporters handle these compounds as actual substrates requires further
investigation.
Compounds reported to have relatively high Cmax values in humans (except for sinapinic acid)
and producing inhibition > ~60% at 100 µM on hOAT1 and/or hOAT3 were selected for IC50 (Ki)
determination (Figures 5.3 and 5.5 and Table 5.1). Subsequently, Cmax, % protein binding, and
IC50 values were used to calculate the drug-drug interaction index [DDI = unbound Cmax / IC50]
for each relevant transporter:compound combination (Table 5.1), where a value greater than 0.1
indicates the potential for drug-drug interactions and the need for an in vivo DDI study for any
investigational drug (recommended by FDA Guidance for Drug Interaction Studies). Clearly,
gallic acid (maximum DDI index of 5.52 and 0.76 for hOAT1 and hOAT3, respectively) and
gentisic acid (maximum DDI index of 7.25 for hOAT3) have a very strong potential for
producing DDIs in vivo.
Gallic acid has been demonstrated to have anti-oxidant, anti-inflammatory, anti-allergenic,
and anti-cancer properties (162). Currently, gallic acid is consumed as a major component in
fruits, vegetables, beverages, herbal supplements, homeopathic remedies, and pharmaceutical
products (162, 163). Pharmacokinetic studies have reported maximum plasma concentrations for
gallic acid ranging from 0.22-10 µM in humans after drinking red wine (300 mL) or after oral
administration of acidum gallicum tablets (50 mg GA), Assam black tea brews (50 mg GA), or a
dietary herbal supplement (800 mg GA) (142, 155). Since the renal clearance of gallic acid was
~8.4 L/h, the unbound renal clearance of gallic acid was estimated as 206 mL/min, which is 1.7
fold higher than the glomerular filtration rate (~120 mL/min) (163). Thus, gallic acid might
undergo active tubular secretion in the kidney. In this study, gallic acid emerged as a potent
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inhibitor for hOAT1 and hOAT3 (IC50: 1.24 and 9.02 µM, respectively), indicating that these
transporters might be involved in its active secretion. Furthermore, the DDI index for hOAT1 at
the lowest reported Cmax (0.22 µM) is 0.12 and, thus, still meets the criteria for warranting in vivo
DDI studies. Human OAT3 requires a Cmax of only 1.5 µM (reported range 0.22-10 µM) to reach
a DDI index > 0.1. Future studies also should focus on gallic acid’s major metabolites,
particularly 4-O-methylgallic acid, which showed an even higher Cmax than unchanged gallic
acid (142). Since these compounds possess a carboxyl group in the aromatic ring, they might be
OAT substrates or inhibitors, and potentially exacerbate gallic acid-associated DDIs.
For gentisic acid on hOAT3 (IC50 = 86.81 µM), the DDI index becomes 0.1 at a Cmax of just
10 µM (reported range 0.7-6,290 µM), if we assume high protein binding of 90% (actual lower
protein binding would serve to decrease the Cmax at which the 0.1 cut-off is reached). Clinically,
gentisic acid becomes very important, as it is a major metabolite of salicylate, one of the most
commonly used non-steroidal anti-inflammatory drugs (NSAIDs) (164). For example, in clinical
practice methotrexate is often taken concomitantly with NSAIDs in the treatment of rheumatoid
arthritis. However, it was reported that this combined therapy might increase methotrexaterelated adverse effects, and aspirin was found to reduce the renal clearance of methotrexate by 30%
(164, 165). Although NSAIDs can reduce glomerular filtration of methotrexate and influence its
fraction of plasma protein binding, inhibition of active renal tubular secretion via OATs might be
an important elimination mechanism, as methotrexate is an organic acid mainly excreted
unchanged in the urine (166, 167). Accordingly, transport of methotrexate by hOAT1 (Km = 554
µM) and hOAT3 (Km = 21.1 µM) was investigated and results indicated a possible role for
hOAT3 in its renal elimination, yet, salicylate showed extremely poor affinity for hOAT3 (Ki =
2.2 mM) (168). However, as the results of the present study suggest, gentisic acid, formed as a
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salicylate metabolite, could inhibit hOAT3 transport activity at clinical concentrations (2-6.29
mM) and be responsible for the observed DDIs (157-159). This may prove to be particularly
relevant for the pediatric population, as the highest reported Cmax value was observed in a clinical
study with subjects aged 2 to 16 y (159).
As indicated, gentisic acid and 4-hydroxybenzoic acid stimulated hOAT1-mediated uptake
and syringic acid stimulated both hOAT1- and hOAT4-mediated uptake, yet all three compounds
inhibited hOAT3 (Figures 5.2, 5.4 and 5.6). Thus, the stimulatory effects were varied and no
consistent pattern or association with compound structural features was identified. Such sporadic
in vitro stimulation/inhibition of transporter activity has been reported previously in the literature
for several drug classes including steroids, anticancer chemotherapeutics, non-steroidal antiinflammatory drugs, and fluoroquinolone antimicrobials (82, 169, 170). For example,
ciprofloxacin stimulated hOAT1 transport activity, but inhibited hOAT3 (82). Stimulation of
MRP2 was observed for sparfloxacin (170). It has been theorized that these effects might be the
result of allosteric interactions with the transporters, with binding promoting conformational
changes that modulate the transport kinetics of substrates (169, 170). The interactions reported
here are certainly consistent with this theory, however the nature and position of any potential
allosteric binding sites within the hOATs remains unclear and requires further investigation,
particularly given the close sequence homology of the OATs and varied effects of the studied
phenolic acids. Regardless, such stimulatory interactions could have important in vivo
consequences. For example, while a gentisic acid-drug interaction on hOAT3 might produce
altered drug pharmacokinetics exhibiting decreased drug elimination and increased terminal halflife, such an interaction on hOAT1 might produce the opposite effect, resulting in increased
elimination and shortened terminal half-life causing a marked loss of drug efficacy.
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Recent studies have identified that some ACNs are degraded to phenolic acids (44, 147, 148).
It was identified in vitro that 4-hydroxybenzoic acid, protocatechuic acid, syringic acid, and
vanillic acid, are the major degradation products of cyanidin, malvidin, peonidin, and
pelargonidin (44). In addition, 4-hydroxybenzoic acid and protocatechuic acid were confirmed as
the major human metabolites of cyanidin-glucosides and pelargonidin-3-glucoside, respectively,
in vivo (148, 160). Thus, while the bioavailability of ACNs is poor, a large portion of ACNs are
degraded to phenolic acids and the concentration of these phenolic acid metabolites might reach
much higher levels than indicated by their bioavailability and actual quantity in dietary sources.
Due to the large amount of ACNs in the human diet, it is vital to investigate the potential
transporter-mediated DDIs induced by these ACN metabolites.
Over 170 species of plants have been used as herbal medicines in the treatment of kidney
injury and disease, and phenolic acids (e.g., p-coumaric acid, ferulic acid, gallic acid, sinapinic
acid) were identified as major components in them (171). Oxidative damage induced by the
formation of free radicals is one mechanism that results in nephropathy (171). Phenolic acids,
bearing oxidizable functional groups, exhibit strong reactive oxygen species/free radical
scavenging ability (140, 172, 173). A ranked order of antioxidant activity for some phenolic
acids, according to their EC50 values, has been reported as gallic acid (0.0237 µM) > gentisic
acid (0.0292 µM) > syringic acid (0.0427 µM) > caffeic acid (0.0478 µM) > protocatechuic acid
(0.0574 µM) > sinapinic acid (0.0724 µM) > ferulic acid (0.0927 µM) > isoferulic acid (5.68
µM) > vanillic acid (14.37 µM) > p-coumaric acid (66.29 µM) > o-coumaric acid (130.05 µM) >
m-coumaric acid (>300 µM) > 4-hydroxybenzoic acid (>800 µM) ≈ salicylic acid (>800 µM)
(172, 173). All of the compounds tested in the present study showed significant interactions with
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hOAT3, while five of them showed significant inhibition on hOAT1, thus OAT-mediated
accumulation in renal proximal tubule cells might explain their nephroprotective effects.
In addition, these phenolic acids might have the potential to treat renal injury induced by
nephrotoxic drugs including β-lactam antibiotics (cephalosporins and penems) and antivirals
(adefovir and cidofovir). OATs have been demonstrated to be involved in the uptake of these
nephrotoxic drugs in proximal tubule cells (174, 175). Some OAT inhibitors, including
probenecid and NSAIDs, efficiently attenuated this drug-induced renal damage at clinically
relevant concentrations (130, 176). Therefore, phenolic acids might prove useful as an alternative
treatment in the management of OAT-mediated nephrotoxicity of drugs, without producing side
effects.
In summary, we have demonstrated the interaction of dietary phenolic acids with hOAT1,
hOAT3, and hOAT4. These results indicated that OAT-mediated food/drug-drug interactions
involving these phenolic acids might occur in vivo. Among the tested compounds, gallic acid and
gentisic acid showed strong potential for food/drug-drug interactions. In the absence of protein
binding and Cmax information, the DDI potential of sinapinic acid could not be fully addressed,
however the IC50/Ki values are consistent with this possibility. Future in vivo interaction studies
between gallic acid and gentisic acid and clinical therapeutics that are known hOAT1 and
hOAT3 substrates appear necessary in order to establish safety guidelines for relevant
pharmaceutical products.
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CHAPTER 6

INTERACTION OF NATURAL DIETARY AND HERBAL ANIONIC COMPOUNDS
AND FLAVONOIDS WITH HUMAN ORGANIC ANION TRANSPORTERS 1
(SLC22A6), 3 (SLC22A8), AND 4 (SLC22A11)
Drawn from manuscript published in Evid Based Complement Alternat Med. Vol.2013, Article
ID 612527, 7 pages, 2013.

6.A INTRODUCTION
In concert with our growing knowledge of drug transporter expression and function,
transporter-mediated drug-drug interactions (DDIs) are being increasingly identified by
numerous in vitro and in vivo studies (3, 177). Recently, government agencies in the United
States (Food and Drug Administration) and Europe (European Medicines Agency), as well as the
pharmaceutical industry, have acknowledged that transporters play a key role in the absorption,
distribution, and excretion of many clinical therapeutics. Organic anion transporter 1 (OAT1;
SLC22A6), OAT3 (SLC22A8), and OAT4 (SLC22A11) are among the transporters identified,
thus far, to impact the pharmacokinetics, and hence dosing, efficacy and toxicity, of some drugs.
OAT1 and OAT3, expressed in the basolateral membrane of renal proximal tubule cells in both
humans and preclinical species, function as key mediators for organic solute flux from blood to
the glomerular filtrate (3, 177). Additionally, OAT4, which is exclusively expressed in the apical
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membrane of human proximal tubules, reabsorbs anionic compounds from the urine (177).
Further, many endogenous substances, including hormones, neurotransmitters and toxins, have
been identified as substrates and/or inhibitors of OATs (3, 177). Thus, the potential clinical
significance of OAT-mediated DDIs is firmly recognized.
Although many studies have exhibited OAT-mediated DDIs for synthesized drugs, relatively
little is known about the potential interaction between OATs and natural products, including
various organic anions, phenolic acids and flavonoids found in herbal supplements and food.
Several dietary flavonoids and their metabolic conjugates (e.g., sulfates and glucuronides) were
identified as potent inhibitors and/or substrates of human (h) OAT1, hOAT3 and hOAT4 (48,
119). Phenolic acids, e.g., contained in the widely used Chinese herbal medicine Danshen (Salvia
miltiorrhiza) or common berries such as strawberries or blueberries, were similarly demonstrated
to interact with these three transporters (52). These studies highlight the strong potential for
hOAT-mediated natural product-drug interaction and the need to investigate further anionic
compounds and flavonoids that are found in popular complementary/alternative medicines and
natural supplements.
Catechin and epicatechin are major components of tea products, possessing anti-oxidative
and purported anti-cancer properties (178, 179). 1,3- and 1,5-dicaffeoylquinic acids are two
enantiomers of dicaffeoylquinic acid with various pharmacological effects, which are widely
distributed in plants (e.g., coffee beans, sweet potato leaves, and fennels) (180). Indeed, 1,3dicaffeoylquinic acid (also known as cynarin) is being actively investigated for its anti-HIV and
immunosuppressive properties (181). Extracts of Ginkgo biloba have gained popularity as an
herbal supplement because they are believed to improve mental sharpness and memory, while
slowing brain aging, and were hoped to be effective in relieving symptoms associated with
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Alzheimer’s disease. Regardless, it is well recognized that several ginkgolic acids, particularly
(13:0), (15:1) and (17:1) (designating the number of carbon atoms in the alkyl side chain) can
produce severe allergic, cytotoxic, mutagenic, carcinogenic, and genotoxic effects (182).
Licorice root (Radix Glycyrrhizae) is employed to relieve a number of maladies including
stomach ulcers, colic, chronic gastritis, sore throat, bronchitis, osteoarthritis, liver disorders,
malaria and tuberculosis. One major component of Radix Glycyrrhizae preparations, glycyrrhizin,
gives rise to two bioactive metabolites, 18α- and 18β-glycyrrhetinic acid, thought to play a role
in these beneficial effects (183). Ursolic acid is a pentacylic triterpene acid occurring naturally in
herbs and fruits. It exhibits anti-inflammatory and anti-carcinogenic activities (184) and is
marketed as an herbal supplement to promote weight loss. Since these compounds have been
identified as major components of first-line/complementary/alternative medicines, foods, and
beverages, humans can be exposed to these compounds through clinical therapies and the daily
diet. Many of these compounds have shown systemic exposure in humans (Table 6.1). Based on
their chemical structures and previous studies, these compounds have the potential to interact
with OATs. Thus, OAT-mediated DDIs may occur in vivo when combined with known OAT
substrates and such information should prove helpful in guiding the safe use and development of
products that contain these compounds.
Therefore, the purpose of the present study was to investigate the inhibitory potential of these
nine compounds, catechin, epicatechin, 1,3- and 1,5-dicaffeoylquinic acids, ginkgolic acids
(13:0), (15:1) and (17:1), 18β-glycyrrhetinic acid, and ursolic acid, on hOAT1-, hOAT3- and
hOAT4-mediated transport. In addition to generating transporter specific inhibition profiles,
dose-response studies were conducted for potent inhibitors in order to derive inhibitory constants
(IC50 and Ki values) to aid evaluation of their potential for clinical OAT-mediated DDIs.
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Table 6.1. Maximum plasma concentration (Cmax) reported in human subjects
Compound

Cmax (µM)

Route of administration

Dose (mg)

Reference

Epicatechin
1,5-Dicaffeoylquinic acid
18β-Glycyrrhetinic acid
Ursolic acid

0.20
0.14
0.11-2.9a
7.4

Oral
Oral
Oral
i.v.

37
600
130-144 (Glycyrrhizin)
186

(178)
(185)
(183, 186, 187)
(184)

a

Assuming plasma concentration of 18α- and 18β-glycyrrhetinic acid is about 1:3 as reported in (183).
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6.B MATERIALS AND METHODS
6.B.1 Purified chemicals
Catechin, 1,3- and 1,5-dicaffeoylquinic acids, epicatechin, ginkgolic acids (13:0), (15:1), and
(17:1), and ursolic acid (all ≥ 97% purity) were purchased from Tauto Biotech (Shanghai, China).
18β-Glycyrrhetinic acid (≥ 97% purity) was obtained from Sigma -Aldrich (St. Louis, MO). The
chemical structures of these compounds are shown in Figure 6.1. Tritiated p-aminohippuric acid
([3H]PAH) and estrone sulfate ([3H]ES) were purchased from PerkinElmer Life and Analytical
Sciences (Waltham, MA) and unlabeled PAH, ES, and probenecid were purchased from SigmaAldrich (St. Louis, MO).
6.B.2 Cell culture
Derivation and culture of stably transfected Chinese hamster ovary (CHO) cells expressing
hOAT1 (CHO-hOAT1) and hOAT4 (CHO-hOAT4), and stably transfected human embryonic
kidney 293 (HEK) cells expressing hOAT3 (HEK-hOAT3), as well as their corresponding empty
vector transfected background control cell lines, has been described previously (82, 130, 150).
6.B.3 Cell accumulation assays
The cell accumulation assay protocol was performed as described in our recent publications
with minor modifications (82, 109). In brief, 2 × 105 cells/well were seeded in 24-well tissue
culture plates and grown in the absence of antibiotics for two days. For transport experiments
cells were pre-incubated in transport buffer without substrates or inhibitors for 10 min after
which time the buffer was replaced with 400 µL of fresh transport buffer containing 1 µM
[3H]PAH (0.5 µCi/mL) or [3H]ES (0.25 µCi/mL) with or without test compounds. After
incubation for times specified in the figure legends, cellular uptake was quenched by quickly
rinsing each well three times with fresh ice-cold transport buffer. Cells were lysed with 1 M
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Figure 6.1. Chemical structures of compounds investigated in this study.
MW, molecular weight.
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NaOH and radioactivity was measured with a liquid scintillation counter and reported as
picomoles of substrate per milligram total protein. All intracellular uptake data were corrected
for background accumulation in corresponding empty vector transfected control cells. Kinetic
calculations were performed using GraphPad Prism Software version 5.0 (GraphPad Software
Inc., San Diego, CA). The half maximal inhibitory concentrations (IC50) and inhibitory constants
(Ki) were calculated using nonlinear regression with the appropriate models. Results were
confirmed by repeating all experiments at least three times with triplicate wells for each data
point. For kinetic analysis, hOAT1 expressing cells showed linear PAH uptake for the initial 3
min with Km = 15.4 µM (130), while hOAT3 expressing cells exhibited linear ES uptake for the
initial 1 min with Km = 14.5 µM (52).
6.B.4 Statistics
Values are expressed as mean ± S.D. or mean ± S.E.M. as indicated. Statistical differences
were assessed using one-way analysis of variance (ANOVA) followed by post-hoc analysis with
Dunnett’s t-test (α = 0.05).
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6.C RESULTS
6.C.1 Inhibition of hOAT1 by natural anionic compounds and flavonoids
Approximately three fold greater accumulation of PAH was observed in CHO-hOAT1 cells
(6.30 ± 0.97 pmol mg protein‒1 10 min‒1) than in empty vector transfected background control
cells (2.12 ± 0.19 pmol mg protein‒1 10 min‒1). The hOAT1-mediated PAH accumulation was
almost completely inhibited by probenecid (Figure 6.2). The nine test compounds, catechin, 1,3and 1,5-dicaffeoylquinic acid, epicatechin, ginkgolic acids (13:0), (15:1) and (17:1), 18βglycyrrhetinic acid, and ursolic acid, were assessed for inhibitory effects on hOAT1-mediated
uptake (Figure 6.2). 1,3- and 1,5-Dicaffeoylquinic acid (64% and 22% inhibition, respectively),
ginkgolic acid (17:1) (42% inhibition) and 18β-glycyrrhetinic acid (56% inhibition) each
significantly inhibited hOAT1-mediated PAH uptake at 50 fold excess. Ursolic acid produced a
significant stimulation of uptake and the other compounds were without effect. Since 1,3dicaffeoylquinic acid and 18β-glycyrrhetinic acid produced inhibition greater than 50%, they
were further characterized by dose-response studies (0.01–500 μM, shown in Figure 6.3).
Estimated IC50 values were 1.2 ± 0.4 µM for 1,3-dicaffeoylquinic acid and 2.7 ± 0.2 µM for 18βglycyrrhetinic acid. Numerous studies investigating the mode of inhibition produced on hOAT1
and hOAT3 for a broad array of compounds have demonstrated the interaction to be competitive
(51, 151, 188-190). Therefore, assuming competitive inhibition of hOAT1, inhibition constants
(Ki) were estimated as 1.1 ± 0.2 µM for 1,3-dicaffeoylquinic acid and 2.5 ± 0.2 µM for 18βglycyrrhetinic acid.
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Figure 6.2. Inhibitory effects of the nine test compounds on hOAT1-mediated PAH uptake
Ten minute uptake of [3H]PAH (1 µM) was measured in CHO-hOAT1 cells in the absence and
presence of test compounds (50 µM) or probenecid (1000 µM). Data represent hOAT1-mediated
transport specifically, i.e., data have been corrected for background PAH accumulation measured
in empty vector transfected cells. Values are mean ± S.D. of triplicate values from a
representative experiment. ** denotes p < 0.01, and *** denotes p < 0.001 as determined by oneway ANOVA followed by Dunnett’s t-test.
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Figure 6.3. Dose-response effects for 1,3-dicaffeoylquinic acid and 18β-glycyrrhetinic acid
on hOAT1-mediated PAH transport
One minute uptake of [3H]PAH (1 µM) in CHO-hOAT1 cells was measured in the presence of
increasing concentrations (10-7 to 5×10-4 M) of test compounds. Data were corrected by
subtracting background PAH accumulation measured in empty vector transfected cells. IC50
values were determined with nonlinear regression and the “log(inhibitor) vs. response” model
using GraphPad Prism software. Experiments were repeated three times with triplicate samples
and graphs shown are from representative experiments with values plotted as mean ± S.D. (n=3).
The data were used to generate mean IC50 ± S.E.M. estimates.
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6.C.2 Inhibition of hOAT3 by natural anionic compounds and flavonoids
Human OAT3 expressing cells showed about 4 fold greater accumulation of ES as compared
to background control cells (10.6 ± 0.5 vs. 2.6 ± 0.3 pmol mg protein‒1 10 min‒1, respectively).
Similar to hOAT1, hOAT3-mediated ES uptake was completely (> 96% inhibition) blocked by
probenecid (Figure 6.4). Five of the compounds, 1,3- and 1,5-dicaffeoylquinic acid, epicatechin,
and ginkgolic acids (15:1) and (17:1) significantly inhibited hOAT3-mediated transport at 50
fold excess (Figure 6.4). 1,3-Dicaffeoylquinic acid and ginkgolic acid (17:1) exhibited 41%
inhibition, while 30-35% reduction of hOAT3-mediated ES uptake was observed for 1,5dicaffeoylquinic acid, epicatechin, and ginkgolic acid (15:1). Catechin, 18β-glycyrrhetinic acid
and ursolic acid failed to produce significant inhibition. Based on the level of inhibition observed,
IC50 values for all of these compounds would be greater than 50 µM, much higher than clinically
relevant concentrations (Table 6.1). Therefore, further dose-response studies were not performed.
6.C.3 Inhibition of hOAT4 by natural anionic compounds and flavonoids
Stably transfected hOAT4-expressing cells showed ~18 fold higher accumulation of ES than
background control cells (42.5 ± 5.1 vs. 2.4 ± 0.2 pmol mg protein‒1 10 min‒1, respectively).
Human OAT4-mediated ES uptake was virtually completely blocked (> 96% inhibition) by selfinhibition (Figure 6.5). Catechin (50 µM) was the only compound that showed a significant
inhibitory effect (32%) on hOAT4 (Figure 6.5). 1,5-Dicaffeoylquinic acid and 18β-glycyrrhetinic
acid produced significant stimulation of ES uptake. Accordingly, the IC50 value for catechin on
hOAT4 transport activity should be greater than 50 µM and no further kinetic studies were
performed.
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Figure 6.4. Inhibitory effects of the nine test compounds on hOAT3-mediated ES uptake
Ten minute uptake of [3H]ES (1 µM) was measured in HEK-hOAT3 cells in the absence and
presence of test compounds (50 µM) or probenecid (1000 µM). Data represent hOAT3-mediated
transport specifically, i.e., data have been corrected for background ES accumulation measured
in empty vector transfected cells. Values are mean ± S.D. of triplicate values from a
representative experiment. * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 as
determined by one-way ANOVA followed by Dunnett’s t-test.

109

Figure 6.5. Inhibitory effects of the nine test compounds on hOAT4-mediated ES uptake
Ten minute uptake of [3H]ES (1 µM) was measured in CHO-hOAT4 cells in the absence and
presence of test compounds (50 µM) or ES (1000 µM for self-inhibition). Data represent
hOAT4-mediated transport specifically, i.e., data have been corrected for background ES
accumulation measured in empty vector transfected cells. Values are mean ± S.D. of triplicate
values from a representative experiment. * denotes p < 0.05, and *** denotes p < 0.001 as
determined by one-way ANOVA followed by Dunnett’s t-test.
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6.D DISCUSSION
Literally hundreds of therapeutic and endogenous compounds have been demonstrated to
interact with OATs (3, 177). Precisely because of their broad, polyspecific nature, OATs are
likely sites for DDIs in vivo. As a consequence, they have been identified worldwide as a family
of “clinically relevant” transporters in recent government guidances to the pharmaceutical
industry (3, 177). Unlike Western drugs, the pharmacokinetic and pharmacological properties of
botanical drug products and natural supplements have not been well investigated. Being naturally
derived, people often view these compounds as “safe” and without potential for causing adverse
events. However, there is increasing evidence demonstrating potent interactions between
components of natural products and OATs, resulting in possible toxicity and DDIs (3, 177). For
example, aristolochic acid, a potent nephrotoxic contaminant sometimes found in certain Chinese
herbal therapies, was identified as a high affinity substrate of murine Oat1, Oat2 and Oat3, as
well as a potent inhibitor of hOAT1, hOAT3 and hOAT4 (36, 39). Additional studies have
demonstrated the OAT-mediated DDI potential for common flavonoid and phenolic acid
components of foods and herbal medicines (48, 119). These investigations showed that many
dietary/phytomedicine-derived organic acids and flavonoids have a high inhibitory potency for
hOAT1, hOAT3 and/or hOAT4 and, according to proposed guidelines established by the FDA
and EMA, high likelihood to result in significant DDIs in vivo (3, 48, 119, 177). Therefore,
further studies on OAT-mediated natural product/drug interactions are needed in order to
establish informed safety and efficacy profiles for botanical products.
In the present study, we characterized the interactions of nine chemically diverse compounds
including flavonoids, chlorogenic acids, phenolic acids, and other organic acids, found as major
dietary or phytomedicine components, with three human OATs: hOAT1, hOAT3, and hOAT4.
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As illustrated, most of the compounds produced significant inhibition of hOAT1 and hOAT3 at a
50 fold excess concentration (Figures 6.2 and 6.4). In marked contrast, only catechin
significantly inhibited hOAT4 under this condition (Figure 6.5). Interestingly, ursolic acid
caused a significant stimulation of hOAT1-mediated PAH uptake while it was without effect on
either hOAT3 or hOAT4 transport activity. Similarly, 1,5-dicaffeoylquinic acid and 18βglycyrrhetinic acid appeared to significantly stimulate hOAT4 transport while decreasing
hOAT1- and hOAT3-mediated uptake. Such sporadic transporter stimulation/inhibition has been
previously reported in the literature for other compounds. For example, for fluoroquinolone
antimicrobials, ciprofloxacin inhibited hOAT3, but stimulated hOAT1 (82) and sparfloxacin was
reported to stimulate multidrug resistance-associated protein 2 activity (170). Such stimulation of
transport activity in vitro also has been reported for steroids, chemotherapeutic agents, and nonsteroidal anti-inflammatory drugs (82, 169, 170, 191). One potential explanation is allosteric
binding of the compounds to the transporters with subsequent alteration of substrate affinity (169,
170). However, these transporters share a high degree of sequence identity and no readily
discernible structural differences corresponding to such a binding site are apparent, and these
effects do not exhibit a consistent pattern among the hOATs. Whether these effects will be
observed in vivo is yet to be determined, however, in such an instance increased (vs. decreased)
elimination and shortened (vs. lengthened) terminal half-life of victim drugs could occur causing
loss of efficacy.
The FDA guidance on drug interaction studies proposed using the DDI index, calculated as
the ratio of unbound Cmax over IC50 or Ki, as an indicator for the assessment of a compound’s
DDI potential, with a value greater than 0.1 indicating the potential need to perform an in vivo
DDI study for an investigational drug. In the current study, 18β-glycyrrhetinic acid exhibited
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strong inhibition of hOAT1 with an estimated IC50 of 2.7 ± 0.2 µM or Ki of 2.5 ± 0.2 µM
(Figures 6.3). Human exposure studies reported Cmax values ranging from 0.11 to 2.9 µM (Table
6.1), perhaps due to interindividual variability, different doses, and/or dosing regimen (single
dose vs. repeated dose). As such, the maximum DDI for 18β-glycyrrhetinic acid is ~1.1;
although this value does not account for plasma protein binding as this is unknown. However, if
we assume it to be highly plasma protein bound, e.g., 90%, the DDI index would be 0.12,
meeting the FDA guidance threshold of 0.1. Therefore, 18β-glycyrrhetinic acid may affect
hOAT1-mediated renal elimination of coadministered therapeutics that are hOAT1 substrates.
1,3-Dicaffeoylquinic acid is a major component found in artichoke and Echinacea purpurea
(192, 193). Pharmacological studies demonstrated that it exhibits antimicrobial and antioxidant
activity (192, 194). Moreover, it has garnered increased interest because of its anti-HIV and
immunosuppressive properties. 1,3-Dicaffeoylquinic acid blocked HIV-1 integrase activity,
leading to interference of insertion of viral DNA into the genome of the victim cell (181).
Another study demonstrated that it inhibited the interaction between CD28 of T-cell receptor and
CD80 of antigen presenting cells, blocking “signal 2” of T-cell activation (193). Due to its
potential development as a therapeutic agent, systemic exposure in clinical applications may
reach high levels. In the present study, 1,3-dicaffeoylquinic acid showed high affinity with
hOAT1 (IC50 = 1.2 ± 0.4 µM; Ki = 1.1 ± 0.2 µM). Therefore, the dose-systemic exposure
relationship and plasma protein binding should be elucidated as part of the future drug
development process for this compound.
It has been reported that flavonoids can interact with OATs (48). Therefore, catechin and
epicatechin, two flavonoid components from green tea were investigated for potential interaction
with hOAT1, hOAT3 and hOAT4. Both compounds exhibited significant inhibition of hOAT4
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and hOAT3 when present at a 50 fold excess, however no inhibition was observed for hOAT1.
Because of low reported clinical plasma concentrations (Table 6.1), these flavonoids were
determined to be unlikely to cause DDIs after normal consumption of tea products. However,
OATs might promote entry of these antioxidants into renal proximal tubules, providing a
nephroprotective effect.
In summary, we investigated the potential interaction of nine flavonoids, phenolic acids,
chlorogenic acids, and other organic acids with hOAT1, hOAT3, and hOAT4. Among the
examined compounds, 1,3-dicaffeoylquinic acid and 18β-glycyrrhetinic acid showed marked
affinity with hOAT1. In humans, systemic exposure of 18β-glycyrrhetinic acid may induce
significant hOAT1-associated DDIs. Future in vivo interaction studies between 18βglycyrrhetinic acid or 1,3-dicaffeoylquinic acid and clinical therapeutics known to be hOAT1
substrates may be necessary to establish safety guidelines for use of pharmaceutical products
containing these compounds to avoid potential DDIs.
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CHAPTER 7
SIMULTANEOUS DETERMINTION OF GALLIC ACID AND GENTISIC ACID IN
ORGANIC ANION TRANSPORTER EXPRESSING CELLS BY LIQUID
CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY

Drawn from manuscript submitted in J Chromatogr B. 2013

7.A INTRODUCTION
Over the last two decades, impressive progress has been made to elucidate the impact of drug
transporters in drug absorption, disposition, and elimination, therapeutic efficacy and adverse
drug reactions (3, 177). In order to understand the role of drug transporters in pharmacokinetics
and avoid potential drug-drug interactions (DDIs), the United States Food and Drug
Administration (FDA) has recently issued guidance documents, requiring investigations on
potential new drug entity-drug transporter interaction on seven identified transporters; organic
anion transporter 1 (OAT1), OAT3, organic cation transporter 2, organic anion transporting
polypeptide 1B1, organic anion transporting polypeptide 1B3, multidrug resistance transporter 1,
and breast cancer resistance protein, prior to approval (52).
Numerous studies demonstrated that OATs handle substances carrying negative charge(s) at
physiological pH (3, 177). Phenolic acids (plant secondary metabolites that are widely
distributed in fruits, vegetables, and beverages) might be OAT substrates, since the PKa values
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for these compounds are much less than 7.4 (43). They are characterized by hydroxylated
aromatic ring(s) bearing carboxyl substituents (140). In general, phenolic acids, including gallic
acid and gentisic acid, possess anti-oxidant, anti-carcinogenic, and anti-inflammatory activities
(162, 163). Gallic acid, in addition to fruits and vegetables, is a major component in herbal
supplements, homeopathic remedies, and pharmaceutical products (139, 162, 163). Gentisic acid
was identified as a major metabolite of salicylate (143). Pharmacokinetic studies have shown that
these compounds undergo renal elimination as the unchanged parent form (144, 163). Our
previous work demonstrated that gallic acid and gentisic acid have high affinity for human
OAT1 and OAT3, with IC50 values in the low micromolar range (52). However, whether these
compounds are actually OAT substrates, or only non-transported inhibitors, remains unclear.
This information is key to determining whether OAT-mediated active secretion is involved in the
renal elimination of these compounds. In addition, since such interaction would result in
preferential tissue distribution, the findings would be helpful to show the target organ(s) in which
these compounds exert beneficial therapeutic effects.
To address this issue, a sensitive, robust, and precise bioanalytical method is required for
quantification of gallic acid and gentisic acid in cell lysate. Compared with other routine
analytical techniques, liquid chromatography (LC) interfaced to mass spectrometry (MS) or
tandem mass spectrometry (MS/MS) has facilitated sensitive and selective quantification in
pharmaceutical studies. For published assays describing LC-MS/MS based measurement of
gallic acid and gentisic acid in a biological matrix, insufficient sensitivity (LLOQ of 0.5 and 9.4
ng/mL, respectively) and limited linear dynamic range (0.5-500 and 9.4-191.5 ng/mL,
respectively) make these methods less desirable for quantifying drug transporter mediatedcellular uptake of gallic acid and gentisic acid (195, 196). In addition, the run-time of the
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reported quantification method for gentisic acid is long (17 min) (196). Furthermore,
electrospray ionization (ESI), which allows analysis of non-volatile, polar molecules compared
with other ion source designs (e.g., atmospheric pressure chemical ionization (APCI)), is more
susceptible to matrix effects, exhibiting as impaired assay accuracy and precision. Unfortunately,
previously published assays did not evaluate matrix effect (195, 196), or only investigated
plasma-derived matrix effect (195, 196). For the purpose of cell-based bioassay, the potential
matrix effect caused by cell lysate matrix should be studied. To the best of our knowledge,
however, no liquid chromatography-tandem mass spectrometry (LC/MS-MS) based assay has
been established to directly measure the uptake of gallic acid or gentisic acid in cell lysate.
In the present study, a rapid, sensitive, and reproducible LC/MS-MS method was developed
and validated to simultaneously determine the concentrations of gallic acid and gentisic acid in
cell lysate. The method requires 100 μL of cell lysate to obtain a lower limit of quantification of
0.33 ng/mL and a chromatographic run time of 3 min for both analytes. Results from postcolumn infusion and the post extraction addition method indicate that the quantification of both
analytes was not affected by matrix effects. Compared with previously described methods, this
new method exhibits higher analytical performance with respect to sensitivity, linear dynamic
range, and speed. Following validation, the assay utility was demonstrated in a measurement of a
cellular uptake study of gallic acid and gentisic acid in OAT-expressing cells.
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7.B MATERIAL AND METHODS
7.B.1 Chemicals and reagent
Gallic acid, gentisic acid, probenecid, and sodium L-ascorbate (≥ 97% purity) were
purchased from Sigma-Aldrich (St. Louis, MO). Danshensu (≥ 96% purity) was used as the
internal standard (IS) and purchased from Tauto Biotech (Shanghai, China). The chemical
structures of gallic acid, gentisic acid, and the IS are shown in Figure 7.1. HPLC-grade acetic
acid (CH3COOH, 99.93%), acetonitrile (CH3CN 99.9%), ethyl acetate (EtOAc, 99.84%), and
formic acid (HCOOH, 99.93%) were purchased from Merck (Darmstadt, Germany). Deionized
water was generated from a Direct-Q1 3 UV water purifying system (Millipore, Bedford, MA).
7.B.2 Instrumentation
An API 4000Qtrap hybrid triple quadrupole/linear ion trap mass spectrometer (AB Sciex.,
Foster City, CA) was interfaced with an electrospray ionization source with liquid
chromatography including a Waters Acquity UPLC® system (Waters Corporation, Milford, PA).
Analyst 1.5 data acquisition software (Waters Corp., Milford, MA, USA) was used to control the
LC-MS/MS system, as well as for data acquisition and processing. Nitrogen gas was generated
from a Parker Hannifin (Haverhill, MA, USA) Tri-Gas Generator LC/MS 5000.
7.B.3 LC-MS/MS condition
The analytes and the IS were separated on a Gemini C18 column (100 mm × 2.0 mm I.D., 5
μm) with a Security Guard column (Gemini C18, 4 mm
× 2.0 mm, 5μm) from Phenomenex
(Torrance, CA, USA). Mobile phases consisted of 0.1% acetic acid in water (A) and 0.05%
formic acid in acetonitrile (B). An isocratic elution (40% A) was conducted with a flow rate of
0.35 mL/min. The total run time was 3 min.
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Figure 7.1. Chemical structures of gallic acid, gentisic acid, and Danshensu (IS) were
drawn using ChemDraw Ultra (PerkinElmer Inc., Waltham, MA)
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The mass spectrometer was operated in the negative ESI mode with selected reaction
monitoring (SRM). The optimized mass spectrometric parameters were as follows: ion source
temperature (TEM = 325 °C), ion transfer voltage (ITV = ‒4500 V), collision gas (CAD = high),
curtain gas (CUR = 14), ion source gas 1 (GS1 = 55) and ion source gas 2 (GS2 = 20). The units
for gases are arbitrary. The dwell time was 200 ms for all test compounds. SRM transitions,
collision energies (CE), declustering potential (DP), and Q3 fragment ion descriptions are shown
in Table 7.1.
7.B.4 Cell culture
Derivation of stably transfected Chinese hamster ovary (CHO) cells expressing murine Oat1
(CHO-mOat1) and murine Oat3 (CHO-mOat3), and corresponding empty vector transfected
background control cell line (CHO-FRT), has been described previously (82). CHO cell lines
were maintained at 37°C with 5% CO2 in DMEM F-12 media (Mediatech, Inc., Herndon, VA)
containing 10% serum, 1% Pen/Strep and 125 µg/ml hygromycin B.
7.B.5 Sample preparation
Cell lysate samples (100 µL) were mixed with 10 µL of the 1000 ng/mL IS working solution
and 10 µL of the 50 µM ascorbic acid working solution to prevent oxidation. Then the sample
was acidified with 5 µL of 2N hydrochloric acid and extracted with 900 µL of EtOAc by vortexshaking for 10 min. After centrifugation at 13000 rpm for 5 min, the upper EtOAc phase (800 µL)
was removed and reduced to dryness under a stream of nitrogen at 40°C at 15-20 PSI. The dry
residue was reconstituted in 150 µL of reconstitution solvent (acetonitrile/H2O; 25:75 v/v)
containing 0.1% acetic acid and 5 µM ascorbic acid, centrifuged at 13000 rpm for 5 min, and 20
µL of the supernatant was introduced into the LC-MS/MS system.
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7.B.6 Calibration and validation.
Blank cell lysate samples (995 µL) were spiked with 5 µL of the gallic acid and gentisic acid
working solution (1000 µg/mL) and then serially diluted with blank cell lysate to generate
nominal concentrations of 2400, 1000, 500, 200, 80, 32, 12.8, 5.12, 2.05, 0.82 and 0.33 ng/mL
for both analytes, respectively. These matrix-based calibration standards were extracted with
EtOAc for analysis. Calibration curves were constructed using linear regression of the peak area
ratio of the analytes to the IS (Y) against the corresponding nominal concentrations of the
analytes in cell lysate (X, ng/mL) with a weighting factor of 1/x2.
The extraction efficiency was assessed by comparing the peak areas of the analytes added to
blank cell lysate at three levels (1, 50, and 2000 ng/mL) before sample clean-up with the same
amount of the analytes added to post-extraction cell lysate blanks (n=6). The stability test
included freeze/thaw stability in cell lysate during and after three -80°C↔25°C (room
temperature) cycles at two levels (1 and 2000 ng/mL), short-term stability in cell lysate at 25°C
for 6 h and long term stability in cell lysate at -80°C for 1 month at two levels (1 and 2000
ng/mL), and post-preparation stability in reconstitution solution at 4°C for 24 h at three levels (1,
50, and 2000 ng/mL). The long term stock solution stability (6 months) was also investigated.
For each concentration level, quality control (QC) standards were prepared and extracted n=6.
QC samples at 1, 50, and 2000 ng/mL (n=6) were determined on the same day or three
different days to evaluate intra-day or inter-day precision and accuracy, respectively. Intraday/inter-day accuracy and precision were calculated as the percentage of mean measured
concentration to the corresponding nominal concentration and coefficient of variation of the
measured concentrations. The lower limit of quantification (LLOQ) was determined based on the
criterion of being within ±20% of precision and accuracy.
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7.B.7 Matrix effects evaluation
Matrix effects were assessed by both post-column infusion and post extraction method. The
procedure for post-column infusion was described previously (197). Briefly, the prepared blank
cell lysate sample was injected while infusing the analytes and the IS (1000 ng/mL) in
reconstitution solution at 15 µL/min into the ESI interface through a mixing tee. Compared to
resulting profiles of mobile phase injection, response change observed from the blank cell lysate
sample indicates ionization suppression or enhancement. Post extraction method was conducted
by comparing the peak areas of the analytes (1, 50, and 2000 ng/mL) and the IS (100 ng/mL)
dissolved in reconstitution solution versus post-spiked extracted cell lysate (n=6). The ratio of
mean peak areas for the test compounds in pure reconstitution solution to those with sample
matrix was used to quantify matrix effects.
7.B.8 Application to cellular uptake study
The protocol for the cellular accumulation studies was adapted from a previously published
study with minor modifications (52). In brief, cells were seeded in 24-well tissue culture plates at
a density of 2 × 105 cells/well and grown in the absence of antibiotics for 48 h. Then, the cells
were equilibrated with 500 µL of transport buffer [Hanks’ balanced salt solution containing 10
mM HEPES (Sigma-Aldrich, St. Louis, MO), pH 7.4] for 10 min. The equilibration buffer was
then replaced with 500 µL of fresh transport buffer containing 10 µM gallic acid or gentisic acid.
After incubation for 10 min, cells were immediately rinsed three times with ice-cold transport
buffer, and lysed with 200 µL 1 N NaOH. Cell lysate was neutralized with 2 M HCl (100 µL).
Aliquots (100 µL) were extracted as described in Section 2.4 for LC-MS/MS analysis and total
protein determination using a Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA).
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7.C RESULTS AND DISCUSSION
7.C.1 LC-MS/MS
The chemical structures of gallic acid and gentisic acid indicate that they are more likely to
be deprotonated to produce [M–H]– in the ESI source, and this was confirmed by comparing the
response of the analytes between positive and negative ESI mode. Parameters for mass
spectrometry were optimized for quantification of gallic acid and gentistic acid in negative mode.
Product ions for gallic acid and gentisic acid were chosen based upon intensity and
reproducibility. A fast isocratic program was used to achieve optimal chromatographic behavior,
with total run time of 3 min. Retention times were 0.98, 2.09, and 1.03 min for selected
transitions of gallic acid (m/z 169.0→125.0), gentisic acid (m/z 153.1→108.0), and the IS (m/z
196.8→135.2), respectively. The chosen mobile phase additive conditions (0.1% acetic acid in
mobile phase A and 0.05% formic acid in mobile phase B) improved chromatographic peak
shape and intensity of the analytes. However, other mobile phase additives (0.1% acetic acid in
mobile phase A and B, 0.05% formic acid in mobile phase A and B, and 0.1% formic acid in
mobile phase A and B) were not suitable for gallic acid, as they resulted in asymmetrical peak
shape or poor retention. Gallic acid and gentisic acid fragmentation patterns were identical with
those previously described (196). Representative chromatograms of blank cell lysate, blank cell
lysate spiked with gallic acid (200 ng/mL), gentisic acid (200 ng/mL), and the IS (100 ng/mL)
are shown in Figure 7.2.
7.C.2 Validation of the analytical method
7.C.2.1 Linearity and specificity
The intensity, shown as peak area ratio of gallic acid or gentisic acid to the IS in cell lysate,
was linear over the range 0.33-2400 ng/mL. The calibration curves for quantification of the
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tested compounds in cell lysate showed a correlation coefficient (r2) greater than 0.995. A
weighting factor of 1/x2 was used for both analytes. The magnitude of linear dynamic range was
much wider than previously reported methods (195, 196). The percent relative standard deviation
for the mean back-calculated values fell within 15%, showing good accuracy for calibration
standards. As shown in Figure 7.2, no co-elution of matrix components from cell lysate was
observed at retention times corresponding to the analytes, demonstrating that the method had
good specificity. Moreover, no cross-interference among the analytes and the IS was found. No
significant peaks were found at retention times corresponding to the analytes and the IS in blank
sample immediately following the calibration standards at upper limit of quantification (2400
ng/mL), suggesting insignificant carryover for this method. An extract peak with constant signal
(1500-3000 cps) was observed in the gallic acid channel, which was not seen in the blank cell
lysate. While the exact reason for this extra peak is unknown, the proposed isocratic elution was
capable of separating this peak from the peak for gallic acid, with retention times of 1.30 min
and 0.98 min, respectively. This extra peak did not affect the calculation of peak area for gallic
acid.
7.C.2.2 Accuracy and precision
Intra-day and inter-day precision and accuracy for the analytes are shown in Table 7.2. The
maximum deviation of accuracy and precision for intra-day and inter-day validation were well
below 13.5%. The LLOQ was determined at 0.33 ng/mL for both analytes, with the precision
and accuracy within +14.1%.
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7.C.2.3 Extraction recovery
The mean extraction efficiency for gallic acid in cell lysate determined by analyzing the cell
lysate QC standards at 1, 50, and 2000 ng/mL were 77.3 ± 9.8%, 76.5 ± 4.8% and 88.2 ± 4.6%
respectively. The results for gentisic acid show a mean extraction recovery of 77.6-86.9% with
the RSD below 3.5% (86.0 ± 3.5%, 86.9 ± 2.2% and 77.6 ± 0.9% for 1, 50, and 2000 ng/mL,
respectively). The extraction recovery of the IS was 51.7 ± 2.3% at 100 ng/mL. As gallic acid,
gentisic acid and the IS each carry a carboxylic group, a low pH environment favors maintaining
unionized compounds in the sample, facilitating extraction. In this study, the chosen condition (5
µL 2N hydrochloric acid) markedly improved extraction efficiency compared with the untreated
condition.
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Table 7.1. Selected reaction monitoring transitions and the optimum LC-MS/MS
conditions
Compound
Gallic acid
Gentisic acid
Danshensu (IS)
a

Q1 (Da)
169.0
153.1
196.8

Q3 (Da)
125.0
108.0
135.2

Declustering potential; b Collision energy.
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Figure 7.2. Example chromatograms for the analytes and IS in a typical blank cell lysate (upper panels), analytes and the IS
dissolved in pure reconstitution solution (middle panels), and extracted cell lysate sample spiked with the analytes at LLOQ
and the IS at 100 ng/mL (lower panels)
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Figure 7.3. Post-column infusion profiles of the analytes and the IS (1000 ng/mL) in the absence (left panels) or presence (right
panels) of cell lysate-derived matrix. Dashed lines indicate the retention time of the test compound
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Table 7.2. Intra- and inter-day precision and accuracy in determination of gallic acid and gentisic acid

Nominal Conc. (ng/mL)
Intra-day
Measured Conc. (ng/mL)
mean ± SD, n =6
Precision (RSD, %)
Accuracy (% bias)
Inter-day*
Measured Conc. (ng/mL)
mean ± SD, n =6
Precision (RSD, %)
Accuracy (% bias)

1

Gallic acid
50

1

Gentisic acid
50

2000

2000

1.06±0.11

50.6±2.08

1745±68.8

1.09±0.08

55.5±1.94

1832±56.9

10.4
6

4.11
1

3.94
-12.7

7.34
9

3.50
11

3.11
-8.4

0.99±0.10

45.2±5.00

1845±143

1.00±0.10

49.1±6.59

1868±100

10.1
-0.7

11.1
-9.5

7.75
-7.7

10.0
0

13.4
-1.8

5.35
-6.6

*QCs analyzed n =3 in three separate days
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7.C.2.4 Matrix effects
Matrix effects were firstly evaluated by post-column infusion of test compounds dissolved in
reconstitution solution at 1000 ng/mL. Post-column infusion profiles were obtained in the ESI
negative mode (shown in Figure 7.3) exhibiting matrix effects of EtOAc-extracted cell lysate on
the response of the tested compounds. When compared to post-column infusion profiles for
mobile phase, no significant matrix effects (indicated by ionization suppression or enhancement)
were observed throughout the entire sample-run window in the presence of matrix components in
the ESI source. The post-extraction addition study revealed that co-eluting matrix failed to
exhibit significant suppression or enhancement (<15%) on the ESI response of both gallic acid
and gentisic acid, confirming that matrix effects did not impact the established assay method.
7.2.C.5 Stability
Stability assessment was conducted by determination of QC standards treated under different
conditions representing post-preparation stability, short and long term storage stability, stock
solution stability, and freeze-thaw stability. Since phenolic compounds can be easily oxidized, an
anti-oxidant was necessary to keep the analytes and the IS stable in the sample during
preparation. In the present study, ~5 µM of ascorbic acid was determined to be sufficient for
preventing oxidation while 20 µM impaired the chromatographic peak shape of gallic acid (data
not shown). The accuracy of treated QC standards was calculated by freshly prepared calibration
standards. QC standards for post-preparation stability exhibited acceptable accuracy and
precision (±7%) at 1, 50, and 2000 ng/mL. Short and long term storage stability results ranged
from −4.2% to 12.5% biases for test levels (1 and 2000 ng/mL). Gallic acid and gentisic acid in
stock solution stored at ‒80°C for 6 months was stable, with peak area response difference never
exceeding 1.7%. Freeze-thaw stability was assessed for three cycles at two levels (1 and 2000
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ng/mL), resulting in biases ranged from 3.6 to 8.2%. The IS, Danshensu, failed to show
significant degradation in reconstitution solution at 4°C for 24h, with a peak area response
difference of 10.9%.
7.C.3 Determination of the intracellular concentration of gallic acid and gentisic acid in OATexpressing cells.
The suitability of the LC-MS/MS method presented here to determine gallic acid and gentisic
acid levels in cell lysates from a cellular uptake study using murine (m)Oat1- or mOat3expressing cells (CHO-mOat1 cells and CHO-mOat3 cells, respectively) was tested. Inhibitor
(probenecid)-sensitive transport activity of these transfected cells was confirmed previously (49).
When incubated with gallic acid (10 µM) for 10 min, the intracellular concentration of gallic
acid in CHO-mOat1 cells was 1.12 ± 0.33 ng/mL, while the concentrations of gallic acid in
CHO-mOat3 cells, CHO-FRT(control cells), or probenecid-treated cells were below the LLOQ
(Figure 7.4). These data indicate markedly increased intracellular uptake in the CHO-mOat1
cells, as compared with CHO-FRT and CHO-mOat3 cells. The absorptive uptake was completely
inhibited by probenecid (known OAT inhibitor) at 1 mM. Normalized with the protein content in
cell lysate, the cellular uptake rate of gallic acid in mOat1-expressing cells was 10.4 ± 3.7
ng/mL/mg protein/10 min. The intracellular concentration of gentisic acid in CHO-mOat1, CHOmOat3 and CHO-FRT background control cells after incubation were below the LLOQ (Figure
7.4).
These results indicate that gallic acid is a substrate for mOat1 and suggest that human OAT1
might be involved in the active renal secretion of gallic acid. This finding is consistent with a
previous clinical pharmacokinetic study showing that the unbound renal clearance of gallic acid
was 1.7 fold higher than the glomerular filtration rate (~120 mL/min) (163). Collectively, these
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data show that the newly developed analytical method can be used to assess cellular uptake of
gallic acid and gentisic acid.
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Figure 7.4. Cellular uptake of gallic acid and gentisic acid in mOat1- and mOat3expressing cells, as well as empty vector transfected background control cell line (CHOFRT). The concentration of gallic acid, gentisic acid, and probenecid (known OAT
inhibitor) for incubation were 10 µM, 10 µM, and 1000 µM. LLOQ, lower limit of
quantification; BLQ, below LLOQ.
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7.D CONCLUSIONS
As the FDA has suggested that potential drug transporter-mediated DDI should be
investigated to avoid unexpected adverse effects, validated bioanalytical methods to directly
measure drug transporter-mediated cellular uptake are needed. In the present study, we reported
a specific, sensitive, and reliable LC-MS/MS method for analysis of gallic acid and gentisic acid
from complex cell lysate samples, with LLOQ of 0.33 ng/mL. Good linearity was obtained with
concentrations ranging from 0.33 to 2400 ng/mL. Method validation results showed acceptable
intra-/inter-day accuracy and precision as well as stability, and insignificant matrix effects.
Compared with previous reported methods, this assay was highly sensitive and rapid, with wider
linear dynamic range, which fits for the purpose of cell-based in vitro novel substrate
identification and screening of potential DDI. Finally, the suitability of this method was
demonstrated in a cellular uptake study in which the intracellular concentrations of gallic acid
and gentisic acid in OAT-expressing cells was measured. The method described here can be
applied to study potential interaction of gallic acid or gentisic acid with any transporter family,
e.g., OATs (SLC22 transporter family), multidrug resistance-associated proteins (MRPs; ABCC
transporter family), and organic anion transporting polypeptides (OATPs; SLCO family), as well
as to investigate their absorption and metabolism profiles with in vitro models, e.g., Caco-2 cells
and primary hepatocytes.
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CHAPTER 8

SYSTEMIC LEVEL EVALUATION OF ORGANIC ANION TRANSPORTERMEDIATED DRUG-DRUG INTERACTION POTENCY IN SALVIA MITIORRHIZA
(DANSHEN) PREPARATIONS: FOCUSING ON CUMULATIVE EFFECTS FROM
MULTIPLE COMPONENTS

8.A INTRODUCTION
Danshen, the dried root of Salvia miltiorrhiza, is used by patients as a part of traditional
Chinese medicine in the treatment of cardiovascular disease (100, 101). The major
pharmacological effects in cardiovascular therapy may include improvement of microcirculation,
preventing platelet adhesion and aggregation, and inhibiting the formation of thromboxane (100,
101). Presently, there are more than 900 commercial Danshen preparations manufactured in
China,

and

injectables

account

for

~30%

of

total

Danshen

products

(http://www.sda.gov.cn/WS01/CL0001/). Typical of herbal medicines, Danshen pharmaceutical
products are actually a mixture of ingredients, including phenolic acids such as lithospermic acid
(LSA), rosmarinic acid (RMA), salvianolic acid A (SAA), salvianolic acid B (SAB, also named
lithospermic acid B), and tanshinol (TSL, also named danshensu), each of which has been
identified as a major component in these preparations (103, 104, 116, 198). However, because of
variations in cultivars, cultivation regions, manufacturing, and lack of standard quality control
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criteria, the content of such components in Danshen preparations can exhibit wide variation
among products from different sources. Such lack of standardization of the major Danshen
components makes it difficult to predict systemic and peak exposure of these components
between products, or to evaluate any exposure-related toxicity and drug-drug interaction (DDI)
potential in clinical applications for products from various manufacturers (103, 199).
The number of reports on drug transporter-mediated DDIs from numerous preclinical and
clinical studies has increased (136). Among these transporter families, the organic anion
transporter (OAT; SLC22) family mediates the renal transcellular solute flux of a multitude of
endogenous substances and xenobiotics that carry negative charge(s) at physiological pH (3).
Because of their broad substrate specificity, many clinically important therapeutics have been
identified as OAT substrates and/or inhibitors, such as antibiotics, antiviral and anticancer agents,
statins, and angiotensin-converting enzyme inhibitors (3). As a result, United States Food and
Drug Administration (FDA) regulatory, industrial and scientific experts have developed
recommendations under what circumstances DDIs with seven selected transporters, including
OAT1 and OAT3, need to be investigated (118, 136).
The DDI index is introduced as the unbound maximum plasma concentration (Cmax or Css) of
a drug component of interest at the highest clinically relevant dose over the in vitro transporter
inhibition potency of the compound (Ki or IC50) as an indicator of DDI potential. Conservatively,
follow-up clinical DDI investigations are recommended when the DDI index ≥ 0.1 (136). For the
majority of drug products, the DDI index is affected by only one or a few ingredients with
constant content even between different manufacturers. However, for herbal medicines and
natural products, the DDI index estimation becomes more complicated as they contain numerous
components that can interfere with drug transporter activity, whether identified as an active

136

component or not. These components, in most cases, show marked similarity in chemical
structure. This fact is quite important for assessment of DDI potential, since drug transporters,
including OATs, interact with an array of compounds with marked diversity in their chemical
structure (136). As a result, it is highly probable that more than one component in an herbal
product could demonstrate a strong potential to interact with any specific transporter. Therefore,
a new parameter to express this multifaceted inhibition potential on transporters, the cumulative
DDI index, is proposed. This parameter, shown as the sum of each component’s DDI index,
reflects the overall DDI potential for multiple-component herbal preparations at clinically
relevant concentrations.
Using Danshen as an example of herbal medicine, our previous work demonstrated that LSA,
RMA, SAA, SAB and TSL each showed significant competitive inhibitory effects on human
(h)OAT1- and hOAT3-mediated substrate uptake, and their corresponding Ki values on hOAT1
and hOAT3 are shown in Table 8.1 (190). Since all of these Danshen components showed
competitive inhibition on human OAT transport activity, it is likely that these compounds share
the same binding site such that cumulative inhibitory effects would emerge after administration
of Danshen products with varying composition of these ingredients. The first aim of the present
study was to compare the inhibitory effects of individual Danshen components (LSA, RMA, and
TSL) vs. a mixture of components on hOAT1 and hOAT3. Pharmacokinetic modeling was used
to predict plasma concentrations for Danshen products after i.v. bolus and i.v. infusion
administration of clinically relevant doses. Finally, the new index, the cumulative DDI index,
was evaluated for Danshen injectables from different manufacturers and different lots/batches
from the same manufacturer. Results from this study demonstrate that the cumulative DDI index,
which shows the overall inhibition potential of Danshen preparations, was significantly higher
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than the DDI index from any single component, indicating that the DDI index for any single
component in a complex mixture is likely to underestimate the true DDI potential of that product.
Additionally, the cumulative DDI indices are highly variable between Danshen injectables from
different manufactures as well as between different lots/batches produced by the same
manufacturer. Such information might be useful in guiding quality control in the manufacture
and clinical application of such pharmaceutical products.
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8.B MATERIALS AND METHODS
8.B.1 Materials
The Danshen components LSA, RMA, and TSL (≥ 96% purity) were obtained from Tauto
Biotech (Shanghai, China). Tritiated PAH ([3H]PAH) and ES ([3H]ES) were purchased from
PerkinElmer Life and Analytical Sciences (Waltham, MA) and unlabeled PAH, ES, and
probenecid were purchased from Sigma-Aldrich (St. Louis, MO).
8.B.2 Tissue culture
Derivation of stably transfected Chinese hamster ovary (CHO) cells expressing hOAT1 and
stably transfected human embryonic kidney 293 (HEK) cells expressing hOAT3, and their
corresponding empty vector transfected control cell lines, has been described previously (52).
CHO cell lines were cultured in phenol red-free RPMI 1640 medium (Gibco Invitrogen., Grand
Island, NY) containing 1 mg/mL G418. HEK cell lines were cultured in DMEM High glucose
medium (Mediatech, Inc., Herndon, VA) containing 125 µg/ml hygromycin B. All cultures
contained 10% FBS and 1% Pen/Strep, and were maintained at 37°C with 5% CO2.
8.B.3 Cell accumulation assays
Cell transport assay procedures were adapted from those previously published (52). In brief,
2 × 105 cells/well were seeded in 24-well tissue culture plates and grown in the absence of
antibiotics for 48 hr. On the day of the experiment cells were equilibrated with transport buffer
for 10 min [500 µL of Hanks’ balanced salt solution containing 10 mM HEPES, pH 7.4].
Equilibration buffer was replaced with 500 µL of fresh transport buffer containing 1 µM
[3H]PAH (0.5 µCi/mL) or 1 µM [3H]ES (0.25 µCi/mL) with or without inhibitors. After
incubation, cells were immediately rinsed three times with ice-cold transport buffer, lysed, and
analyzed via liquid scintillation counting. Substrate accumulation was reported as picomoles of
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substrate per milligram protein. The concentrations of LSA, RMA, and TSL were chosen to
exhibit mild inhibition≤( 61%).

Results were confirmed by repeating all experiments at least

three times with triplicate wells for each data point in every experiment.
8.B.4 Derivation of cumulative DDI index
Commonly, the influence of a single competitive inhibitor on transporter activity is described
as follows;

V0
I
= 1+
Vi
Ki
where V0, Vi, and I represent Vmax in the absence of inhibitor, Vmax in the presence of inhibitor
and the relevant concentration of the inhibitor, respectively. According to the “Guidance for
Industry: Drug Interaction Studies” issued by the FDA, I/Ki was proposed as an indicator for
estimating the DDI potential (118). However, assuming independent competitive inhibition by
all inhibitors in the presence of multiple (n) inhibitors, the influence on transport activity
becomes;

V0
I
I
I
= 1 + 1 + 2 + ⋅⋅⋅ + n
Vi
K i ,1 K i ,2
Ki ,n
where In and Ki,n represent the relevant concentration and inhibition constant of the individual
inhibitors (n), respectively. As illustrated, the sum of In/Ki,n for n inhibitors plays an equivalent
role on transporter function as I/Ki for a single competitive inhibitor. As a result, for Danshen
preparations, which include multiple components known to be competitive OAT inhibitors (190),
the sum of In/Ki,n, designated as the cumulative DDI index, was used to describe the DDI
potential of these complex mixtures.
8.B.5 Pharmacokinetic modeling
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In order to determine relevant plasma concentrations for various doses of the different
Danshen components, pharmacokinetic models had to be developed. Pharmacokinetic modeling
was performed with WinNonlin software (version 5.2.1, Pharsight, St. Louis, MO, USA) using
plasma concentration data from a previously reported clinical pharmacokinetic study on human
subjects after a single 60 min i.v. infusion of a Danshen injectable (104). The doses were 5 mg, 3
mg, 160 mg, 65 mg, and 90 mg for caffeic acid (CA), LSA, RMA, SAB, and TSL, respectively
(104). All observed plasma concentrations were above the assay LLOQ (8 ng/mL for all
components), except for those of RMA at the last two time points (104). As a result, these two
points were excluded from pharmacokinetic calculations. Initially, several pharmacokinetic
compartment models were investigated during the model selection process. An i.v. infusion twocompartment model with first-order elimination was chosen as the final pharmacokinetic model
based on the law of parsimony (simplest model) and goodness of fit including Akaike Criteria
(AIC), Schwarz Bayesian Criterion (SBC), Weighted Sum of Square of Residuals (WSSR),
visual inspection of weighted residuals versus observed concentrations, and fitted and observed
plasma concentrations versus time. The schematic representation of this model is as follows

where k10 is the elimination rate constant from compartment 1, k12 is the distribution rate constant
from compartment 1 to compartment 2, k21 is the distribution rate constant from compartment 2

141

to compartment 1, and V1 represents volume of compartment 1. Compartments 1 and 2 represent
central and peripheral compartments, respectively.
8.B.6 Simulation of plasma concentrations and estimation of cumulativeDDI index
The content of the Danshen components, LSA, RMA, SAB and TSL in Danshen injectables
from different manufacturers, or from different lots/batches produced by a single manufacturer,
were obtained from the literature (103, 104, 138, 198, 200). In order to estimate the DDI index,
the plasma concentration-time profile of each Danshen component was simulated for patients
administered these Danshen injectables under two clinically relevant scenarios: i.v. bolus
administration and 60 min i.v. infusion administration. Simulated plasma concentration-time
profiles were generated using a two compartment model with first-order elimination, assuming
that all four Danshen components follow dose-proportional pharmacokinetics. The final
pharmacokinetic model parameters were fixed. In addition, Yang et al. (2007) determined that,
for RMA, SAB, and TSL, the fraction unbound in human plasma was 9.5%, 6.8%, and 100%
(137). In the absence of LSA plasma binding data, it was assumed that LSA is highly protein
bound (90%), leaving the fraction unbound in human plasma as 10%. Unbound plasma
concentrations were estimated as the product of plasma concentration times, the fraction
unbound in plasma. The DDI index was estimated as the predicted unbound Cmax or Css in
plasma over Ki for each component. The cumulative DDI index for a specific Danshen
preparation was calculated as the sum of individual DDI indices for each component.
8.B.7 Statistics
Data are reported as mean ± S.D. Statistical differences were assessed using one-way
ANOVA followed by post-hoc analysis with Dunnett’s t-test (α = 0.05).
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Figure 8.1. Cumulative inhibitory effects of LSA, RMA, and TSL on hOAT1 and hOAT3
A: Inhibition of hOAT1-mediated uptake of [3H]PAH (1 µM) by LSA (10 µM), RMA (1 µM),
and TSL (50 µM) individually or the mixture of these three components was measured in CHOhOAT1 cells (10 min). B: Inhibition of hOAT3-mediated uptake of [3H]ES (1 µM) by LSA (0.5
µM), RMA (0.5 µM), and TSL (10 µM) individually or as mixture of these three components
was measured in the HEK-hOAT3 cells (10 min). All data were corrected by background
substrate accumulation measured in corresponding empty vector control cells. OAT-expressing
cell showed signicantly reduced cellular uptake of substrate (p < 0.001) when treated with single
Danshen component or the mixture. Values are mean ± S.D. of triplicate values. All treated
groups showed significant inhibiton on hOAT1 and hOAT3 (p < 0.001). *** denotes p < 0.001
and *denotes p < 0.05 as determined by one-way ANOVA followed by Dunnett’s t-test to
compare invidual compounds group vs. mixed group.
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Figure 8.2. Modeling of published experimental data for human plasma concentrations of Danshen components, LSA, RMA,
SAB, and TSL after i.v. infusion using a two-compartment model.
Original data (shown as open circle) were taken from reference (104). The doses were 3 mg, 160 mg, 65 mg, and 90 mg for LSA,
RMA, SAB, and TSL, respectively.
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Table 8.1. Estimated Ki values (µM) of Danshen components for hOAT1 and hOAT3
Compound
LSA
RMA
SAA
SAB
TSL

hOAT1
20.8 ± 2.1
0.35 ± 0.06
5.6 ± 0.3
22.2 ± 1.9
40.4 ± 12.9

hOAT3
0.59 ± 0.26
0.55 ± 0.25
0.16 ± 0.03
19.8 ± 8.4
8.6 ± 3.3

Values are reported as mean ± S.E.M. (n=3). These values were obtained from reference (190).
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Table 8.2. Estimated parameters for two-compartment model with first-order elimination
to describe pharmacokinetic properties of Danshen components after i.v. infusion
Compound
LSA
RMA
SAB
TSL

V1
(L)
1.9±0.1
18.9±3.3
4.1±0.6
10.4±1.3

k10
(1/hr)
0.25±0.03
3.30±0.34
2.74±0.38
1.58±0.19

k12
(1/hr)
0.29±0.07
0.28±0.07
0.86±0.34
0.32±0.21

k21
Vdss
CLtot
t1/2elimination
(1/hr)
(L)
(L/hr)
(hr)
0.35±0.15 3.43±0.53 0.48±0.04 6.04±1.78
0.44±0.09 23.4±4.0 61.6±2.8 0.81±0.23
0.60±0.25 9.44±1.94 11.2±0.7 1.45±0.48
0.55±0.35 16.4±3.4 16.4±1.1 1.62±0.87

Values are reported as mean ± S.E.M.
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Table 8.3. Reported content of Danshen components in injectables from different
manufacturers
Manufacturer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

LSA
NRb
NR
NR
NR
NR
3.88
1.7
NR
NR
NR
NR
NR
NR
NR
NR
3

Maximum Dose (mg)a
RMA
SAB
10.2
17.2
4.2
13.8
4.6
7.0
5.6
16.2
12
12.6
10.3
39.5
3.4
6.8
6.6
NDc
14.1
343
5.1
2.0
18.1
50.16
4.4
2.9
3.2
2.5
7.7
16.8
3.5
10.0
160
63

a

TSL
21.2
41.4
31.2
29.8
80.6
37.8
45.2
98.4
ND
25.4
42.9
59.7
49.0
52.5
51.5
90

Reference
(103)
(103)
(103)
(103)
(103)
(198)
(198)
(200)
(200)
(200)
(200)
(200)
(200)
(200)
(200)
(104)

Used for i.v. infusion administration, which is four-fold of the maximum dose for i.v.
bolus administration; bNot reported; cNot detectable (value set to 0 for DDI index
calculations in Tables 8.5 and 8.6)
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Table 8.4. Reported content of Danshen components in injectables from a single
manufacturer with different batches/lots. Data were reported from reference (138).
Batches
1
2
3
4
5
6
7
8
9
10
11
12
13
14

RMA
1.9
3.5
2.5
2.7
2.4
2.0
3.3
2.5
2.2
2.5
1.2
2.6
2.7
3.4

Maximum Dose (mg)a
SAB
1.3
1.7
1.5
2.0
1.6
1.0
1.4
1.7
1.1
1.9
0.3
1.7
1.6
1.9

a

TSL
24.7
29.0
25.9
24.9
23.1
19.1
27.1
24.8
21.3
27.3
9.0
27.1
28.5
28.9

Used for i.v. infusion administration, which is four-fold of the maximum dose for i.v.
bolus administration
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Table 8.5. Estimation of individual and cumulative DDI indices for Danshen injectables from different manufacturers after i.v.
bolus administration on hOAT1 and hOAT3
Manufacturers
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

LSA
—a
—
—
—
—
0
0
—
—
—
—
—
—
—
—
<0.005

Dose-related DDI index for hOAT1
RMA
SAB
TSL
Cumulative
0.10
<0.005
0.06
0.16
0.04
<0.005
0.12
0.16
0.05
<0.005
0.09
0.14
0.06
<0.005
0.09
0.15
0.12
<0.005
0.24
0.36
0.10
0.01
0.11
0.21
0.03
<0.005
0.14
0.17
0.07
0
0.30
0.37
0.14
0.09
0
0.23
0.05
<0.005
0.08
0.13
0.18
0.01
0.13
0.32
0.04
<0.005
0.18
0.22
0.03
<0.005
0.15
0.18
0.08
<0.005
0.16
0.24
0.03
<0.005
0.15
0.18
0.02
0.27
1.60
1.89

LSA
—
—
—
—
—
0.16
0.07
—
—
—
—
—
—
—
0.13

Dose-related DDI index for hOAT3
RMA
SAB
TSL
Cumulative
0.06
0.01
0.30
0.37
0.03
<0.005
0.58
0.61
0.03
<0.005
0.44
0.47
0.04
<0.005
0.42
0.46
0.08
<0.005
1.14
1.22
0.07
0.01
0.54
0.78
0.02
<0.005
0.64
0.73
0.04
0
1.40
1.44
0.09
0.10
0
0.19
0.03
0
0.36
0.39
0.11
0.01
0.61
0.73
0.03
<0.005
0.85
0.88
0.02
<0.005
0.70
0.72
0.05
<0.005
0.74
0.79
0.02
<0.005
0.73
0.75
0.02
1.02
1.27
2.43

— DDI index could not be calculated as no value was reported (NR in Table 8.3). Values in italic indicate DDI index ≥ 0.1 threshold
value. Values in bold italic indicate DDI index ≥ 1.

a
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Table 8.6. Estimation of individual and cumulative DDI indices for Danshen injectables from different manufacturers after i.v.
infusion administration on hOAT1 and hOAT3
Manufacturers
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

LSA
—a
—
—
—
—
0.01
0.01
—
—
—
—
—
—
—
—
0.01

Dose-related DDI index for hOAT1
RMA
SAB
TSL
Cumulative
0.11
0.01
0.12
0.24
0.05
<0.005
0.23
0.28
0.05
<0.005
0.17
0.22
0.06
<0.005
0.16
0.22
0.13
<0.005
0.45
0.58
0.11
0.01
0.21
0.33
0.04
<0.005
0.25
0.29
0.07
0
0.54
0.61
0.15
0.10
0
0.26
0.06
<0.005
0.14
0.20
0.20
0.02
0.24
0.46
0.05
<0.005
0.33
0.38
0.03
<0.005
0.27
0.30
0.08
0.01
0.29
0.38
0.04
<0.005
0.28
0.32
0.02
0.50
1.76
2.28

LSA
—
—
—
—
—
0.51
0.22
—
—
—
—
—
—
—
—
0.39

Dose-related DDI index for hOAT3
RMA
SAB
TSL
Cumulative
0.07
0.01
0.55
0.63
0.03
<0.005
1.08
1.11
0.03
<0.005
0.81
0.84
0.04
0.01
0.77
0.82
0.08
<0.005
2.09
2.17
0.07
0.01
0.98
1.57
0.02
<0.005
1.17
1.41
0.05
0
2.56
2.61
0.10
0.12
0
0.22
0.04
<0.005
0.66
0.70
0.13
0.02
1.11
1.26
0.03
<0.005
1.55
1.58
0.02
<0.005
1.27
1.29
0.05
0.01
1.36
1.42
0.02
<0.005
1.34
1.36
0.02
1.12
2.34
3.87

— DDI index could not be calculated as no value was reported (NR in Table 8.3). Values in italic indicate DDI index ≥ 0.1 threshold
value. Values in bold italic indicate DDI index ≥ 1.

a
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Table 8.7. Estimation of DDI index for Danshen injectables from different batches in the same manufacturer after i.v. bolus
administration on hOAT1 and hOAT3
Batches
1
2
3
4
5
6
7
8
9
10
11
12
13
14

Dose-related DDI index for hOAT1
RMA
SAB
TSL
Cumulative
0.02
<0.001
0.07
0.09
0.03
<0.001
0.09
0.12
0.02
<0.001
0.08
0.10
0.03
<0.001
0.07
0.10
0.02
<0.001
0.07
0.09
0.02
<0.001
0.06
0.08
0.03
<0.001
0.08
0.11
0.02
<0.001
0.07
0.09
0.02
<0.001
0.06
0.08
0.02
<0.001
0.08
0.10
0.01
<0.001
0.03
0.04
0.03
<0.001
0.08
0.11
0.03
<0.001
0.09
0.12
0.03
<0.001
0.09
0.12

Values in italic indicate DDI index ≥ 0.1 threshold value.
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Dose-related DDI index for hOAT3
RMA
SAB
TSL
Cumulative
0.01
<0.001
0.35
0.36
0.02
<0.001
0.41
0.43
0.02
<0.001
0.37
0.39
0.02
<0.001
0.35
0.37
0.02
<0.001
0.33
0.35
0.01
<0.001
0.27
0.28
0.02
<0.001
0.38
0.40
0.02
<0.001
0.35
0.37
0.01
<0.001
0.30
0.31
0.02
<0.001
0.39
0.41
0.01
<0.001
0.13
0.14
0.02
<0.001
0.38
0.40
0.02
<0.001
0.40
0.42
0.02
<0.001
0.41
0.43

Table 8.8 Estimation of DDI index for Danshen injectables from different batches in the same manufacturer after 1 hr i.v.
infusion administration on hOAT1 and hOAT3
Batches
1
2
3
4
5
6
7
8
9
10
11
12
13
14

Dose-related DDI index for hOAT1
RMA
SAB
TSL
Cumulative
0.02
<0.001
0.14
0.16
0.04
<0.001
0.16
0.20
0.03
<0.001
0.14
0.17
0.03
<0.001
0.14
0.17
0.03
<0.001
0.13
0.16
0.02
<0.001
0.11
0.13
0.04
<0.001
0.15
0.19
0.03
<0.001
0.14
0.17
0.02
<0.001
0.12
0.14
0.03
<0.001
0.15
0.18
0.01
<0.001
0.05
0.06
0.03
<0.001
0.15
0.18
0.03
<0.001
0.16
0.19
0.04
<0.001
0.16
0.20

Values in italic indicate DDI index ≥ 0.1 threshold value.
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Dose-related DDI index for hOAT3
RMA
SAB
TSL
Cumulative
0.01
<0.001
0.64
0.65
0.02
<0.001
0.75
0.77
0.02
<0.001
0.67
0.69
0.02
<0.001
0.65
0.67
0.02
<0.001
0.60
0.62
0.01
<0.001
0.50
0.51
0.02
<0.001
0.70
0.72
0.02
<0.001
0.64
0.66
0.02
<0.001
0.55
0.57
0.02
<0.001
0.71
0.73
0.01
<0.001
0.23
0.24
0.02
<0.001
0.70
0.72
0.02
<0.001
0.74
0.76
0.02
<0.001
0.75
0.77

8.C RESULTS
8.C.1 Cumulative inhibitory effects of LSA, RMA, and TSL on hOAT1 and hOAT3
Accumulation of PAH in the CHO-hOAT1 cell line (4.6 ± 0.3 pmol/mg protein/10 min) was
markedly greater than that in the empty vector background CHO-EV cells (0.9 ± 0.3 pmol/mg
protein/10 min; Figure 8.1A). LSA (10 µM), RMA (1 µM) and TSL (50 µM) produced 61 ± 3%,
60 ± 1%, and 52 ± 6% inhibition on hOAT1-mediated PAH uptake, respectively. Further,
application of these three compounds together (at the specified concentrations) yielded a
significantly increased inhibition (72 ± 7%) on hOAT1 transport activity, compared to the
individual inhibitory effects of each compound (Figure 8.1A). Stably transfected hOAT3expressing (HEK-hOAT3) cells showed significantly enhanced accumulation of ES (~4 fold)
relative to empty vector background HEK-EV cells (6.2 ± 0.5 vs. 1.5 ± 0.2 pmol/mg protein/10
min, respectively; Figure 8.1B). Similarly, LSA (0.5 µM), RMA (0.5 µM) and TSL (10 µM)
produced approximately 20 ± 2%, 53 ± 6%, and 45 ± 2% inhibition, respectively. When these
compounds were included as a mixture in the incubation solution at the above concentrations, the
observed inhibition significantly increased to 81 ± 10%. Therefore, LSA, RMA and TSL, known
competitive inhibitors for hOAT1 and hOAT3, showed a cumulative inhibitory effect on
hOAT1- and hOAT3-mediated uptake.
8.C.2 Pharmacokinetic modeling of clinical data
Performing an iterative model discrimination process revealed that an open twocompartmental model with i.v. infusion and first-order elimination yielded the lowest values of
AIC, SBC, and WSSR, and this model was used to fit the plasma concentration-time profile data
for LSA, RMA, SAB and TSL (Figure 8.2). Moreover, weighted residuals were randomly
distributed in the weighted residuals vs. observed concentrations plot (data not shown). The
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observed and predicted concentration-time profiles for each Danshen component are shown in
Figure 8.2. Final pharmacokinetic model parameter estimates for each Danshen component are
summarized in Table 8.2. Data for CA, another component in Danshen preparations, failed to fit
any of the tested models. Overall, the model produced excellent fits of the actual data.
8.C.3 Estimation of cumulative DDI index and evaluation of OAT-mediated DDI potency for
Danshen injectables
In clinical practice, Danshen injectables are commonly administered by i.v. bolus injection or
i.v. infusion. The model parameters for LSA, RMA, SAB and TSL were used to simulate plasma
concentration using the two compartment model with i.v. bolus or i.v. infusion administration
and first-order elimination for a given dose, assuming the examined Danshen components exhibit
“dose-proportional pharmacokinetics” and that the pharmacokinetic behavior of each Danshen
component is not affected by the presence of any of the other components. As the plasma
concentration of LSA, RMA, SAB or TSL did not reach steady-state (Css) after 60 min i.v.
infusion, Cmax values (plasma concentration at 1 h) were used for estimation of individual DDI
index and cumulative DDI index.
As shown in Table 8.3, the content of Danshen components in injectables from different
manufacturers has been determined (103, 104, 198, 200). Marked variation was observed
between Danshen products from different manufacturers, with the content of LSA, RMA, SAB
and TSL, showing 2.3-, 73-, 175-, and 4.9-fold variation, respectively. In addition, for Danshen
injectables produced by a single manufacturer, the content of RMA, SAB, and TSL showed 3-,
6.7-, and 3.2-fold variation between different lots/batches (Table 8.4). As a consequence, the
predicted Cmax values of of LSA, RMA, SAB and TSL in these injectables exhibited the same
range of variation. With this information, the DDI index (for individual components) and the
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cumulative DDI index (for mixtures) were calculated (Tables 8.5 and 8.6). Most of these
investigated Danshen injectables showed hOAT1- and hOAT3-mediated DDI potential
(cumulative DDI index > 0.1), and the majority of preparations exhibited stronger interaction
potential with hOAT3 compared to hOAT1. Among Danshen components, TSL emerged as
making the greatest contribution to DDI potential, while LSA and RMA also showed substantial
individual contribution in some products. SAB failed to exhibit DDI potential in most injectables.
The DDI indices for individual components and the cumulative DDI indices were also calculated
for different batches/lots of a Danshen injectable produced by the same manufacturer (Tables 8.7
and 8.8) (138). These Danshen products showed significant hOAT3-mediated DDI potential for
both i.v. bolus injection and i.v. infusion use. In addition, the RMA and TSL content in some
batches were high enough to cause hOAT1-mediated DDIs when delivered as i.v. bolus or i.v.
infusion administration.
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8.D DISCUSSION
Botanical drug products are currently increasing in popularity because of renewed interest in
complementary and alternative therapies. Herbal medicines, which are derived from plants, are
always considered “natural” and, therefore, are often perceived as safe by patients and the
general public. However, because of their wide use as complementary and alternative medicines,
they are often used in combination therapy with other prescribed and OTC drugs. As a result,
numerous clinical cases of phytomedicine-associated DDIs have been identified (201-203),
making it necessary to explore the DDI potential between herbal medicines and co-administered
drugs more systemically. Because herbal drugs contain mixtures of plant components or extracts,
they are extraordinarily complex in their composition, particularly when compared with
prescription medications, which commonly contain a few active ingredients. An important caveat
to herbal medicines is that some of the major components may not have any therapeutic benefit,
but still possess significant DDI potential due to high systemic/peak exposure in vivo. Further,
these components often share structural and physicochemical properties and, as such, might exert
cumulative DDI effects. Currently, most transporter-mediated DDI studies focus on the
interaction of each single component with the drug in question and, therefore, may underestimate
the overall DDI potential for complex botanical drug products (201-203).
Presently, the individual DDI index, calculated as [unbound]Cmax/Ki (or IC50), is thought to
reasonably predict in vivo DDI potential for a compound on a specific transporter. However, for
herbal medicines, it is necessary to consider the overall inhibitory effects induced by all of the
components in order for the DDI index to reflect the interaction potential for the product as a
whole. In addition, the content of major components in herbal products is often influenced by
factors such as extraction methods, cultivars, cultivation region, manufacturing processes, and
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quality control criteria, which differ among manufacturers. Therefore, it might be more relevant
to explore pharmaceutical product-specific DDI indices rather than compound-related indices.
In this study, the cumulative inhibitory effect of major Danshen components on OATmediated substrate uptake was assessed. Human OAT1 and hOAT3 transport activity was
significantly lower when the components were applied as a mixture (LSA, RMA and TSL) as
compared with being applied individually. These results suggested that in some situations the
traditional DDI index might not reflect the true inhibition level of a multi-component system.
Therefore, the cumulative DDI index, calculated as the sum of DDI indices for each individual
component, was proposed in the present study to evaluate the DDI potential for such mixture.
The individual DDI indices for the single compounds, LSA (10 µM), RMA (1 µM), and TSL (50
µM), as well as the cumulative DDI index for a mixture at those concentrations, on hOAT1 were
0.45, 2.9, 1.2, and 4.6, respectively. Such DDI indices predicted inhibition levels of 33%, 74%,
55%, and 82% for LSA, RMA, TSL, and the mixture, respectively, which corresponded closely
with the observed inhibition profiles, 61 ± 3%, 60 ± 1%, 52 ± 6%, and 72 ± 7% for RMA, TSL,
and the mixture, respectively. Similarly, the individual DDI indices for LSA (0.5 µM), RMA
(0.5 µM) and TSL (10 µM), as well as the cumulative DDI index for the mixture, were 0.9, 0.9,
1.2, and 3.0, respectively, indicating that the predicted inhibition levels (46%, 48%, 54%, and 74%
for LSA, RMA, TSL and the mixture, respectively) were comparable with the observed values,
(61 ± 3%, 60 ± 1%, 52 ± 6%, and 81 ± 10% for LSA, RMA, TSL and the mixture, respectively).
These data support use of the cumulative DDI index as a suitable indicator for evaluation of the
DDI potential for complex mixtures.
The same threshold value of DDI index≥ 0.1

(transport activity decreased by 9%), as

currently recommended for further individual component assessment, was maintained for the
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cumulative DDI index. The estimated cumulative DDI indices for investigated Danshen
injectables on hOAT1 and hOAT3 were greater than 0.1 in most cases. In addition, the
cumulative DDI indices for hOAT3 were much greater than those for hOAT1 for most
investigated Danshen injectables. As shown in Tables. 8.5 and 8.6, the cumulative DDI indices
for hOAT3 exceeded 1 for a number of Danshen injectables, administered by i.v. bolus injection
and 60 min i.v. infusion administration, indicating that more than 50% of hOAT3 transport
function could be inhibited. Only one product induced a cumulative DDI index
˃ 1 on hOAT1
due to a high RMA content. In general, the results demonstrate a strong potential that OAT
function likely would be impaired in vivo after administration of these products, manifesting as
reduced renal elimination of co-administered drugs that undergo OAT-mediated active secretion
(Tables 8.5-8.8).
Among these Danshen components, TSL can be identified as the main contributor to the
cumulative DDI index because of its relatively high content in preparations and low degree of
plasma protein binding. Collectively, TSL exhibited higher DDI indices for hOAT1 and hOAT3
compared to the other components. Further, the data suggested that the contribution of SAB can
be ignored. However, the impact of LSA and RMA on DDI potential cannot be ignored. In some
Danshen injectables, RMA showed equal or greater contribution to the cumulative DDI index for
hOAT1 (Tables 8.5 and 8.6). The content of LSA was available only for two investigated
products. Nevertheless, LSA’s high affinity for hOAT3 yielded an individual DDI index for LSA
that accounts for a significant portion of the cumulative DDI index (Tables 8.5 and 8.6).
Similarly, as shown in Table 8.7, such effects can yield a cumulative DDI index above the
threshold value (0.1), while neither of the single component (RMA and TSL) DDI indices were
greater than 0.1. In other words, considering only single component DDI assessment would
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suggest no concern for Danshen-mediated in vivo DDIs, whereas the cumulative DDI index
would indicate such a concern.
Like other herbal medicines, there is great variation in the content of major constituents of
Danshen injectables. The content of LSA, RMA, SAB, and TSL, showed 2.3-, 73-, 175-, and
4.9-fold variation between Danshen products from different manufacturers (Table 8.3).
Additionally, RMA, SAB and TSL showed 3-, 6.7- and 3.2-fold variation in content between
different lots/batches of a product produced by a single manufacturer (Table 8.4). As a result,
such variation leads to marked differences in the cumulative DDI indices for these products.
According to Tables 8.5 and 8.6, Danshen products from different manufacturers exhibited 2.3and 3.1-fold difference in the hOAT1-associated cumulative DDI index for i.v bolus and i.v.
infusion administration, respectively. Such discrepancy was even higher for the hOAT3associated cumulative DDI index, which exhibited 7.6- and 11.9-fold differences for i.v bolus
and i.v. infusion administration, respectively. Variability in composition between batches/lots led
to ~3-fold range in cumulative DDI indices (Tables 8.7 and 8.8). Clearly, estimating a general
DDI potential for the range of Danshen injectables is difficult. In order to help address this
problem, standardization of content and quality control measures should be established.
Danshen also is used in clinical therapy as tablets and “dripping pills” (100). The phenolic
acid components investigated in the present work are also major components in these oral dosage
forms. Unlike injections, TSL was the only component detectable in plasma after oral
administration of Danshen products (116, 204). Therefore, TSL might be the only component
with the potential of causing OAT-mediated DDIs in vivo after oral administration of Danshen
preparations. However, there is a marked discrepancy in plasma concentration of TSL in clinical
pharmacokinetic studies. Pei et al. reported that Cmax of TSL was ~7.5 µg/mL (38 µM) after oral
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administration of 250 mg Danshen pills (204), while another independent investigation revealed
that the Cmax of TSL was much lower (~50 ng/mL or 0.25 µM) even with a higher dose (750 mg
Danshen pills) (116). Knowing that Danshen pills used in these studies were produced by the
same manufacturer, the large difference in TSL Cmax might be due to variation in the content of
TSL between different batches. Unfortunately, the actual content of TSL was not reported (204).
Without further studies to demonstrate the peak exposure of TSL, it is impractical to estimate
DDI potential for Danshen oral dosages forms. However, a TSL Cmax = 7.5 µg/mL might be
sufficient to cause significant DDI (DDI index = 0.9 and 6 for hOAT1 and hOAT3, respectively),
while a Cmax of 50 ng/mL is not (DDI index < 0.1 for both hOAT1 and hOAT3).
There are some limitations to the present study. Currently, there is a lack of clinical
pharmacokinetic data for the Danshen components CA and SAA, which are also potent OAT
inhibitors (51, 190). Potential phase 2 metabolites of Danshen components may also impact OAT
function. As a result, the contribution of these compounds to OAT-mediated DDIs cannot be
estimated, potentially indicating that even the cumulative DDI potentials reported herein may
actually underestimate the true DDI potential of Danshen injectables. Additionally, DDIs
between each compound likely may occur, especially for TSL, which could undergo OATmediated renal elimination in vivo. The presence of CA, LSA, SAA and SAB in Danshen
preparations might affect this renal elimination of TSL, and plasma concentration of TSL may be
elevated depending on the achieved systemic exposures of CA, LSA, SAA and SAB, which in
turn, influences TSL-associated DDIs. Finally, such DDI potential estimation was based on the
peak exposure level. As shown in Table 8.2, considering the relative t1/2elimination of these Danshen
components, especially for TSL (t1/2elimination = 1.6 hr), the main determinant for DDI potential of
Danshen injectables, the DDI duration window might be short (< 2 hr).
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In conclusion, the major Danshen components, LSA, RMA, and TSL, were demonstrated to
elicit cumulative inhibitory effects on hOAT1- and hOAT3-mediated substrate uptake. The
cumulative DDI index was introduced as a more comprehensive index to evaluate DDI potential
for multiple-component Danshen injectables. Even though TSL appears to exert a dominant
contribution to the cumulative DDI index, the potential impact of LSA and RMA cannot be
ignored. The large cumulative DDI indices (particularly those
˃ 1)

suggested that Danshen

injectables have a strong potential to cause OAT-mediated DDIs in vivo and underscore the need
for improved manufacturing standards to eliminate such wanton product variability and protect
the public.
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CHAPTER 9

OVERALL CONCLUSIONS AND FUTURE DIRECTIONS

Natural products have been used as first-line therapeutics, complementary/alternative
medicines, and dietary supplements for thousands of years (205). Currently, herbal therapy is
receiving renewed interest throughout the world as products produced from plants are considered
“natural” and therefore often perceived as having no potential for toxic effects by patients.
However, information about the safety and efficacy profiles for these compounds is still limited
compared to western drugs. Indeed, many side effects associated with natural products have been
reported over the last two decades (131, 132). A number of studies have demonstrated that
transporter proteins, including OATs, can be sites of DDIs, and that transporter-mediated DDIs
contributed to reported side effects (39, 77, 129). While some natural compounds are known
substrates (e.g., aristolochic acid, caffeic acid, dihydrocaffeic acid, dihydroferulic acid, and
ferulic acid ) or inhibitors (ellagic acid, stevioside, and caffeic acid) of OATs, the interaction of
most natural products with OATs are virtually unknown (48, 50, 51). As a result, it is necessary
to explore OAT-mediated natural product-drug interactions to improve herbal product safety and
efficacy. This dissertation thus characterized the potential interaction of 22 selected natural
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compounds as major organic acid components of herbal medicines/food and exhibiting
significant systemic exposure.
Danshen (Salvia miltiorrhiza) is a commonly used Chinese herbal medicine for the treatment
of cardiovascular diseases (100-102). In Chapters 3 and 4, the inhibitory effects of hydrophilic
Danshen components on the function of mOat1 and mOat3 were assessed. At 1 mM, all of tested
compounds, including LSA, RMA, SAA, SAB, and TSL, showed significant inhibition on
mOat1 and mOat3. Kinetic analysis demonstrated a competitive mechanism of inhibition for
LSA, RMA, SAA. Ki values were estimated as 14.9 ± 4.9 µM for LSA, 5.5 ± 2.2 µM for RMA,
4.9 ± 2.2 µM for SAA, 236 ± 90 µM for SAB, and 136 ± 17 µM for TSL on mOat1-mediated
transport and as 31.1 ± 7.0 µM for LSA, 4.3 ± 0.2 µM for RMA, 21.3 ± 7.7 µM for SAA, 845 ±
287 µM for SAB, and 1940 ± 486 µM for TSL on mOat3-mediated transport. Further work was
conducted to study the influence of five Danshen components (LSA, RMA, SAA, SAB, and TSL)
on human OATs, including hOAT1, hOAT3, and hOAT4 (shown in Chapter 4). Similarly, these
compounds exhibited competitive inhibition of hOAT1 and hOAT3. At clinical plasma
concentrations, the calculated DDI indices were much greater than 0.1, indicating a strong
interaction potential for LSA, RMA and TSL on both hOAT1 and hOAT3 and for LSA on
hOAT3. In addition, notable species differences appeared to exist in terms of inhibitory potency
among mouse and human. Generally, Danshen components showed preferential affinity (by 1-2
orders of magnitude) for human OATs compared with their murine orthologs.
Numerous studies have demonstrated that phenolic acids exert beneficial health effects such
as anti-oxidant, anti-carcinogenic, and anti-inflammatory activities (140). In addition, people are
exposed to these compounds from dietary sources, including common fruits, vegetables, and
beverages (43). Some phenolic acids have been identified as the substrates or inhibitors of OATs
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(50, 51). In Chapter 5, the potential interaction of nine dietary phenolic acids, including pcoumaric acid, ferulic acid, gallic acid, gentisic acid, 4-hydroxybenzoic acid, protocatechuic acid,
sinapinic acid, syringic acid, and vanillic acid with hOAT1, hOAT3, and hOAT4 was investigated.
At 100 µM, all compounds significantly inhibited hOAT3 transport, while ferulic, gallic,
protocatechuic, sinapinic, and vanillic acid significantly blocked hOAT1 activity. Sinapinic acid
was the only test compound exhibiting significant inhibition on hOAT4 (~35%). Estimated IC50
values ranged from 1.24 to 18.1 µM for hOAT1 and from 7.35 to 87.4 µM for hOAT3 for
selected compounds exhibiting potent inhibition from the preliminary screening. Given the
expected clinical unbound plasma concentrations, maximum DDI indices for gallic and gentisic
acid are much greater than 0.1, indicating a very strong potential for DDIs on hOAT1 and/or
hOAT3. Therefore, gallic acid from foods or herbal supplements, or gentisic acid from
salicylate-based drug metabolism, may significantly alter the pharmacokinetics of concomitant
drugs that are hOAT1 and/or hOAT3 substrates.
As shown in Chapter 6, the potential interaction of some natural dietary/herbal anionic
compounds, including flavonoids (catechin and epicatechin), chlorogenic acids (1,3- and 1,5dicaffeoylquinic acid), phenolic acids (ginkgolic acids (13:0), (15:1), and (17:1)), and other
anionic compounds (ursolic acid and 18β-glycyrrhetinic acid), with hOAT1, hOAT3, and
hOAT4 were also investigated. The most important finding of this part was that 1,3dicaffeoylquinic acid and 18β-glycyrrhetinic acid exhibited high affinity with hOAT1, with IC50
values estimated as 1.2 ± 0.4 μM and 2.7 ± 0.2 µM, respectively. These data indicate that 1,3dicaffeoylquinic acid and 18β-glycyrrhetinic acid have the potential to cause significant hOAT1mediated DDIs in vivo, which should be considered during clinical use and in future drug
development.
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Among test phenolic acids, gallic acid and gentisic acid undergo renal elimination as their
unchanged form (144, 163). As mentioned in Chapter 5, gallic acid and gentisic acid showed
strong affinity with hOAT1 and hOAT3. Therefore, OATs might be involved in urinary
excretion of these compounds. In Chapter 7, a new, rapid, and sensitive LC-MS/MS method was
developed and validated for the simultaneous determination of gallic acid and gentisic acid in
cell lysate, using Danshensu as the IS. Compared to previously reported LC-MS/MS-based
methods, the established method increased speed, sensitivity and linear dynamic range. The total
run time was 3 min and calibration curves were linear over the concentrations of 0.33–2400
ng/mL for both compounds (r2>0.995). In addition, adverse matrix effects were investigated in
samples with cell lysate-derived biological matrix. This assay was successfully applied in a
cellular uptake study to determine the intracellular concentrations of gallic acid and gentisic acid
in mOat1- and mOat3-expressing cells. Gallic acid was identified as a novel substrate of mOat1
using the method.
Most herbal medicines contain multiple components. Because of the marked similarity in
their chemical structures, some, if not all, of these components may be involved in drug
transporter-mediated DDI. As a result, investigations on a single component may underestimate
the combined DDI potency for botanic products. In Chapter 4, five Danshen components (LSA,
RMA, SAA, SAB, and TSL) showed significant inhibition on hOAT1 and hOAT3. In Chapter 8,
the cumulative DDI index, defined as the sum of DDI indices for individual components, was
calculated for Danshen injectables. Clearly, the cumulative DDI index was significantly higher
as compared to individual component-related DDI indices for most Danshen pharmaceutical
products. These results indicate that it is necessary to identify major components of herbal
therapeutics, whether considered as active ingredients or not, and to investigate their DDI
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potential. In addition, due to the variation in cultivation regions, extraction strategy, and
manufacturing processes, quality control for herbal medicines is always difficult. In the present
study, the cumulative DDI indices were highly variable among different manufacturers or
batches. As a result, DDI potency could be different if patients take the same nominal dose of
Danshen product, but from different sources. For herbal therapeutics like Danshen, standardized
quality control criteria should be established.
These in vitro studies have essentially explored the potential inhibitory effects of natural
anionic compounds on human and murine OATs. However, to the best of my knowledge, there
have been no studies to demonstrate OAT-mediated natural product-drug interaction in vivo.
Indeed, the findings in this work suggest further in vivo studies to confirm DDIs. To achieve this
goal, species differences in transporter affinity need to be considered when choosing an
appropriate animal model to demonstrate DDI. In Chapter 4, human OATs showed markedly
higher affinity with Danshen components compared to murine orthologs. As a result, a clinically
relevant concentration in mice would underestimate the clinical DDI magnitude. To solve this
problem, a suitable animal model with minimal species differernce should be chosen. Otherwise,
the dosing regimen for animal studies would need to be adjusted in order to balance the
discrepancy between species. Additionally, DDI evaluations should be conducted with
combination of multiple ingredients in addition to single components. With this information and
in vitro results, the effects of the complete preparation or particular components can be specified
from pharmacokinetic studies.
Previous studies demonstrated that typical substrates of OATs are small or medium
molecules with negative charge(s) at physiological pH (3). However, it is not well defined what
the influences of physicochemical properties are for interaction. In 2013, VanWert et al.
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investigated the in-depth structure-activity relationship (SAR) of β-lactam antibiotics with
respect to their inhibitory activity on mOat3 and hOAT3 (206). They found that a prohibitive
hydrogen bond donor group in noninhibitors adjacent to a hydrophobic moiety was important for
binding to Oat3 (206). In our study, SAR for phenolic acids with OATs was also performed
through collaboration with scientists in the Medicinal Chemistry Department of our University.
Unfortunately, there were no conclusive results, possibly due to an insufficient number of test
compounds. In the future, as information on the interaction of natural anionic compounds and
OATs becomes available, additionally SAR studies should be conducted to provide better
understanding on OAT-substrate interaction and potentially indentify new strategy for targetdelivered drug synthesis.
In Chapter 7, a sensitive, specific, and robust LC-MS/MS method was developed to
determine the concentration of gallic acid and gentisic acid in cell lysate, and gallic acid was
identified as a substrate of mOat1. However, the intracellular concentration of gallic acid in both
mOat3-expressing and empty vector control cells were below the LLOQ, leaving open the
possibility of gallic acid may be a substrate of mOat3. Similarly, whether gentisic acid is a
substrate of mOat1 or mOat3 is still unclear. Future research requires modifications (e.g.,
increased assay sensitivity, number of cells, incubation time, and subsrate concentrations) to
accurately measure the cellular uptake of gallic acid and gentisic acid in these cell lines. In
addition, it is necessary to determine cellular uptake of gallic acid and gentisic acid in hOAT1and hOAT3-expressing cells. Unbound renal clearance of gallic acid is higher compared to GFR,
indicating that gallic acid undergoes net renal tubular secretion (163). If marked cellular
accumulation of gallic acid is observed in hOAT1- and hOAT3-expressing cells, these
transporters might be involved in the active secretion of gallic acid. For gentisic acid, although a
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significant portion is eliminated in the urine as the unchanged form, it is still necessary to
determine unbound renal clearance in clinical studies in order to clarify the potential contrition of
hOATs. Even if hOAT1 and hOAT3 transport gentisic acid, their actual contribution for renal
elimination might be negligible if unbound renal clearance is not higher than GFR.
Overall, the results indicated a strong DDI potential on OATs for natural anionic components.
Future studies need to elucidate such interactions in different populations. As indicated in
Chapter 1, OAT-associated SNPs have been found in the human population. These OAT SNPs
may lead to ultra, normal, reduced, or null transport activity. In addition, pathological conditions
(e.g., acute and chronic renal failure) influence OAT expression in the kidney. Other factors,
including gender and age, also are known to have an impact on OAT expression and function. As
a result, OAT-mediated DDI potential may be highly variable among these groups. Information
on OAT expression and activity regulation would be helpful to predict OAT-mediated DDIs in
patients with specific biological or pathological characters, moving towards personalized
medicine. Another aspect for future study is to demonstrate potential interaction of other OATs
(e.g., OAT2, OAT7, and OAT10) with these test compounds. As OATs have a broad
substrate/inhibitor specificity, it is highly possible that test compounds may interact with these
transporters and affect organic anion solute flux in other organs such as liver. Furthermore,
pharmaceutical industries which are developing herbal products need to refine standardization
criteria for the manufacturing process. Finally, generation of humanized transgenic mice
becomes increasingly important in an attempt to develop a model system that minimizes interspecies variation of drug transporter affinities. The combination of humanized transgenic mice
with knockout mice might serve as suitable complementary preclinical animal models to
demonstrate clinically relevant DDIs.
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APPENDIX I
ORGANIC ANION TRANSPORTER SUBSTRATES AND INHIBITORS (REPORTED FROM 2010 TO 2012)
Compound

Transportera Interactionb

Systemc

1-butanesulfonic acid

hOAT1
mOat1
rbOat1

I

CHO

1-propanesulfonic acid

hOAT1
mOat1
rbOat1

I

CHO

Km

Kinetics (µM)
Ki

514±72.1 (0.25 PAH)
313±26.9 (0.25 PAH)
421±89.4 (0.25 PAH)
2036±28.3 (0.25 PAH)
4156±1079 (0.25 PAH)

CHO
hOAT1
2,3-dimercapto-1-propanesulfonic acid

mOat1
rbOat1

3-mercapto-1-propanesulfonic acid
3-monoglucuronyl-glycyrrhetinic acid
Aminopterin
Amitriptyline

hOAT1
mOat1
rbOat1
hOAT1
hOAT1
hOAT1

83±3 (0.25 PAH)
104.6±13.1 (5 CF)
85.1±8.8 (5 CF)
55±4.9 (0.25 PAH)
72±9.9 (0.25 PAH)
237.4±23 (5 CF)
123±14 (5 CF)
204±54.2 (0.25 PAH)
151±19.8 (0.25 PAH)
204±34.9 (0.25 PAH)

HEK293
I

CHO
CHO
HEK293

I

CHO

S
I
I

HEK293
X.laevis
S2

190

IC50d

49.0±18.3
573.9

160±58 (0.221 PAH)
354 (5 PAH)

Reference

(207)

(207)
(207)
(208)e
(207)
(207)
(208)e
(207)
(209)
(210)
(211)

Appendix I Continued
Compound
Arginine

Aristolochic acid I

Aristolochic acid II
Bestatin
Caffeic acid
Caffeic acid-3-O-glucuronide
Caffeic acid-4-O-glucuronide
Caffeic acid-3-O-sulfate
Caffeic acid-4-O-sulfate
Cephalexin
Chlorpyrifosmethyl
Cyclo-trans-4-L-hydroxyprolyl-Lserine
Daidzein-7-O-glucuronide
Daidzein-7,4’-O-disulfate
Diazepam
Dihydrocaffeic acid
Dihydroferulic acid
Dihydrocaffeic acid-3-O-glucuronide
Dihydrocaffeic acid-4-O-glucuronide
Dihydrocaffeic acid-3-O-sulfate
Dihydrocaffeic acid-4-O-sulfate
Dihydroferulic acid-4-O-sulfate
Ferulic acid-4-O-sulfate

Transportera Interactionb

Systemc

Km

Kinetics (µM)
Ki
IC50d
1600±300 (5 CF)
0.5
0.80±0.15
0.44±0.08 (5 PAH)

Reference

mOat1
hOAT1
hOAT1
hOAT1
mOat1
rOat1
hOAT1
mOat1
hOAT1
hOAT1
hOAT1
hOAT1
hOAT1
hOAT1
hOAT1
hOAT1
hOAT1

I
I
I
S
S
S
I
S
S
S/I
I
S/I
S
S
S
S
I

CHO
HEK293
S2
HEK293
CHO
HEK293
S2
CHO
HEK293
HEK293
X.laevis
HEK293
HEK293
HEK293
HEK293
HEK293
S2

hOAT1

S

HEK293

(215)

hOAT1
hOAT1
hOAT1
hOAT1
hOAT1
hOAT1
hOAT1
hOAT1
hOAT1
hOAT1
hOAT1

I
I
I
S/I
S/I
S
S
S/I
S/I
S/I
S

HEK293
HEK293
S2
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293

(119)
(119)
(211)
(50)
(50)
(50)
(50)
(50)
(50)
(50)
(50)

191

0.79±0.01
1.06±0.09 (5 PAH)
1.50±0.37
679±7
28.6±3.7

5.22 (25 PAH)
16.6±3.7 (0.221 PAH)

38.9±3.3

324.6

83.5
21.4±4.2

76.7±16.3
115±31
54.2±3.6

191.5 (5 PAH)

133.3 (5 PAH)

(212)
(39)
(40)
(41)
(36)
(213)
(40)
(36)
(214)
(50)
(51)
(50)
(50)
(50)
(50)
(215)
(211)

Appendix I Continued
Compound

Transportera Interactionb

Fenitrothion

hOAT1

Ferulic acid

hOAT1

Gaboxadol
Gallic acid
Genistein-4’-O-sulfate
Genistein-7-O-glucuronide
Glycitein-7-O-glucuronide
Indoxyl sulfate
Isoferulic acid
Isoferulic acid-3-O-glucuronide
Isoferulic acid-3-O-sulfate
Lithospermic acid
Lumiracoxib
Ketoconazole
α-Ketoglutarate
Malathion
Mianserin
Probenecid
Protocatechuic acid
Pyruvate
Quercetin-3-O-glucuronide
Quercetin-3’-O-glucuronide
Quercetin-3’-O-sulfate
Quercetin-7-O-glucuronide
Rifampin
Rosmarinic acid
Salvianolic acid A

Systemc

rOat1
hOAT1
hOAT1
hOAT1
hOAT1
mOat1
hOAT1
hOAT1
hOAT1
mOat1
hOAT1
hOAT1
mOat1
hOAT1
hOAT1

I
S/I
I
S
I
S/I
I
I
I
I
S
S/I
I
I
I
I
I
I

S2
HEK293
CHO
X. laevis
CHO
HEK293
HEK293
HEK293
X. laevis
HEK293
HEK293
HEK293
CHO
X. laevis
X. laevis
X. laevis
S2
S2

hOAT1

I

X. laevis

hOAT1
mOat1
mOat1
hOAT1
hOAT1
hOAT1
hOAT1
hOAT1
mOat1
mOat1

I
I
I
S/I
I
S/I
S/I
I
I
I

Km

Kinetics (µM)
Ki
IC50d
51.2
26.6 (5 PAH)
9.01 (25 PAH)

151±58
1.24±0.36 (1 PAH)
5.07±1.81

18 (30 CF)

32.7±5.3
14.9±4.9

134.0
99.0

CHO
CHO
HEK293
HEK293
HEK293
HEK293
X. laevis
CHO
CHO

192

3.3±1.1 (0.221 PAH)
319 (1 PAH)
40±3 (30 CF)
114.2 (5 PAH)
312.6 (5 PAH)
17 (3 PAH); 14 (10
MTX)
18.08±2.59 (1 PAH)
4300±600 (5 CF)

1.73±0.38

1.22 (25 PAH)
62.2
5.5±2.2
4.9±2.2

79.1 (1 PAH)

Reference
(211)
(50)
(52)
(216)
(52)
(119)
(119)
(119)
(217)
(50)
(50)
(50)
(49)
(218)
(219)
(212)
(211)
(211)
(220)
(52)
(49)
(212)
(119)
(119)
(119)
(119)
(219)
(49)
(49)

Appendix I Continued
Compound

Transportera Interactionb

Systemc

Km

Kinetics (µM)
Ki

IC50d

Reference

Salvianolic acid B
Sinapinic acid
Spermidine
Spermine
Sulfasalazine
Tanshinol
Triazolam
Vanillic acid
Aristolochic acid I
Aristolochic acid II

mOat1
hOAT1
mOat1
mOat1
hOAT1
mOat1
hOAT1
hOAT1
mOat2
mOat2

I
I
I
I
I
I
I
I
S
S

CHO
CHO
X. laevis
X. laevis
X. laevis
CHO
S2
CHO
CHO
CHO

Orotic acid

hOAT2
rOAT2

S

HEK293

hOAT2

S

HEK293

1168±335

(222)

hOAT3

S

HEK293

44±5

(223)

I

CHO

I

CHO
CHO

Uric acid
N-({(5S)-3-[4-(1,1dioxidothiomorpholin-4-yl)-3,5difluorophenyl]2-oxo-1,3-oxazolidin-5yl}methyl)acetamide
1-butanesulfonic acid
1-propanesulfonic acid

hOAT3
mOat3
rbOat3
rbOat3
hOAT3

2,3-dimercapto-1-propanesulfonic acid

mOat3
rbOat3

HEK293
I

CHO
CHO
HEK293

193

11.02±1.55 (1 PAH)
2000±700 (30 CF)
1600±600 (30 CF)
4.6 (10 MTX)
86.0

185.2 (5 PAH)
7.65±2.92 (1 PAH)

0.36±0.05
0.67±0.19

(49)
(52)
(212)
(212)
(220)
(49)
(211)
(52)
(36)
(36)
(221)

5098±184.3 (0.015 ES)
10975±2647 (0.015 ES)
5640±715.9 (0.015 ES)
40±7.4 (0.015 ES)
31.6±6.6 (5 CF)
172±36 (5 CF)
85±16.9 (0.015 ES)
18±2.5 (0.015 ES)
52.4±7.6 (5 CF)
172±22 (5 CF)

(207)
(207)
(207)
(208)e
(207)
(207)
(208)e

Appendix I Continued
Compound
2,4-dichlorophenoxyacetate
2,4-dihydroxyphenylacetic acid
3-mercapto-1-propanesulfonic acid
3-monoglucuronyl-glycyrrhetinic acid
4-hydroxybenzoic acid
5-hydroxyindoleacetic acid
Aminopterin
Aristolochic acid I

Aristolochic acid II
Bestatin
Bumetanide
Caffeic acid
Caffeic acid-3-O-glucuronide
Caffeic acid-4-O-glucuronide
Caffeic acid-3-O-sulfate
Caffeic acid-4-O-sulfate
Celecoxib
Cephalexin
p-Coumaric acid
Cyclo-trans-4-L-hydroxyprolyl-Lserine
Daidzein-7-O-glucuronide
Daidzein-7,4’-O-disulfate

Transportera Interactionb
mOat3
mOat3
hOAT3
mOat3
rbOat3
hOAT3
hOAT3
mOat3
hOAT3
hOAT3
hOAT3
hOAT3
mOat3
hOAT3
mOat3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3

Systemc

I
I

CHO
CHO

I

CHO

S
I
I
I
I
I
S
S
I
S
S
I
S/I
I
S
S
S
S
I
S
I

HEK293
HEK293
CHO
X. laevis
HEK293
S2
HEK293
CHO
S2
CHO
HEK293
X. laevis
HEK293
X.laevis
HEK293
HEK293
HEK293
HEK293
S2
HEK293
HEK293

hOAT3

S

HEK293

hOAT3
hOAT3

S/I
S/I

HEK293
HEK293

194

Km

Kinetics (µM)
Ki
IC50d
2.0±0.4
347±98
2139±289 (0.015 ES)
2325±268 (0.015 ES)
2320 ±785 (0.015 ES)

30.1±2.9
67.8±7.2
59.2±14.9 (0.0184 ES)
0.4
0.84±0.10

0.65±0.08 (0.05 ES)

0.51±0.06
1.28 ± 0.18 (0.05 ES)
1.05±0.36
632±14
7.8 (2 ES); 5.4 (10 MTX)
30.8 (100 CF)
5.4±1.3 (0.0175 ES)

35.3

Reference
(109)
(109)
(207)
(209)
(52)
(109)
(210)
(39)
(40)
(41)
(36)
(40)
(36)
(214)
(220)
(50)
(51)
(50)
(50)
(50)
(50)
(224)
(215)
(52)
(215)

19.1±1.9

(119)
(119)

Appendix I Continued
Compound

Transportera Interactionb

Dehydroepiandrosterone sulfate

mOat3

Dihydrocaffeic acid
Dihydrocaffeic acid-3-O-glucuronide
Dihydrocaffeic acid-4-O-glucuronide
Dihydrocaffeic acid-3-O-sulfate
Dihydrocaffeic acid-4-O-sulfate
Dihydroferulic acid-4-O-glucuronide
Dihydroferulic acid-4-O-sulfate
Ferulic acid
Ferulic acid-4-O-glucuronide
Ferulic acid-4-O-sulfate
Gallic acid
Genistein-4’-O-glucuronide
Genistein-7-O-glucuronide
Gentisic acid
Glycitein-7-O-glucuronide
Hippuric acid
Homovanillic acid
Isoferulic acid-3-O-glucuronide
Isoferulic acid-3-O-sulfate
Lithospermic acid
Lumiracoxib
Penicillin G
Probenecid

hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
hOAT3
mOat3
mOat3
hOAT3
hOAT3
mOat3
hOAT3
mOat3
mOat3
hOAT3
mOat3
hOAT3
hOAT3
hOAT3

Protocatechuic acid
Quercetin-3-O-glucuronide
Quercetin-3’-O-glucuronide
Quercetin-3’-O-sulfate

I
S
S/I
S
S
S
S
S
S
I
S
S
I
S/I
S/I
I
S/I
I
I
S
S
I
I
I
I
I
I
S/I
S/I
S/I

Systemc
CHO
X. laevis
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
CHO
CHO
HEK293
HEK293
CHO
X. laevis
CHO
CHO
CHO
CHO
HEK293
HEK293
HEK293

195

Km

Kinetics (µM)
Ki
3.8±1.1

21.4±4.2

IC50d

14.2 (100 CF)

7.35±3.73 (1 ES)

9.02±3.24 (1 ES)
7.94±1.42
86.81±21.78 (1 ES)
17.6±3.9
79.3±4.0
135±27

31.1±7.0
1.9±0.4 (0.0184 ES)
60.7±5.9
0.8±0.2
87.36±28.57 (1 ES)

5.25±0.86

0.43 (100 CF)
1.31 (100 CF)
0.75 (100 CF)

Reference
(109)
(109, 225)
(50)
(50)
(50)
(50)
(50)
(50)
(50)
(52)
(50)
(50)
(52)
(119)
(119)
(52)
(119)
(109)
(109)
(50)
(50)
(49)
(218)
(109)
(109)
(52)
(49)
(119)
(119)
(119)

Appendix I Continued
Compound
Quercetin-7-O-glucuronide
Rosmarinic acid
Salicylate
Salvianolic acid A
Salvianolic acid B
Sinapinic acid
Sulfasalazine
Syringic acid
Tanshinol
Vanillic acid
Aristolochic acid I
Aristolochic acid II
Caffeic acid-3-O-sulfate
Caffeic acid-4-O-sulfate
Ferulic acid-4-O-sulfate
Isoferulic acid-3-O-sulfate
Perfluorooctanoate
Sinapinic acid
6-Hydroxybenzbromarone
Benzarone
Benzbromarone
Captopril
Enalapril
Fenofibric acid
Fenofibric acid (reduced)
Indomethacin

Transportera Interactionb
hOAT3
mOat3
mOat3
mOat3
mOat3
hOAT3
hOAT3
hOAT3
mOat3
hOAT3
hOAT4
hOAT4
hOAT4
hOAT4
hOAT4
hOAT4
hOAT3

S/I
I
I
I
I
I
I
I
I
I
I
I
I
S
S
S
S

Systemc

Km

HEK293
CHO
CHO
CHO
CHO
HEK293
X. laevis
HEK293
CHO
HEK293
HEK293
S2
S2
HEK293
HEK293
HEK293
HEK293

hOAT4

S

CHO

hOAT4
hURAT1
hURAT1
hURAT1
hURAT1
hURAT1
hURAT1
hURAT1
hURAT1

I
I
I
I
I
I
I
I
I

CHO
MDCK
MDCK
MDCK
MDCK
MDCK
HEK293
HEK293
MDCK

196

Kinetics (µM)
Ki

IC50d

4.3±0.2
343±93
21.3±7.7
25.74±1.56 (1 ES)
3.0 (10 MTX)

22.4
61.3±8.35 (0.05 ES)
72.0±9.32 (0.05 ES)

172±46
(pH6);
310± 30
(pH7.4)

Reference
(119)
(49)
(109)
(49)
(49)
(52)
(220)
(52)
(49)
(52)
(39)
(40)
(40)
(50)
(50)
(50)
(50)
(226)

0.23±0.05 (100 U)
0.12±0.03 (100 U)
0.05±0.02 (100 U)
>5000 (100 U)
648±77 (100 U)
35.7±3.9 (20 U)
570±25 (20 U)
40.7±2.20 (100 U)

(52)
(227)
(227)
(227)
(227)
(227)
(228)
(228)
(227)

Appendix I Continued
Compound

Transportera Interactionb

Systemc

Irbesartan

hURAT1

I

Losartan

hURAT1

I

Orotate
Perfluorooctanoate
Phenylbutazone

hURAT1
hURAT1
hURAT1

S
S
I

X. laevis
HEK293
X. laevis
HEK293
HEK293
MDCK

Probenecid

hURAT1

I

MDCK

Sulfinpyrazone
Telmisartan
Valsartan
2,4-dichlorophenoxyacetate
2,4-dihydroxyphenylacetic acid
5-hydroxyindoleacetic acid
Dehydroepiandrosterone sulfate
Hippuric acid
Homovanillic acid
Penicillin G
Probenecid
Salicylate

hURAT1
hURAT1
hURAT1
mOat6
mOat6
mOat6
mOat6
mOat6
mOat6
mOat6
mOat6
mOat6

I
I
I
I
I
I
I
I
I
I
I
I

MDCK
X. laevis
X. laevis
CHO
CHO
CHO
CHO
CHO
CHO
CHO
CHO
CHO

a

Km

Kinetics (µM)
Ki
IC50d
121.7 (20 U)
571±28 (20 U)

5.2±0.4
64.1±30.5
197±48.5 (100 U)
86.39±0.07 (10 U)
41.7±3.70 (100 U)
716±34.3 (100 U)

15.7±2.0
61.4±7.1
48.9±10.3
38.8±3.1
59.9±4.9
3.0±0.5
1450±480
8.3±2.5
49.0±4.4

Reference
(229)
(228)
(229)
(230)
(226)
(227)
(231)
(227)
(227)
(229)
(229)
(109)
(109)
(109)
(109)
(109)
(109)
(109)
(109)
(109)

Transporter species: h, human; m, mouse; r, rat; rb, rabbit; bInteraction: I, inhibitor; S, substrate; cExpression system: CHO, Chinese
hamster ovary cells; HEK293, human embryonic kidney cell line; MDCK, Madin Darby canine kidney cell line; S2, cell line derived
from second segment of proximal tubule; X. laevis, Xenopus laevis oocytes; dIC50: concentration of inhibited substrate is shown in
parentheses (in µM), substrate abbreviations: CF, carboxyfluorescein; ES, estrone sulfate; MTX, methotrexate; PAH, paraaminohippurate; U, Urate; eThis reference reported values for both the oxidized and reduced forms of this substrate, respectively.
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